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 ABSTRACT 
Postmenopausal osteoporosis is the most prevalent form of osteoporosis and results in fragility 
fractures. Smoking is one of the major risk factors for osteoporosis and is known to aggravate 
bone loss in postmenopausal women due to increased oxidative stress and inflammation. Diet-
based interventions using berries have shown bone protective affects in animal studies partially 
due to antioxidant and anti-inflammatory properties of their phenolic compounds. The goal of 
this research was to determine the effects of antioxidant-rich fruits in the prevention of 
postmenopausal bone loss. Our first study examined the dose dependent effects of blackberries in 
preventing bone loss in an ovariectomized rat model of postmenopausal osteoporosis. Findings 
from the animal study indicated that blackberries consumed at the level of 5% (w/w) and not 
10% (w/w) may modestly prevent ovariectomy-induced bone loss. Next, we conducted a clinical 
study to determine the effects of berries on bone loss. To explore this objective, postmenopausal 
smokers were required to consume 45g of blackberries or blueberries for a 9 month period. Bone 
mineral density of total body, and sites were determined at baseline and after 9 months. In 
addition, biomarkers of bone metabolism and biomarkers of oxidative stress were measured. This 
study found that blackberries and not blueberries modestly protected against smoking-induced 
bone loss of the total body bone mineral density. No significant changes were noted on 
biomarkers and other bone indices. The results of this research are inconclusive. Future studies 
are necessary to confirm these findings and explore mechanisms by which berries may prevent 
bone loss and effective doses in both postmenopausal smokers and nonsmokers. 
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I. INTRODUCTION 
Osteoporosis is one of the most prevalent and debilitating bone diseases in the United 
States (US) and worldwide 
1
. The disease impacts the quality of life of individuals affected and 
results in enormous direct and indirect socioeconomic costs. Current annual cost for the 
treatment of osteoporosis related fractures in the United States is estimated at $18 billion and 
will increase to $25.3 billion by 2025
1
.  
Postmenopausal osteoporosis is the most prevalent form of osteoporosis 
1
. In the United 
States, nearly half of all women over the age of 50 will suffer an osteoporosis-related fracture, 
resulting in more than 1.5 million fractures a year 
2
. In addition to hormone deficiency, smoking 
is considered a major risk factor in the pathogenesis of osteoporosis 
3
. According to 2010 Centers 
for Disease Control and Prevention statistics, 21% of women aged 45-64 in the US are cigarette 
smokers 
4
. Cigarette smoke contains over 10
15 
free radicals/g in what is known as the tar phase; 
the smoke that is drawn into the mouth of an active smoker 
5
. These radicals have a life span of 
few hours to months 
5
, and result in increased oxidative stress in smokers compared to non-
smokers. This is because long-term smoke exposure results in systemic oxidants-antioxidants 
imbalance hence oxidative stress 
6
.  
 Oxidative stress in biological systems occurs due to an imbalance between the free 
radicals and the body’s antioxidant mechanism 7. Higher levels of oxidative stress are evidenced 
by elevated levels of products of lipid peroxidation such as isoprostanes and thiobarbituric acid 
reactive substances (TBARS) 
6
. Also, depleted levels of plasma antioxidants including vitamins 
A and C and reduced glutathione have been reported in smokers 
6
.  
In women, heavy smoking throughout adult life has been reported to result in 5-10% less 
bone by the age of 45-50 years, compared to non-smokers 
8
. Studies have demonstrated that 
2 
 
oxidants from cigarette smoke down regulate the expression of three important genes involved in 
bone metabolism, osteocalcin, type 1 collagen and alkaline phosphatase. These genes are 
important mediators of bone formation and essential for bone structure 
9
.  
Although pharmacological options for prevention and treatment of postmenopausal 
osteoporosis exist, the incidence of postmenopausal osteoporosis remains high. This is mainly 
due to poor adherence to treatment, side effects associated with treatments, and poor access to 
safe products 
10
. Intervention studies on postmenopausal osteoporosis are necessary to develop 
alternative feasible nutritional strategies that women can embrace to reduce fracture risk. Natural 
alternative therapies such as diet modification and phytotherapy are perceived to be safe and 
have little to no side effects 
11
. 
Consumption of a diet high in fruits and vegetables is known to improve serum oxidant 
states in vivo, and reduce the incidence of cancer, vascular diseases, and other degenerative 
diseases 
12
. Fruits and vegetables are rich sources of bioactive components including, vitamins, 
minerals, fiber, and phytochemicals including phenolic compounds 
13
. Phenolic compounds are 
widely studied for their strong superoxide scavenging capacity 
12
. In fact, these compounds 
account for 80% of total antioxidant capacity in most fruits and vegetables 
14
. The antioxidant 
capacities of certain phenolic compounds (e.g. flavonoids) may be stronger than vitamins C and 
E based on molar concentrations 
14
.  
Berries are a rich source of phenolic compounds plus several other nutrients including, B 
vitamins, ascorbic acid (vitamin C), carotenoids (β carotene) and tocopherols, calcium, selenium, 
and dietary fiber 
15
. Blueberries primarily contain the class of phenolic compounds known as 
flavonoids, which includes: anthocyanins, catechin, epicatechin, quercetin, kaempferol, 
myrecetin, and phenolic acids (e.g., gallic acid, p-hydroxybenzoic acid, chlorogenic, p-coumaric, 
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caffeic, ferulic, and ellagic acids) 
16, 17
. Blackberries on the other hand contain chiefly 
anthocyanins, flavonols, and hydrolyzable tannins or ellagitannins 
18
. Considering the abundance 
of literature on blueberries compared to blackberries, a thorough review of blackberries was 
written as part of this thesis paper.  
Recently, the effects of berries and their extracts on bone health have been explored. 
Animal studies have demonstrated that phenolic compounds from berries scavenge ROS formed 
by phagocytes (i.e. monocytes, macrophages and neutrophils) 
19
 resulting in bone resorption 
20
. 
Polyphenols such as chlorogenic acid, caffeic acid, and rutin in dried plum have prevented bone 
loss in animal models by reducing oxidative stress biomarkers 
21
. Recently, blueberries and 
blackberries have shown bone protective effects in an ovariectomized (OVX) rat model of 
postmenopausal osteoporosis 
22, 23
. These animal studies provide some evidence of a positive 
impact of antioxidant-rich berries on bone metabolism, paving way for clinical trials that fully 
explore their effects in humans.  
The overall goal of this research was to determine the effects of antioxidant-rich fruits in 
the prevention of postmenopausal bone loss. To achieve this goal our objectives were as follows: 
 1) to examine the dose-dependent effects of blackberries in the prevention of bone loss 
in an ovariectomized rat model of postmenopausal osteoporosis, and  
2) to determine the role of antioxidant-rich blueberries and blackberries in prevention of 
smoking-induced bone loss in postmenopausal women.  
Hypothesis for the animal study was that antioxidant-rich blackberries will dose-
dependently prevent bone loss in an ovariectomized (OVX) rat model of postmenopausal 
osteoporosis. For the clinical study, the hypothesis was that consumption of antioxidant rich 
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blackberries or blueberries for nine months will prevent smoking-induced bone loss in 
postmenopausal women. 
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II. LITERATURE REVIEW 
OSTEOPOROSIS 
Osteoporosis is a metabolic bone disease that affects the bone quality and density and is 
characterized by low bone mass and microarchitectural deterioration of bone tissue. This leads to 
porous bone, fragility and increased fracture risk 
1
. Osteoporosis progresses silently, and unless a 
fracture occurs, the disease is mostly asymptomatic. The main areas of the body at risk of 
fracture are the lumbar spine, hip, and wrist although fractures can occur on any bone in this 
condition 
2
. The most common fractures on the lumbar spine are known as vertebral fractures. 
Low grade vertebral fractures occur on disks and when they eventually compress, they become 
compression fractures. Compression fractures are responsible for loss of height and deformities 
such as kyphosis, or stooped posture, associated with osteoporosis 
2
. The lifetime risk of 
vertebral fracture has been estimated to be 15.4% after age 45 years, although true risk is likely 
to be higher. Hip fractures are the most debilitating, and contribute significantly to age-related 
deaths. In fact, even with rehabilitation, only 30% of hip-fracture patients regain pre-fracture 
function 
3
. Measurements of the bone mineral density at these three regions lumbar spine, hip, 
and wrist are used as predictors of fracture risk. The FDA has approved some techniques for 
measurement of bone mass and density based on their ability to predict fracture risk 
1
. These 
include: central computed tomography (CT), peripheral CT which focuses on the forearm or tibia 
and dual energy x-ray absorptiometry (DXA) which is used to measure BMD and BMC of total 
body and necessary body regions. DXA is considered the gold standard technique for measuring 
bone mass due to its accuracy and precision 
1
. The World Health Organization defines bone loss 
according to stages of severity: osteoporosis as BMD greater than -2.5 standard deviations below 
the young adult reference mean BMD and osteopenia as BMD between -1.5 and -2.5 standard 
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deviations below the young adult reference mean BMD. Estimates from the National 
Osteoporosis Foundation state that 10 million Americans are already afflicted with osteoporosis 
and another 42 million individuals are osteopenic and at risk for osteoporosis-related fractures 
2
. 
POSTMENOPAUSAL OSTEOPOROSIS 
Postmenopausal osteoporosis, also known as primary osteoporosis, is the most common 
form of osteoporosis. In the United States, a conservative estimate is that nearly half of all 
women over the age of 50 will suffer an osteoporosis-related fracture, resulting in more than 1.5 
million fractures a year
2
. Current annual cost for treatment of osteoporosis related fractures in the 
United States is estimated at 18 billion 
2
. Due to the large population of aging baby boomers and 
the fact that people are living longer, experts estimate that these costs will increase to $25.3 
billion by 2025
2
. 
A woman is defined as postmenopausal if 12 consecutive months of amenorrhea is 
confirmed without medical reasons. Before menopause sets in, women experience a pre-
menopausal period known as the perimenopause stage. During perimenopause, ovarian 
production of estrogen gradually declines 
4
. This decline eventually leads to a 90% reduction of 
serum estradiol by the time a woman is confirmed to be menopausal 
5
. This loss of estrogen 
causes a bone loss of about 5% for cancellous bone and 1 to 3% for cortical bone per year in 
early postmenopausal women (1-5 years after menopause) 
5
,
 6
. In addition, during early 
menopause, women loose approximately 3% of bone in the spine per year 
7
 accounting for 50% 
of lifetime vertebral bone loss 
7
. In fact, 20 years into menopause, women lose up to 50% of 
trabecular bone and 30% of cortical bone 
6
. It is now well understood that estrogen is essential 
for bone resorption and formation process to remain coupled 
7
. The 90% reduction in serum 
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estrogen in the early menopause rapidly increases bone turnover and the rate of resorption 
without a matched increase in bone formation, hence irreversible bone loss 
7
. 
There are other hormonal and environmental factors that affect skeletal health. Decreased 
secretion of the growth hormone and inadequate or lack of physical activity may lead to impaired 
osteoblast function and less bone formation resulting in bone loss 
5
. Also, environmental factors 
such as a diet low in calcium intake in early years of life, low body weight at 1 year or at 
maturity, delayed puberty, and early menopause may control an individual’s bone mass 7. 
Furthermore, after menopause, bone loss may be accelerated by certain drugs such as 
corticosteroids. Corticosteroids are medications that relieve inflammation and their actions 
resemble certain hormones made by your own body. When taken long-term (more than 6 
months) or at high doses, these drugs can cause bone loss that leads to osteoporosis and fractures 
7
 . These medications, also known as steroids and glucocorticoids may be used in the treatment 
of many conditions including arthritis and asthma. Tumors of the pituitary gland or diseases such 
as metabolic syndrome, diabetes and cancer have also been known to cause bone loss 
7
. 
In summary, although there are many factors that may affect skeletal health, estrogen 
deficiency plays a key role in postmenopausal bone loss, increasing bone turnover and the rate of 
resorption without a matched increase in bone formation. This change results in an imbalance in 
remodeling and irreversible bone loss 
7
. Major mechanisms by which estrogen deficiency leads 
to bone loss are discussed later in this chapter. 
THE OVARIECTOMIZED RAT MODEL OF POSTMENOPAUSAL 
OSTEOPOROSIS 
The FDA requires that potential agents proposed for any human therapy are evaluated in 
animal models 
8
. Previous and current research assures the suitability of the ovariectomized 
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(OVX) rat in demonstrating the efficacy and safety of postmenopausal-related therapies before 
use in humans 
8
. Ovariectomy in young but skeletally mature rats makes the rat’s sex-hormone 
deficient, and stimulates accelerated loss of bone that is similar to what occurs in women 
following menopause 
9
. Investigations have found the OVX rat model mimics postmenopausal 
cancellous bone loss when studies are conducted in less than 12 months and optimally within 6 
months of life 
8
. OVX rat model is reported to undergo rapid loss of trabecular bone mass and 
strength after ovariectomy 
10, 11
. A study by Laib and others reported a 40% rapid decrease in 
bone volume and a two-fold decrease in tibia cancellous bone volume after ovariectomy 
11
. Other 
reported similarities in OVX rat model and postmenopausal women include: increased resorption 
rate compared to formation rate and an initial rapid phase of bone loss followed by a slower 
phase. Both also report more cancellous than cortical bone loss, and decreased intestinal 
absorption of calcium. Another similarity is that in both, obesity provides protection against bone 
loss. Finally, they exhibit similar treatment effects after administration of exercise, hormones 
such as estrogen, parathyroid hormone and calcitonin, and drug therapies tamoxifen, and 
bisphosphonates 
9
. 
There are disadvantages linked to the use of the OVX-rat as a model of postmenopausal 
osteoporosis. These include the fact that long bone of the rat grows longitudinally briefly after 
ovariectomy which can slightly affect results, however the use of 9-12 month old rats lessens the 
effects of this disadvantage 
12
. Secondly, haversian systems in rats are either lacking or poorly 
developed unlike the well-developed haversian system in humans. 
12
. Finally, the OVX rat model 
does not experience fragility fractures as seen in humans 
13
. Despite these limitations, the OVX 
rat model is a suitable rat model to study postmenopausal osteoporosis 
8
.  
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SKELETAL SYSTEM  
The adult human skeleton is a highly specialized organ comprised of 206 bones, each 
formed by a process known as modeling, and every bone constantly being renewed in a process 
known as remodeling 
14
. The skeleton serves three main functions although depending on 
position each bone may serve more than one specific function including, 1) mechanical support 
and levers for muscles, 2) protection of vital organs, and 3) repository for calcium and 
phosphorous 
15
. Bones are also rich sources of growth factors and cytokines that may have both 
inhibitory and stimulatory effects on bone functions 
14
. Bone may be classified according to 
process of formation into flat bones and long bones. Flat bones are such as the skull, mandible, 
and scapula while the long bones include the femur, tibia, and radius 
14
. Structurally, bone tissue 
is divided into trabecular bone and compact bone 
16
. Trabecular bone is also known as spongy or 
cancellous bone has 75%-95% porosity and is found in the cuboidal bones such as flat bones and 
the ends of long bones. The pores are interconnected and filled with marrow. Compact bone is 
also called cortical bone and its porosity is only 5%-10%. Cortical bone forms a cortex or shell 
around vertebral bodies and other spongy bones and also is found in the shafts of long bones. 
The pores in the cortical bone consist of three categories of spaces: 1) Haversian canals that are 
about 50μm in diameter and contain capillaries and nerves, 2) Volkmann’s canals are transverse 
canals that connect Haversian canals to each other and also contain blood vessels, and 3) 
Resorption cavities which are more temporal in nature and are created by osteoclasts in the 
process of bone remodeling 
16
. In terms of function, although there may be differences due to 
species or situation, cancellous bone is considered to be more metabolically active than cortical 
bone, which largely serves a mechanical role 
14
. 
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Mature bone has an outer fibrous sheath known as the periosteum, and the inner surface 
which is in direct contact with the marrow known as the endosteum. Periosteum is made of 
connective tissue and it covers all bone surfaces except at joints where the articular cartilage 
lines the joints. The periosteum contains bone cells, nerves and blood vessels to ensure 
nourishment, and is held strongly by collagenous fibers known as Sharpeys’fibers that penetrate 
the bone tissue. The endosteum is a membranous sheath well served with blood vessels and bone 
cells and covers the surface of the cancellous bone and lines Volkmann’s canals 14. 
BONE TISSUE  
Bone tissue is composed of three primary components- water, organic matrix (largely 
collagen), and minerals 
17
. These components are commonly categorized into: collagen, 
hydroxyapatite mineral, small amounts of proteoglycans, noncollagenous proteins, and water. 
Collagen is a rigid, rod-like protein molecule composed of two alpha chains consisting of 
repeating amino acids with glycine in every third position and a high content of proline and 
lysine. These chains form a triple helix that is stabilized by the hydroxylation of proline and 
lysine residues by ascorbic acid 
18
. Although several types of collagen are identified in animals, 
the predominant collagen in bone is type I. Collagen is found in tendons, skin, and ligaments, 
and has great structural properties. Collagen can spontaneously organize itself into strong fibers 
which give bone flexibility and tensile strength. In addition, collagen provides the nucleation of 
bone mineral crystals, which account for the rigidity and compressive strength in bone 
16
. The 
inorganic mineral of bone almost entirely consists of hydroxyapatite crystals that contain 
carbonate, citrate, sodium, and magnesium 
17
. The crystals are rods or hexagonal plates. 
Proteoglycans are proteins that carry sulfated carbohydrate component known as 
glycosaminoglycan attached to them 
17
. Glycosaminoglycans are important binding sites for 
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fibroblast, endothelial growth factors and extracellular matrix proteins such as fibronectin and 
interstitial collagens 
17
. Osteocalcin which is important in new bone mineralization is the most 
abundant noncollagenous protein 
16
. Bone marrow is found in the spaces in the trabeculae of all 
bones. It contains red blood cells, white blood cells, and platelets providing a continuous supply 
of oxygen and nourishment ensuring the tissue’s demands for immunity and coagulation are 
adequately met 
16, 19
.  
BONE CELLULAR COMPONENTS 
The formation and maintenance of bone extracellular matrix is carried out by four major 
cellular components- osteoclasts, osteoblasts, and osteocytes and bone lining cells 
16
. According 
to Riasz, osteoclasts and osteoblasts are derived from multipotent hematopoietic cells and not 
monocyte/macrophage lineage as previously thought 
20
. Osteoclasts differentiate as 
mononucleated cells that express tartrate resistant acid phosphatase (TRAP) and calcitonin 
receptors even before fusion occurs 
20
. Mature multinucleated osteoclasts erode their way 
through bone by demineralizing adjacent bone with acids and then dissolving its collagen with 
enzymes 
16
.On the other hand osteoblasts are mononucleated bone forming cells akin to the 
fibroblasts, which are cells that produce structural molecules in other tissues. Osteoblasts are 
responsible for the production of osteoid, the organic portion of the bone matrix. The boundary 
that separates osteoid and calcified bone is known as the calcification or mineralization front 
16
. 
Osteocytes are former osteoblasts that become buried in bone and sits in the cavities called 
lacunae. These cells communicate among themselves and to active osteoblasts via tunnels known 
as canaliculi or little canals 
16
. Bone lining cells are retired osteoblasts that escaped being buried 
in newly formed bone and are found on the surface after bone formation. These cells are 
flattened against the bone surface with gaps in between them and via these gap-junctions 
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maintain communication with osteocytes 
16
. Both lining cells and osteocytes work to transfer 
minerals into and out of the bone 
21
 and are important for sensing mechanical strain 
16
.  
The development and differentiation of cellular components is controlled by growth 
factors, cytokines, and systemic hormones 
22
. These growth hormones and cytokines are 
produced in the bone marrow microenvironment. It is proposed that these processes occur 
through positive and negative feedback loops, cascades formed by growth hormones and 
cytokines, and via hormonal control and/ or action of local mediators
 6
. 
Several cytokines and local regulatory factors influence hematopoiesis and affect 
osteoclast development 
22
. These cytokines include interleukin 1(IL-1), interleukin 11 (IL-11), 
interleukin 3 (IL-3), interleukin 6 (IL-6), tumor necrosis factor –alpha (TNF-α) and granulocyte 
macrophage-colony stimulating factor (M-CSF). The cytokines that inhibit osteoclast 
development and in turn bone resorption include interferon-γ, IL13, IL-4, IL-10, and IL-18 20.  
Mesenchymal stem cells (MSCs) differentiate into functional osteoblasts capable of bone 
formation through a complex multistep process 
20
. Commitment of MSCs to form osteoblasts, 
osteoblastogenesis, is orchestrated by bone morphogenetic proteins (BMPs) 
23
. Osteoblast 
differentiation is also influenced by several factors, including transforming growth factor β 
(TGFβ), platelet-derived growth-factor (PDGF), insulin-like growth factors (IGFs), and members 
of the fibroblast growth factor (FGF) family and peptide hormones (e.g. parathyroid hormone 
PTH) 
20
. 
MODELING AND REMODELING  
Modeling is the process responsible for skeletal change in size and shape during growth 
and development of bones. Modeling occurs as a result of independent action of osteoblasts and 
osteoclasts while remodeling is defined as resorption and formation that occur at the same site 
20
. 
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According to Martin et al. modeling and remodeling are distinguished from one another in four 
main ways: 1) modeling at a particular site is continuous and prolonged, while remodeling is 
more episodic with a precise beginning and end, 2) remodeling occurs throughout life although 
the process is slower after growth stops, 3) modeling involves independent actions of osteoclasts 
and osteoblasts while remodeling involves a series of coupled actions of osteoclastic and 
osteoblastic cells, and 4) modeling results in altered bone size, shape, or both while remodeling 
has no effect on shape or size
 16
. Bone formation dominates during periods of skeletal growth 
such as during childhood and adolescence, but once the skeleton has reached maturity, new bone 
tissue is formed through remodeling 
14
. The rate of remodeling is age dependent although there is 
evidence that remodeling results in complete regeneration of the skeletal tissue every 10 years 
22
. 
Remodeling is considered a vital process because longitudinal growth does not give rise to bone 
of correct geometry. Moreover, during growth each child loads on his or her skeleton differently, 
thus requiring customization. On the other hand, remodeling repairs microscopic damages to the 
skeleton and prevents fatigue fracture and maintains calcium homeostasis 
16
. At the beginning of 
the third decade of life, there is a steady decrease in bone mass due to the higher rate of 
resorption. Bone remodeling becomes uncoupled and the osteoclast activity becomes greater than 
the osteoblast activity resulting in bone loss 
20
. 
SYSTEMIC HORMONES REGULATING BONE METABOLISM 
A large number of local and systemic factors activate and regulate functions of the 
skeleton. Two major calcium-regulating hormones, the parathyroid hormone (PTH) secreted by 
the parathyroid gland and dihydroxycholecalciferol (1, 25 (OH)2 D) control bone remodeling 
24
. 
Parathyroid hormone regulates bone remodeling by enhancing mobilization of calcium from the 
skeleton 
19
. The active hormonal vitamin D, 1, 25 (OH)2 D or calcitriol, is critical for optimal 
15 
 
intestinal absorption of calcium and phosphorus and maintaining skeletal growth and 
development 
25
. Calcitriol also exerts a tonic inhibitory effect on PTH synthesis 
26
. Calcitonin, a 
hormone produced by cells in the thyroid gland to oppose effects of PTH, appears to play a lesser 
role in regulating bone turnover even although it inhibits bone resorption by acting directly on 
the osteoclasts 
27
.The growth hormone is another systemic hormone which increases both 
circulating and local levels of insulin-like growth factor–I (IGF-I). Growth hormone (GH) plays 
a role in bone modeling and remodeling, and directly stimulates cartilage cell proliferation. GH 
and IGF stimulate both formation and resorption and determine skeletal size before epiphyseal 
closure 
24
.  
Sex hormones are critical in the regulation of skeletal development and bone remodeling 
24
. Both estrogen and androgen hormone receptors are found in bone cells 
27
. Estrogens acts on 
the skeleton through direct effects on cartilage and by its effects on other hematopoietic cell 
lineages. Estrogen deficiency is believed to be the single most important factor in pathogenesis 
of postmenopausal osteoporosis 
24
. 
ESTROGEN AND BONE 
Estrogen regulates the cytokine receptor activator of nuclear factor kappa B ligand 
(RANKL) which acts directly on the hematopoietic lineage of osteoclasts resulting in osteoclast 
recruitment and activity 
24
. RANKL is expressed on the surfaces of bone marrow stromal or 
osteoblast precursor cells, T-cells, and B-cells 
28
. Receptor activator of nuclear factor for kappa 
B (RANK) is its cognate receptor found on osteoclast lineage cells 
29
. The binding of RANKL to 
RANK is essential in the formation, development, and function of osteoclasts, and suppresses 
their apoptosis 
24
. RANKL action is opposed by osteoprotegerin (OPG), a neutralizing soluble 
antagonistic receptor, produced by osteoblasts to bind to RANKL and ensure a balance between 
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bone loss and formation. The RANKL/RANK/OPG regulatory system is vital in osteoclast 
formation and function and is responsible for the antiresorptive role of estrogen 
28
. After 
postmenopausal stage, RANKL production is increased and/or OPG expression is decreased 
resulting in bone loss 
30
.  
Expression of RANKL and OPG is also influenced by PTH, vitamins, and other 
molecules. For instance, RANKL production is increased while OPG is inhibited by PTH and 
glucocorticoid 
31
. Vitamin K is also reported to modulate osteoblastogenesis and 
osteoclastogenesis in bone marrow cells via the RANKL pathway 
32
. Hormonal 1, 25-(OH)2 D 
enhances RANKL expression without any effect on OPG 
33
. Other factors include tumor growth 
factor β (TGF β) that amplifies OPG production while IFN-γ suppresses RANKL induced 
osteoclastogenesis 
34
. 
In addition, estrogen affects bone formation by prolonging the lifespan of the osteoblast 
through inhibition of osteoblast apoptosis at the cellular level 
35
. Estrogen prefers the 
development of osteoblasts to adipocytes from their common precursor cells 
36
. Kousteni and 
colleagues demonstrated that estrogen inhibits apoptosis of osteocytes in the OVX rat model 
35
. 
Since osteocytes play a critical role in sensing mechanical loading, a reduction in the number of 
osteocytes may result in bone loss similar to that found in weightless conditions 
37
. 
INFLAMMATION AND BONE LOSS 
Inflammation is a normal immune response stimulated by pro-inflammatory cytokines 
and is a protective mechanism against invading microorganisms and infectious agents 
38
. 
However, excessive and prolonged inflammation may cause extensive tissue and organ damage 
and even death due to septic shock 
38
. The link between bone loss and inflammation is that pro-
inflammatory factors TNF-α, IL-1, IL-6, and ROS also function as bone resorbing cytokines. 
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Nuclear factor kappa B (NF-kappa B) is a transcription factor that is important in modifying the 
intracellular regulation of the immune response, inflammation, and cell cycle coordination 
39
. 
NF-kB also functions as a regulator for the expression of TNF-α, interleukin (IL)-1, and 
interleukin (IL)-6 among other important pro-inflammatory cytokines 
39
. Conditions associated 
with prolonged inflammation result in chronic elevation of these factors, TNF-α, IL-1, IL-6, and 
increased ROS resulting in bone loss. Examples of conditions associated with bone loss include 
periodontal disease 
40
, autoimmune diseases, rheumatoid arthritis multiple sclerosis, and 
inflammatory bowel disease 
41
. 
ROLE OF ESTROGEN IN INFLAMMATION  
There are functional estrogen receptors on osteoblasts and osteoclasts which when 
activated block the synthesis of pro-inflammatory and bone resorbing cytokines IL-6, IL-1, and 
TNF-α 42 Estrogen deficiency, therefore, creates an environment for increased inflammatory 
mediators and results in accelerated bone turnover characterized by increased bone resorption 
compared to bone formation
42
, 
43
. Reactive oxygen species (ROS) (e.g.O2-, H2O2, NOO-) 
produced in states of inflammation, further enhance inflammation through the activation and 
phosphorylation of stress kinases. c-Jun N terminal kinase 
44
, and transcription factors such as 
NF-ĸB and activator protein-1 (AP-1) 45. 
ESTROGEN, OXIDATIVE STATUS AND BONE LOSS 
Estrogen is an efficient scavenger of free radicals generated in both the aqueous and the 
lipophilic phases, and its antioxidant activity has been found to be up to 2.5 times that of vitamin 
C and vitamin E 
46. Estrogen’s antioxidant effects are attributed to the aromatic hydroxyphenol 
structure of the A ring although estrogen receptors may mediate some antioxidant action as well 
47
. Recently, it also has been suggested that estrogen augments intracellular oxidant defenses 
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lowering the concentration of ROS within cells 
48
. Estrogen inhibits bone resorption by 
suppressing the production of cytokines IL-1, IL-6, M-CSF, prostaglandin (PG) E2, and TNF-α, 
which are stimulators of ROS production 
6
.  
Experiments using ovariectomized animal models have demonstrated that in states of 
depleted intracellular antioxidants, mainly glutathione and thioredoxin, osteoclast activity 
increases via up-regulation of TNF-α 49. TNF-α is a pro-inflammatory cytokine associated with 
activation of inflammation and osteoclastic activity 
49
. In estrogen-deficient animal models, 
administration of antioxidants (e.g. N-acetyl cysteine or ascorbic acid) has shown to increase 
levels of glutathione and thioredoxin, and decrease TNF-α production 48 Cell culture experiments 
have also shown that administration of glutathione and thioredoxin in osteoclasts protects against 
bone loss during estrogen deficiency 
48
. For example, to investigate the effects of ovariectomy 
and estrogen on oxidant defenses in bone, Lean and colleagues found that administering a single 
dose of 17-β estradiol (10μg/kg) subcutaneously- the standard replacement dose for rodents 
normalized previously low levels of thiol antioxidant system within 24 hours 
48
. This experiment 
demonstrates that estrogen increases oxidant defenses and its deficiency may directly or 
indirectly promote bone resorption 
48
. 
ESTROGEN, CALCIUM ABSORPTION AND PTH IN BONE HEALTH 
Estrogen plays an important role in calcium absorption in the gut 
50
 and its reabsorption 
in the kidney 
51
. Reduced estrogen production leads to both decreased intestinal calcium 
absorption and high loses of calcium in urine 
51
. This provides evidence that estrogen regulates 
renal tubular calcium absorption 
51
. Intestinal mucosal cells contain estrogen receptors that have 
been shown to respond to 17-β-estradiol by enhancing calcium transportation 52. The effect of 
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low estrogen on calcium absorption in the intestines and the increased loss through the kidneys 
can each account for late phase bone loss in postmenopausal women 
53
.  
Estrogen indirectly effects bone resorption through its effect on PTH secretions. The slow phase 
of bone loss in postmenopausal women is linked to both an increase in PTH levels and actions, 
and to senescence of osteoblasts. These factors are similar in both men and women age 60 and 
above and are attributed to calcium deficiency. Calcium deficiency is as a result of reduced 
absorption in the intestines and less reabsorption in the kidneys due to organ atrophy. Bone loss 
may also be attributed to a vitamin D deficiency due to decreased 1-alpha-hydroxylase activity in 
the kidneys in women who do not get enough sunlight
54, 55
  
SMOKING AND BONE LOSS 
Tobacco use is the number one preventable cause of mortality and morbidity in the 
United States (CDC 2009). Cigarette smoking is a risk factor for cardiovascular diseases 
56
, 
several neoplasmic conditions including cancer of the throat, tongue, lung, and bladder 
57
. 
Smoking is also a major risk factor for osteoporosis 
58
. As mentioned earlier, radicals inhaled 
from cigarette smoke down regulate the expression of three important genes: osteocalcin, type 1 
collagen, and alkaline phosphatase which are key mediators of bone formation and structure 
59
. 
Moreover, there are over 150 known toxic compounds that have been found in cigarettes, 
although nicotine is the main chemical substance and one that leads to addiction 
59
. Nicotine is 
known to alter bone metabolism, increase fracture risk, and compromise healing after a fracture 
by delaying bone callous formation and remodeling 
60
. Tobacco use is also implicated in poor 
spinal fusion 
61, 62
. Chronic administration of nicotine has been linked to low bone mineral 
density, low bone mineral content, and shorter bones 
63
.  
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The following are summaries of human studies that report the negative effects of 
cigarette smoking on bone. 
A population-based cohort study of subjects aged 60 years and older reported that 
smoking levels recorded 16–18 years earlier were accurately indicative of lower BMD at the hip 
in both men and women even after adjustment for multiple confounders including age, exercise, 
alcohol use, body mass index and hormone use 
64
. Krall and Dawson-Hughes 
65
 also found that 
bone density at the radius of the wrist was inversely related to pack-years of smoking exposure in 
postmenopausal women, after controlling for confounders such as BMI and years after 
menopause 
65
. A large Danish study of 2015 postmenopausal women aged 45–58 years revealed 
significant negative associations between smoking and bone mass in the lumbar spine, femoral 
neck, and total body. This study reported a 3% deficit at the femoral neck in current smokers 
when their BMD was compared with non-smokers 
66
. Additionally, smoking was correlated with 
a 4% lower BMD at the spine compared with non-smokers in a three year study of 153 early 
postmenopausal women 
67
. Similarly, a Southern Californian longitudinal study of 8600 
postmenopausal women found that current smokers had an increased hip fracture risk compared 
to those who had never smoked 
68
. 
Effects of smoking on bone health are best summarized using three meta-analyses 
published over the past 10 years 
69
. The first by Wong and colleagues gathered 29 published 
cross-sectional studies examining 2156 smokers and 9705 non-smokers, and 19 cohort and case-
control studies representing 3889 hip fractures and reported the following:  
69
: (i) in women, 
smoking accounts for one in eight hip fractures; (ii) the relative risk of hip fracture in smokers 
compared with non-smokers is strongly associated with age, thus the longer one smokes the 
higher the risk for fracture; (iii) the difference in BMD at the femoral neck, radius, and heel bone 
21 
 
(calcaneus) in smokers compared to non-smokers increased with age and BMD of smokers fell 
2% more than that of non-smokers every 10 years; (iv) smoking has a direct effect on BMD that 
cannot be attributed to variations in body mass, menopausal history, exercise levels, or hormone 
therapy 
69
. 
The second meta-analyses by Ward and Klesges pooled data from 86 studies representing 
40753 subjects 
70
. The results were as follows:  (i) smokers had less bone mass at hip, lumbar 
spine, forearm and calcaneus; (ii) smoking cessation had a beneficial effect on bone mass, with 
BMD being between life-long non-smokers or current smokers; (iii) smoking increased the 
lifetime risk of hip fracture by 31% in women and 40% in men, and of lumbar spine by 13% in 
females and 32% in males; and (iv) smoking accounted for up to 10% of all hip fractures. These 
results mean that an estimated 34000 hip fractures per year in the United States alone are 
attributable to smoking 
70
. 
The third and most recent meta-analysis of 10 prospective cohort studies in five 
continents examined 59232 subjects and reported that, smoking increased fracture risk by 25% 
when risk in smokers was compared with the risk in never-smokers. The highest risk reported 
was for hip fracture. Secondly, smoking-associated fracture risk was related to body mass index 
but the effects were not significant 
69
. 
MECHANISMS BY WHICH SMOKING CAUSES BONE LOSS  
Smoking and bone loss has been investigated and some mechanisms by which it causes 
bone loss have been identified as: 1) reduced active vitamin D in plasma, 2) malabsorption of 
calcium, and 3) oxidative stress and 4) inflammation.  
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Reduced Active Vitamin D in Plasma  
There is evidence that high concentration of nicotine in plasma is associated with low 1, 25 (OH) 
2D levels in animal models 
71
. Fung and colleagues reported a 25% decrease in serum levels of 
1, 25 (OH) 2D when seven month old female rats were treated with 4.5mg/kg/day of nicotine. 
The dose was administered via subcutaneous osmotic pumps for 90 days and results compared to 
both control group and low nicotine group (3mg/kg/day) 
71
. The role of vitamin D and calcium in 
bone health is discussed earlier and cannot be over emphasized. 
Malabsorption of calcium 
 In humans, tobacco use is associated with decreased calcium absorption 
65
. Since 
restoration of systemic plasma calcium balance is extremely crucial, the body increases retention 
or withdraws calcium from the skeleton 
72
. Long periods of calcium insufficiency thus cause 
bone loss since bone resorption will be higher than formation. The importance of calcium in 
bone metabolism is also discussed earlier in this paper. 
Oxidative stress 
Studies have shown that long-term smoke exposure can result in systemic oxidants-
antioxidants imbalance evidenced by increased products of lipid peroxidation such as 
isoprostanes and thiobarbituric acid reactive substances (TBARS) (indices of lipid peroxidation 
and oxidative stress), and depleted levels of plasma antioxidants including vitamin A and C and 
GSH related antioxidants in plasma of smokers 
73
. The major free oxygen radicals or reactive 
oxygen species (ROS) responsible for oxidative stress in biological systems are hydroxyl radicals 
(OH·), peroxide anions (O·2- ), hydrogen peroxide (H2O2), and nitric oxide (NO) 
74
; smoking is 
an additional source of radicals 
75
. These radicals account for oxidation of specific enzymes, 
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proteins, lipid peroxidation, and DNA causing cell and tissue damage 
74
. Damaging effects of 
ROS are mitigated by endogenous antioxidant enzymes such as superoxide dismutase (SOD), 
glutathione peroxidase (GPx), and catalase 
49
 as well as by dietary antioxidants 
76
. Aged 
osteoporotic women are reported to have decreased plasma antioxidants and tend to benefit from 
dietary antioxidants such as vitamin C. Vitamin C supplementation is known to improve BMD in 
postmenopausal women 
77
. 
 Free radicals such as NO from cigarette smoke activate NF-kappa B which is oxidative 
stress-responsive transcription factor that induces bone resorption 
78
. Additionally, H2O2 is 
known to inhibit differentiation markers in osteoblastic cells in marrow stromal cells modifying 
differentiation of vascular and bone cells 
79
. Rothem et al reported lowered osteoblastic 
proliferation and induce cell death when osteoblast-like cells (MG63) are incubated for 72 h in 
levels of nicotine similar to that of habitual cigarette smokers 
59
. Furthermore, smokeless tobacco 
extracts and nicotine in isolation have also been reported to suppress the growth of osteoblast-
like cells in vitro 
80
 and decrease collagen synthesis 
81
. 
Inflammation  
In addition to oxidative stress, cigarette smoke causes systemic inflammation. Serum 
levels of pro-inflammatory and bone resorbing cytokines IL-1 and IL-6 were reported to be 
elevated in 21 three-month old male Sprague-Dawley rats treated with 7mg/kg/ body weight of 
nicotine. The study also reported decreased trabecular bone volume and thickness at metaphyseal 
region of left femurs, and decreased mineral appositional rate and bone formation rate 
82
. 
Population-based studies have consistently reported a low-grade systemic inflammatory state in 
smokers 
83, 84
. This inflammatory state in humans is characterized by increased circulatory 
inflammatory mediators such as acute phase proteins and pro-inflammatory cytokines, C-reactive 
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protein (CRP), fibrinogen, and interleukin-6, as well as increased white blood cell count (WBC) 
73
. Studies such as the large-scale NHANES III study using 7,685 subjects, confirmed systemic 
inflammation and revealed a strong independent dose-response relationship between cigarette 
smoking and elevated levels of CRP, fibrinogen, and blood leukocytes 
85
. Another study that 
analyzed data on 4,187 smokers, 4,791 former smokers, and 8,375 never-smokers and adjusted 
for cofactors reported a dose-effect relationship between the number of cigarette smoked per day 
and plasma fibrinogen concentrations 
86, 87
. Biomarkers such as urinary 8-iso-PGF2α, a major F2-
isoprostane, plasma GPx, and enzymatic SOD are reliable in vivo biomarkers of oxidative stress 
and inflammation 
77
. A Swedish study involving 48 women and 53 men aged between 22-85 
years reported that high urinary concentration of 8-iso-prostaglandin-F2α (8-iso-PGF2α) were 
significantly correlated with low BMD of total body, lumbar spine, and heel 
88
. 
TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS 
Osteoporosis medications fall into two categories: the antiresorptive medications that 
slow the breakdown of bone and the anabolic treatments that help build bone. These medications 
work with the body systems to protect bone mineral density and reduce the risk of fractures. 
Currently, teriparatide is the only Food and Drug Administration (FDA) approved anabolic 
medication available. Several FDA approved antiresorptive drugs are available and include 
bisphosphonates, calcitonin, estrogen therapy/hormone therapy, and selective estrogen receptor 
modulators (SERMs). These treatments have risks associated with their use, but all are geared 
towards elimination or reduction of fracture risk 
1
. Selected approved therapies are discussed 
below.  
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Raloxifene 
Raloxifene was approved for women only and is taken as an oral tablet daily for 
treatment of osteoporosis. It is a drug derived from benzothiophene and is a SERM that comes in 
a brand name Evista ®. SERMs represent a class of drugs that act as either estrogen receptor 
agonists or antagonists in a tissue-selective manner 
89
. This pharmacologic profile of raloxifene 
enables it to act by demonstrating estrogen-like effects on the skeleton and cardiovascular 
system, and anti-estrogen effects on the breast and endometrium 
90
. In study a large human study, 
7,705 postmenopausal women aged 31–80 years with osteoporosis; raloxifene was successful in 
increasing lumbar spine and femoral neck BMD by 2–3%, while reducing the risk of vertebral 
fractures by 30%–50%. Additionally, the drug decreased the incidence of breast cancer 91. Side 
effects associated with the use of raloxifene include: increased risk for blood clots in the leg 
veins and/or the lungs, increased hot flashes, leg cramps, and fluid retention 
89
.  
Estrogen therapy 
Estrogen therapy (ET) is administration of estrogen hormone alone as opposed to 
hormone therapy (HT) which refers to estrogen with progesterone hormone therapy. Estrogen 
used in many clinical trials may be conjugated equine estrogen, estradiol, estrone, esterified 
estrogen, ethinyl-estradiol, and mestranol. Estrogen replacement is used in the treatment of bone 
loss prevention of fractures risks 
53
 and increase in bone mass of the spine, hip, and total body
1
. 
Therapies that use estrogen either target estrogen receptors directly or increase the diminishing 
hormone level. As discussed earlier, estrogen favors bone formation by up-regulating osteoblast 
activity and suppressing osteoclast activity. Estrogen increases synthesis of growth factors in 
osteoblasts if administered in high doses and may increase mean wall thickness and other 
histomorphometric indices of osteoblast activity in humans 
92
. In a Framingham cohort study that 
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evaluated effects of hypogonadism and estradiol levels on BMD in men and women, estradiol 
levels were strongly correlated with BMD at forearm, spine, and hip 
93
. However, while estrogen 
can prevent osteoporosis in postmenopausal women, it also increases the risk of other health 
problems. Estrogen therapy use is associated with possible estrogen-dependent tumors such as 
breast cancer, stroke, ischemic attack, pulmonary embolus, deep vein thrombosis, or complex 
hyperplasia 
94
.  
Parathyroid hormone (PTH) 
 Parathyroid hormone is approved for the treatment of osteoporosis in both women and 
men who are at particularly high risk for fractures, including subjects who are younger than age 
65 and have low bone mineral density measurements (T scores ≤3.5) 95. Teriparatide 
recombinant human PTH 1–34 (contains the first 34 amino acids of human PTH) 96and is 
currently the only FDA approved in the first in a class of osteoporosis medications called 
anabolics. Teriparatide is available in a brand name Forteo® and taken as a daily injection. The 
action of PTH on bone requires the presence and contact with a combination of several 
specialized cells including, bone marrow stromal cells, and hematopoietic precursors of 
osteoclasts, mature osteoclasts and osteoblasts and works to form new bone 
97
. PTH enhances the 
formation of trabecular bone when administered intermittently, but not chronically 
98
. In fact 
certain dosages and continuous administration of PTH are associated with bone resorption. The 
results of large study in which, 1637 postmenopausal osteoporotic women were receiving PTH 
indicated for two years demonstrated that PTH reduced fracture risk by 65% and increased 
vertebral lumbar spine bone mineral density by 9%–13% 99. Teriparatide therapy is not 
recommended for
 
more than 2 years since longer use may induce osteosarcoma as observed
 
in a 
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rat model of carcinogenicity 
95
 Side effects associated with PTH use include: headache, 
hypercalcemia, dizziness, leg cramps, marrow fibrosis, tunneling resorption, and nausea 
100
.  
Bisphosphonates 
Bisphosphonates are compounds derived from pyrophosphate. The drugs in this class are 
antiresorptive and act by slowing down the breakdown of bone by inhibiting hydroxyapatite 
formation 
3
. Other mechanisms by which bisphosphonates slow bone loss include initiation of 
osteoclast apoptosis 
101
, suppression of protein tyrosine phosphatases 
102
 and disruption of the 
formation of cytoskeletal actin-ring in polarized resorbing osteoclasts 
103
.Osteoporosis drugs 
available in this class are alendronate (Fosamax®), ibandronate (boniva®), risedronate 
(Actonel®)and zoledronic acid (Reclast®). Despite proven efficacy, regular administration of 
bisphosphonates is known to cause gastrointestinal problems such as upset stomach, diarrhea, 
pain in arms and legs, dysphagia, esophageal and stomach ulcers 
104
. 
Calcitonin 
Calcitonin is a polypeptide hormone that has been used to treat osteoporosis and other 
diseases involving accelerated bone turnover for over 25 years 
105
. In our bodies, calcitonin is 
produced in the C cells of the thyroid 
27
 and salmon calcitonin is clinically administered for 
treatment of osteoporosis 
105
. This hormone acts on the osteoclasts by inhibiting the 
differentiation of osteoclast precursors 
106
 and suppressing the proliferation of progenitor cells 
106
. Several controlled clinical studies have demonstrated that calcitonin is an antiresorptive 
hormone that preserves or increases bone mineral density (BMD) and reduce the risk of vertebral 
fractures. An added advantage of calcitonin is its direct analgesic effect. Calcitonin has been 
demonstrated to be clinically useful in improving pain, from the acute vertebral fractures of 
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osteoporosis and other sources of musculoskeletal pain unlike any other therapy 
105
. Calcitonin is 
available in two brand names, Fortical® and Miacalcin®). 
NUTRIENTS AND BONE METABOLISM 
Protein 
Protein is important in bone formation although there is a possibility that animal protein 
has deleterious bone resorbing effects when consumed in excess 
107
. The main functions of 
protein are growth; tissue repair, and muscle function and a spare source of energy when 
carbohydrates are lacking in the diet 
107
. The current Dietary Reference Intake (DRI) is 0.8mg/kg 
body weight 
108
. Protein is involved in bone metabolism, in the formation of the organic bone 
matrix as collagen, in mineralization, and in calcium intake and metabolism 
109
. Past studies 
report that diets high in protein increased urinary calcium loss, but it is unknown whether the 
calcium excreted is purely from bone or from increased calcium absorption 
110
. There are 
mechanisms that explain the possible deleterious effects of foods rich in animal protein. 
Considering that the extracellular fluid pH is tightly controlled between 7.35 and 7.45 
111
, hepatic 
oxidation of sulfur-containing amino acids (e.g. methionine and cysteine) to sulphuric acid and 
ammonium ions causes a reduction in blood pH 
107
. Also, consumption of protein from meat, 
dairy, and legumes has potential to cause renal acid loads resulting in diet-induced, low grade 
metabolic acidosis 
112
. Both processes induce bone loss due to the key role played by bone 
minerals in buffering the net acid load of the diet 
107
. A diet low in protein however, is associated 
with reduced intestinal calcium absorption, which results in increased serum PTH, a situation 
that leads to bone resorption 
110
. Dietary alkali load is achieved through consumption of 
vegetables and fruits since potassium, sodium; calcium and magnesium generate bicarbonates or 
citrate salts which lower extracellular pH 
112, 113
. However, protein intake requires careful 
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balance due to its importance in other body processes including growth through regulation of 
insulin-like growth factor (IGF), a recognized mediator of anabolic processes 
107
. Studies on 
effects protein on bone are inconsistent, although beneficial effects have been reported in high 
protein intake in the setting of adequate calcium intake 
107
. 
Calcium 
Calcium is an essential skeletal component that plays a critical role in many other body 
functions. Calcium is plays a key role in blood coagulation, enzyme activity, muscle contraction, 
membrane permeability, and hormones secretion 
114
. A constant concentration of calcium is 
required in extracellular fluids to maintain health in humans. Blood calcium homeostasis is 
maintained through the endocrine system mainly by regulation of vitamin D, parathyroid 
hormone and calcitonin 
114
. As mentioned earlier, calcium is stored in the bone and when dietary 
calcium is inadequate or its absorption impaired, the body withdraws calcium from bone, hence 
loss of bone mineral density. There is clear evidence that an increased level of blood calcium 
causes low levels of PTH and vice versa 
114
. Moreover, high blood levels of phosphorous inhibit 
the formation of 1, 25 (OH) 2D resulting in low blood calcium and PTH stimulation 
114
. Calcium 
supplementation is reported to be beneficial to postmenopausal women by increasing BMD, 
because calcium deficiency causes an increase in PTH levels and PTH action aggravates bone 
loss 
115
. Calcium can be intravenously infused to bring PTH levels to normal 
115
. 
Vitamin D 
Vitamin D is a fat soluble prohormone that is obtained from sun exposure, food, and 
supplements in a biologically inert form. Vitamin D must undergo two hydroxylation reactions to 
be activated in the body. The two inert forms of vitamin D are ergocalciferol or vitamin D2 and 
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cholecalcificerol or vitamin D3 which must be converted to the active form, 1,25 (OH) 2D 
5
. It is 
believed that the body stores of vitamin D are best reflected in the serum levels of their 
precursors D2 and D3 (25-OH-vitamin D). Several major mechanisms by which vitamin D affects 
bone have been identified. First, the active form of vitamin D works together with PTH and 
calcitonin to regulate calcium homeostasis. These hormones regulate calcium homeostasis by 
increasing and decreasing calcium absorption in the gut and modulating bone remodeling and 
growth 
5
. Secondly, vitamin D reduces fracture risk by improving muscle function 
115
. 
Furthermore, in humans, decreased levels of 25-OH-vitamin D, below 30ng/ml (80 nM) is 
associated with elevated levels of PTH 
55
 resulting in bone turnover and ultimately bone loss. 
Vitamin D has also been reported to stimulate production of OPG in human osteoblast lineage 
cells which in turn suppresses osteoclastogenesis 
116
.  
Micronutrients 
Micronutrients, magnesium (Mg), fluoride (F), and Vitamin K are considered vital in 
bone health. Fluoride is mainly found in calcified bone tissue and plays key role in dental health 
117
. Magnesium deficiency is a recognized risk factor for osteoporosis 
118
 possibly because 
approximately two thirds of the mg found in the body is stored in the bone and is an essential 
cofactor for over 300 enzymes 
118
.  
Vitamins are essential factors for metabolism, growth, reproduction, and immunity 
119
. 
Vitamins, A, K, E, and C have shown bone protective effects in epidemiological studies 
77
. Some 
vitamins are vital in the development and maintenance of bone health. Vitamin A for instance is 
important for bone formation, but excess intake may lead to toxicity associated with bone loss 
and a higher risk for hip fracture 
120
.  
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Recent work has focused on the role of vitamin K in bone health since its role in blood 
coagulation is fairly well understood 
121
. Evidence suggests that vitamin K is essential for the 
post-translational conversion of glutamyl residues to carboxyglutamyl (Gla) residues in vitamin 
K-dependent proteins prothrombin and osteocalcin 
121
. Furthermore, vitamin K is an important 
factor in the modulation of osteoblastogenesis and osteoclastogenesis in bone marrow cells via 
the RANKL pathway 
32
. 
Vitamin E, contained in small amounts in most fruits and some vegetables, is a strong 
antioxidant that scavenges reactive oxygen species protecting cells from oxidative damage. 
Vitamin E supplementation is associated with maintaining BMD 
122
. Epidemiological studies 
propose that low dietary intake of vitamins E and C is linked to increased hip fracture in smokers 
123
. 
Vitamin C, also known as ascorbic acid, is found in most fruits and vegetables. Vitamin 
C is a key antioxidant vitamin recognized as an elemental component in the formation and 
maturation of stable collagen in connective tissue 
77
. It is also required in hydroxylation of lysine 
and proline necessary for collagen formation. Overt vitamin C deficiency is characterized by 
non-organized and thinner growth plate, thinner trabecular network, very low collagen synthesis, 
and decreased differentiation of osteoblasts from mesenchymal cells
77
. Studies have shown that 
through vitamin C, TGFβ may act to stimulate osteoblast differentiation resulting in increased 
bone formation 
124
. Low vitamin C intake in growing guinea pigs results in higher than normal 
bone turnover 
125
. Several epidemiological studies have found an association between dietary 
vitamin C intake and BMD in postmenopausal women 
126
. 
Current evidence suggests that antioxidants both dietary and endogenous and especially 
vitamin C plasma concentrations are reduced in elderly osteoporotic women 
123
. In an 
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observational study of 533 non-smokers, randomly selected postmenopausal women, Pasco and 
others 
123
 studied the associations among the use of antioxidant supplements, vitamins C and E, 
serum levels of biochemical markers of bone turnover CTX-1 and BSAP, and whole body BMD. 
This study found that only 22 participants were users of vitamin C and E, and duration of 
antioxidant supplement use was negatively associated with age-adjusted and weight-adjusted 
serum CTX-1. The results further showed that mean CTX-1 levels were 0.022 units lower for 
each year of exposure and differences were not significant for adjusted serum BSAP or whole 
body BMD 
123
. Dietary supplementation with antioxidant vitamin E or C suppresses bone 
resorption in nonsmoking postmenopausal women 
123
.  
FRUITS AND HEALTH 
It is widely accepted that a diet high in plant-based foods decreases the risk for many 
degenerative diseases 
127
. Consumption of fruits and vegetables has been associated with reduced 
incidence of chronic inflammatory conditions including various cancers 
128, 129
, cardiovascular 
disease, 
130,131
, and osteoporosis 
132
.Current efforts in human health are focused on preventing 
diseases that may progress due to oxidative stress. Oxidative stress leads to cell and tissue 
damage and is the etiology of many chronic diseases including cardiovascular conditions and 
osteoporosis 
133
. There is growing evidence that dietary antioxidants from fruits and vegetables 
reinforce the endogenous antioxidant defense systems present in the body and prevent chronic 
diseases 
127
.  
Fruits are a source of bioactive components including, minerals, fiber, vitamins and 
phytochemicals 
134
. Vitamins found in fruits include, C, A, E, K and B1, B2, B6, niacin, folate, 
and pantothenic acid 
134
. Minerals contained in fruits are essential cofactors in formation of many 
enzymatic processes and metabolic processes hence adequate amounts prevent chronic 
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conditions 
134
. Most fruits contain important bone forming minerals, potassium, calcium, 
phosphorus, magnesium and sodium 
135
. Other important minerals found in varying amounts in 
fruits include: selenium, manganese, copper, and zinc 
134
. Soluble and insoluble fibers found in 
fruits slow down digestion hence increasing absorption of nutrients. For example, Ohta and 
others noted increased absorption of magnesium and calcium administered together with dietary 
fructooligosaccharides 
136
 
Fruits also contain phenolic compounds with superoxide scavenging capacities 
127
. 
Phenolic compounds function as antioxidants by easily donating hydrogen atoms from their 
aromatic hydroxyl groups and by supporting unpaired electrons 
137
. Phenolic compounds 
classified as antioxidants must meet two basic conditions when present at low concentrations 
relative to the substrate: i) delay, retard, or prevent oxidation and ii) the radical formed must be 
stable 
138
. 
Phenolic compounds account for 80% of total antioxidant capacity in most fruits and 
vegetables 
139
. The antioxidant capacities i.e. oxygen radical absorbance capacity (ORAC), of 
certain phenolic compounds including flavonoids may be stronger than vitamin E and C based on 
molar concentrations 
139
. Using eight healthy elderly women, Cao et al 
119
 investigated the effects 
of consuming either 240g of strawberries, 294g of spinach, 300mls of red wine, or 1250mg of 
vitamin C on serum antioxidant capacity. The study confirmed increased serum antioxidant 
capacity from all four foods 
119
. 
EFFECTS OF PHENOLIC COMPOUNDS PRESENT IN BLUEBERRY AND 
BLACKBERRY ON HEALTH 
The major groups of phenolic compounds present in berries are reported to be flavonoids, 
flavonols, flavanols, ellagitannins, gallotannins, proanthocyanidins, and phenolic acids 
140
. 
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Flavonoids include one of the largest and most important groups of the phenolic compounds, the 
anthocyanins, which are prevalent in berries reaching 10g/kg in some varieties. In the United 
States the most current estimation of anthocyanin intake is 12mg/day 
141
. Blueberries contain 
mainly the flavonoids: anthocyanins, catechin, epicatechin, quercetin, kaempferol, myrecetin, 
and phenolic acids (e.g., gallic acid, p-hydroxybenzoic acid, chlorogenic, p-coumaric, caffeic, 
ferulic, and elagic acids)
 142, 143
. Blackberries on the other hand contain primarily anthocyanins, 
flavonols, and hydrolysable tannins, chiefly ellagitannins 
144
. Anthocyanins display biological 
activities including antioxidant, anti-inflammatory, antimicrobial and anti-carcinogenic activities 
145
. These reports are especially useful in the prevention of obesity-induced inflammation which 
is a major risk for cardiovascular diseases, type II diabetes, and certain types of cancer 
145
. 
Anthocyanins are reported to improve vision and induce apoptosis of cancer cells 
146
. 
Anthocyanins have also demonstrated positive effects on blood vessels and platelets that may 
reduce the risk of coronary heart disease 
146
. For example, antioxidant activity of anthocyanins 
from blackberries, red raspberries, sweet cherries, blueberries and strawberries inhibited human 
LDL oxidation 
144
. Animal studies show that a type of anthocyanins, cyanidin-3-glucosides 
improved hyperlipidemia and hyperglycemia in mice fed a high-fat diet 
145
.  
Anthocyanins elicit anti-inflammatory properties by suppressing the production of pro-
inflammatory mediators such as nitric oxide and prostaglandin E2 through nuclear factor- kappa 
B inactivation in lipopolysaccharide-stimulated macrophages 
145
. Recently blueberry and 
cranberry anthocyanins and hydroxycinnamic acids demonstrated anti-inflammatory properties 
against H2O2 and TNF-α induced damage to human microvascular endothelial cells 
147
. 
Blueberry anthocyanins also inhibited inflammation of neural cells 
148
 and mitigated the effects 
of age related neural behavior decrements 
149
. Joseph and colleagues reported reversal of age 
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related dysfunction using blueberry extract. Eight weeks on 1.86% blueberry diet, forty 19-
month-old adult male rats had improved motor performance on two motor tests that rely on 
balance and coordination 
149
. 
Procyanidins have potential health benefits and are reported to reduce the production of a 
vasoconstrictive peptide endothelin-1 produced by endothelial cells and linked with chronic 
inflammation of the arterial wall 
150
. Moreover, procyanidins known as A-type derived from 
cranberries are known to be protective against urinary tract bacterial infections 
151
, cancer, and 
vascular diseases 
152. Bioactive berry phenolics are exploited in today’s market as food 
supplements. 
BLACKBERRIES AND BLUEBERRIES AND BONE HEALTH 
Animal studies have demonstrated that phenolic compounds from berries scavenge ROS 
formed by phagocytes (i.e. monocytes, macrophages and neutrophils) 
38
 resulting in bone 
resorption 
153
. Polyphenols such as chlorogenic acid, caffeic acid, and rutin in dried plum have 
prevented bone loss in animal models by reducing oxidative stress biomarkers 
154
. Resveratrol 
the major phenolic compound in grapes has potential bone protective properties as demonstrated 
by its ability to increase intracellular bone formation markers in experimental studies 
155
. Dried 
plum and blueberries have some structurally similar phenolic and flavonoids compounds 
156
. 
Recently blueberries have shown bone protective effects in ovariectomized (OVX) rat model of 
postmenopausal osteoporosis. Feeding 5% blueberries (w/w) down regulated mRNA levels of 
three bone matrix proteins: alkaline phosphatase (ALP), tartrate-resistant acid phosphatase 
(TRAP), and collagen type 1 (COL) and significantly improved total bone mineral density 
157
. 
Similarly, supplementation with blackberries at the level of 5% (w/w) protected bone mineral 
density at fourth lumbar vertebra, right tibia, and left femur compared to controls in an 
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ovariectomized rat model of postmenopausal osteoporosis 
158
 Although whole berries were 
administered in the blueberry and black berry animal studies, phenolic compounds are thought to 
be the major bioactive compounds responsible for bone health effects. The mechanism is still 
unclear although it is reasonable to speculate that the compounds work by lowering oxidative 
stress.  
METABOLISM AND BIOAVAILABILITY OF ANTHOCYANINS  
Although studies have revealed the human health benefits of anthocyanins, low 
bioavailability has been suggested by the low concentration observed in plasma and urine after 
ingestion of anthocyanins 
159
. Anthocyanins have been detected in human plasma in glycosylated 
form by HPLC analysis 
160
. After 1.5g of anthocyanin intake given as an elderberry extract, Cao 
and Prior 
161
 reported a maximal plasma anthocyanin concentration of 100μg/L after 30mins in a 
human study. The anthocyanins were detected in their glycosidic forms 
161
.  
Jian and colleagues 
159
 evaluated the impact of chemical structure of anthocyanins on 
absorption and metabolism. Anthocyanin-rich extracts fed to rats for 3 months demonstrated that 
anthocyanin diglucosides are better absorbed than their corresponding monoglucosides 
159
. The 
study also showed that intact acylated anthocyanins are absorbed into plasma and excreted 
through urine 
159
. 
Matsumoto and others 
162
 fed a single dose of 3.57mg cyanidin-3-glycoside per kg body 
weight to subjects and detected within 2 hours in plasma (0.120 nM) and urine samples (0.11% 
of total ingested) 
162
. The anthocyanins in this study were from blackcurrant concentrate. 
Investigating the bioavailability of anthocyanins from red wine, Lapidot and others traced 
anthocyanins in human urine after consumption of 300mL of red wine containing approximately 
218mg of anthocyanins. An estimated 1.5 - 5.1% of anthocyanins were recovered in urine 12 
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hours after consumption and highest anthocyanin levels were reached within 6 hours after 
consumption 
163
. Consumption of 1.2g anthocyanins from freeze-dried wild blueberry powder 
led to identification of 11 different anthocyanins in serum 
160
. Maximal serum concentration 
reached 4 hours later revealed the most abundant compound, cyaniding-3-glucoside ranged from 
5.43-16.9ng/mL. Others identified include malvidin 3-galactoside, malvin-3-glucoside and 
delphinidin-3-glucoside accounting for 27, 20 and 10 % of the total respectively 
160
.  
A study by Mazza et al., compared serum antioxidant status of subjects after consumption 
of blueberry powder plus a high fat meal to serum antioxidant status after a high fat meal without 
blueberry powder 
160
. Subjects consumed a McDonald’s meal containing 853 calories, (46.7g of 
fat-15.5g saturated fat) for the study 
160
. Blueberry consumption was associated with a significant 
increase in serum lipid-soluble antioxidant status and prevented a decrease in serum antioxidant 
capacity postprandial 
160
. Unlike other flavonols, such as quercetin glycosides, the bioavailability 
of anthocyanins has been found to be consistently low across all studies. The amount appearing 
in urine is often 0.1% of ingested dose 
141
. Low bioavailability of anthocyanins from red grape 
juice, elderberry extract, boysenberry concentrate, and blackcurrant has been confirmed 
141
. The 
highest anthocyanin recovery reported to date is a urinal excretion of 1.80% after consumption of 
200g of strawberry yielding 179 μM of pelargonidin-3-glucoside 164. 
Therefore, current evidence suggests that anthocyanins are absorbed rapidly and reach 
maximal plasma concentration 15-60 minutes after consumption, and they are excreted 6-8 hours 
later 
141
. The quick appearance in the circulatory system has led to the interpretation that 
anthocyanins are absorbed in the stomach 
141
. Although gastric absorption of anthocyanins is 
proven 
165
, evidence also suggests that absorption of cyanidin-3-glucoside may occur in the 
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jejuna and duodenal tissue 
166
. There is also evidence that intact anthocyanin glycosides appear 
to be absorbed, distributed, and then excreted in urine 
141
.  
Anthocyanins may accumulate in tissue, and this may explain the apparent contradiction 
of observed benefits and low plasma availability of anthocyanins 
159
. Gut microflora also play a 
role involved in anthocyanin bioabsorption. For example, anthocyanin glycosides are degraded 
by colonic bacteria into aglycones and smaller phenolic compounds 
167
. Aura et al used cyanidin-
3-glucoside and rutinoside as inoculums in human fecal microbiota and reported that through 
deconjugating enzymes, rutinoside is metabolized into cyanidin-3- glycoside. Additionally, gut 
microflora were found to deglycosylate anthocyanins and produce protocatechuic acid as the 
major metabolite 
167
. At present, it is unclear how anthocyanins and their metabolites enter 
circulation, are distributed to tissues in vivo and exert beneficial health effects 
141
. However, cell 
culture studies have demonstrated that anthocyanins can penetrate mammalian cell walls. These 
experiments show their potential bioactivity such as protection against oxidative stress, induction 
of apoptosis, and changes in inflammatory response in vitro 
141, 168
. 
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III. THE BLACKBERRY FRUIT: A REVIEW ON ITS COMPOSITION AND 
CHEMISTRY, METABOLISM AND BIOAVAILABILITY, AND HEALTH 
BENEFITS                        
  
ABSTRACT 
Blackberry (Rubus sp.) fruit contains high levels of anthocyanins and other phenolic compounds, 
mainly flavonols and ellagitannins, which contribute to its high antioxidant capacity and other 
biological activities. Blackberry phenolic composition and concentrations are known to be 
influenced by genetics, growing conditions, and maturation. Despite our knowledge of their 
chemistry, research specific to blackberry phenolic compounds’ health benefits, metabolism, 
bioavailability, and mechanism by which they confer health benefits is scarce. Blackberry 
phenolic compounds have protective effects on age-related neurodegenerative diseases, and bone 
loss in vivo, and can inhibit LDL and liposomal oxidation in vitro. Blackberry extracts have also 
exerted anti-mutagenic effects in vitro and in vivo by modifying cell signaling pathways and 
suppressing tumor promotion factors. However, the anti-obesity, anti-diabetic, antimicrobial, and 
anti-inflammatory properties of blackberry phenolic compounds need investigation. Similarly, 
studies that elucidate the in vivo physiologically effective concentrations of blackberry phenolic 
compounds are necessary. 
KEYWORDS: blackberry, anthocyanins, bioavailability, flavonoids, health benefits. 
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INTRODUCTION 
Worldwide commercial production of blackberry (Rubus sp.) is estimated to be 
approximately 154,578 tons annually (1). North America, Europe, Asia, South America, Oceania 
Central America and Africa [in descending order of tons cultivated] are the main regions for 
blackberry production (2). Wild blackberries are also cultivated in considerable amounts, and in 
some regions may negatively affect the net sales of commercially cultivated fruit (2). 
The “berry” weighs from 3-12 g depending on variety, and is best described as an 
aggregate fruit made up of several drupelets, each containing a seed (1). Blackberries are mostly 
consumed fresh but can be processed and sold as individually quick frozen packs, bulk frozen, 
seedless or seed puree, freeze-dried, or as juice or concentrate (1). In industry, blackberries are 
used for the production of dietary supplements, ice-cream, jam, marmalade and other 
confectionaries (3). 
Blackberry is a fruit of interest because of its high content of anthocyanins and 
ellagitannins (ETs) as well as other phenolic compounds that contribute to its high antioxidant 
capacity (4). Several studies document the high antioxidant activity of blackberries based on 
their oxygen radical absorbance capacity (ORAC) compared to other fruits (4). In fact, 
blackberries’ medicinal qualities have been known since the 16th century in Europe where they 
were used to treat infections of the mouth and eyes (5).  
Epidemiological and clinical studies (6-10) suggest that consumption of anthocyanins and 
other flavonoids found in most fruits and vegetables may decrease the risk of obesity, coronary 
heart disease, degenerative conditions, and various types of cancer. These health benefits and 
mechanisms by which anthocyanins confer them have been explored in vitro (7, 11, 12) and in 
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animal models (13-16). This review presents current knowledge on the chemistry, composition, 
metabolism and bioavailability, and health benefits of blackberries.  
NUTRIENT COMPOSITION 
Blackberry chemical composition varies based on variety, growing conditions, stage of 
ripeness, and harvest and storage conditions (17). In addition to valuable polyphenolic 
compounds, blackberries contain carbohydrates, and several essential vitamins and minerals 
(Table 1) (18). 
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The principle sugars in blackberries are glucose, fructose and sucrose and their ratios 
differ among cultivars (19). The principle sugars are glucose and fructose in the ratio of 
approximately 3.24 - 2.88g/100g FW and 0.81-1.17 g/100 g FW glucose to fructose. Sucrose 
content is estimated to be 0.24 g/100 g FW (19). Levels of glucose, fructose, total sugars and 
total soluble solids increase markedly as the fruit ripens from light red to dark bluish purple 
stages (20). 
Blackberries contain malic acid as the primary organic acid although different acids 
including ascorbic acid have been detected in the fruit (3). Fan-Chiang (19) reported the 
following averages of nonvolatile organic acids from 52 samples of blackberry: 280 mg/100g 
FW malic acid; 293 mg/100g FW lactoisocitric acid; 599 mg/100g FW isocitric acid; and 572 
mg/100g FW citric acid. Furthermore, trace amounts of shikimic, fumaric and succinic acids 
were identified (19). These organic acids in blackberries are important for stabilizing 
anthocyanins and ascorbic acid, and extending the shelf-life of fresh and processed berries (17). 
The balance in proportion of organic and phenolic acids in berries is evaluated for overall index 
of fruit quality, whereas low pH is considered an indicator of poor quality (17). Another 
important quality index for berries is the ratio of total soluble solids to total titratable acidity. 
This ratio   
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Table 3.1. Chemical composition of blackberries From the U.S. Department of 
Agriculture Nutrient Database (18) 
ND, not detected 
  
Proximates and 
carbohydrates  vitamin content  mineral content  
water (g) 88.20 
total ascorbic acid 
(mg) 21.00 calcium (mg) 29.00 
energy (Kcal) 43.00 thiamin (mg) 0.02 iron ( mg) 0.62 
protein (g) 1.39 riboflavin (mg) 0.03 magnesium (mg) 20.00 
total lipids (g) 0.49 niacin ( mg) 0.65 phosphorus (mg) 22.00 
ash (g) 0.37 pantothenic acid (mg) 0.28 potassium (mg) 162.00 
carbohydrate (g) 9.61 vitamin B6 (mg) 0.03 sodium (mg) 1.00 
total fiber (g) 5.30 total folate (µg) 25.00 zinc (mg) 0.53 
total sugars (g) 4.88 vitamin B12 (µg) ND copper (mg) 0.17 
sucrose (g) 0.07 vitamin A (IU) 214.00 manganese (mg) 0.65 
glucose (g) 2.31 α-tocopherol (mg) 1.17 selenium (mg) 0.40 
fructose (g) 2.40 β- tocopherol (mg) 0.04   
maltose (g) 0.07 γ-tocopherol (mg) 1.34   
galactose (g) 0.03 Δ-tocopherol (mg) 0.90   
starch (g) ND vitamin K (µg) 19.80   
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Table 3.2. Total Phenolics and Total Anthocyanin Values of Blackberries across Studies 
a
Calculated as cyanidin 3-galactoside equivalents; 
b
Calculated as cyanidin 3-glucoside 
equivalents FW: fresh weight; NA not available 
  
total phenolics 
(mg GAE/100) 
g FW) 
total anthocyanins 
(mg/100 g FW) 
number of cultivars source 
NA 114-242
 b
 6 (4) 
292-446 NA 6 (23) 
248-633 NA 12 (27) 
NA 70-201
b
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(28) 
NA 58-219
a
 12 (29) 
822-844 154-225
 b
 2 (30) 
NA 80-230
 b
 27 (31) 
418-555 111-123
 b
 2 (32) 
NA 133-172
 b
 3 (33) 
193-352 67-127
 b
 7 (34) 
495-583 95-155
 b
 2 (35) 
221 -342 38-72
 b
 5 (36) 
114-178 31-118
 b
 4 (37) 
NA 83-326
 b
 16 (38) 
 682-1056 131-256 
b
 11 (39) 
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increases in blackberries as the fruit ripens from purple to dark bluish purple stages, reflecting 
the large increase in sugars and decline in organic acids (20). 
Blackberries contain cell wall hydrolase and oxidase enzymes, such as polyphenol 
oxidase and peroxidase, which contribute to deterioration of quality in fresh, damaged, or pureed 
fruit (17). Enzyme activity results in loss of texture, brown pigment formation, and destruction of 
phytochemicals that affects acceptability of particularly fresh fruit (17). Refrigeration, reduced 
oxygen, addition of enzyme inhibitors, pH modification and addition of reducing agents to 
control secondary oxidation are some of the techniques currently used to control enzyme activity 
(17). 
PHENOLIC COMPOSITION 
Blackberries are a rich source of polyphenolics including, anthocyanins (21), ETs (22), 
flavonols (23), flavan-3-ols, and procyanidins (24). The berries also contain appreciable levels of 
phenolic acids (25) and low levels of lignans (26). Total phenolics in blackberries have been 
shown to range from 114 to 1056 mg/100 g fresh weight (FW) (Table 2).Besides genetics, fruit 
maturity can influence levels of total phenolics in blackberries. For example, analysis of three  
blackberry cultivars namely ‘Chester Thornless’, ‘Hull Thornless’, and ‘Triple Crown’ berries 
demonstrated that total phenolic content significantly decreases as the fruit matures from the 
green to ripe stages (33). However, in another study involving tropical highland blackberries 
levels of total phenolics fluctuated as the fruit ripened from light red (580 mg/100g FW) to 
purple (460 mg/100g FW) to dark bluish purple (520 mg/100g FW) stages (20).  
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Anthocyanins 
Anthocyanins are the phenolic compounds responsible for the red to purple to black 
pigments of fruits and vegetables (28) and are recognized for their potential health benefits (7). 
Anthocyanins are flavonoids by classification and are predominantly found in berries and red 
grapes (4). They are anthocyandinins glycosylated with one or more sugar moieties at the C3 
position of the flavan structure (25). Approximately 94% of blackberry anthocyanins occur in 
nonacylated form and 90% of these exist as monoglycosides while 10% are found as 
diglycosides (21) (Table 3). 
Blackberry anthocyanins are mainly cyanidin derivatives with glucose, rutinose, xylose 
and arabinose moieties attached at C3 (21, 25) (Figure 1). Blackberry anthocyanins identified 
include: cyanidin 3-glucoside, cyanidin 3-galactoside, cyanidin 3-xyloside, cyanidin 3-dioxalyl-
glucoside, cyanidin 3-rutinoside, cyanidin 3-sophoroside and cyanidin 3-glucosylrutinoside 
cyanidin 3-arabinoside, malvidin 3-arabinoside, perlargonidin 3-glucoside, cyanidin 3-(3-
malonyl) glucoside and cyanidin 3-(6-malonyl) glucoside (40, 41). Cyanidin 3-dioxaloyl-
glucoside, a zwitterionic anthocyanin is unique to blackberries (42). Studies show that 
anthocyanin content of blackberry varies due to differences in variety, environmental conditions, 
and cultivation site, degree of ripeness and processing (43). Cho et al. reported total anthocyanin 
content of 6 blackberry genotypes to range from 114.4 mg/100g fresh weight (FW) to 241.5 
mg/100g FW (4). In a similar study, Fan-Chiang and Wrolstad found monomeric anthocyanin 
content in 51 cultivars ranged from 70 to 201 mg/100 g FW and, the cyanidin derivatives 
dominated in all samples with a mean peak area of 83% (28).   
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Table 3.3 A Summary of Anthocyanins, Flavonols, and ETs Identified in Blackberries 
anthocyanins flavonols ellagitannins 
cyanidin 3-galactoside quercetin 3-galactoside sanguiin H-6 
cyanidin 3-glucoside quercetin 3-glucoside lambertianin C 
cyanidin 3-arabinoside,  quercetin 3-rutinoside pedunculagin 
cyanidin 3-xyloside quercetin 3-xylosylglucuronide lambertianin D 
alvidin 3-arabinoside quercetin 3-glucosylpentoside galloyl-bis-HHDP glucose 
perlargonidin 3-glucoside kaempferol 3-glucuronide sanguiin H-10 isomer (2) 
cyanidin 3-rutinoside kaempferol 3-glucoside sanguiin H-6 minus gallic acid moiety 
cyanidin 3-sophoroside kaempferol 3-galactoside lambertianin C minus ellagic acid moiety 
(4) cyanidin 3-glucosylrutinoside kaempferol 3-xylosylglucuronide galloyl-HHDP glucose 
cyanidin 3-(3-malonyl) glucoside  quercetin 3-glucuronide sanguiin H-2 
cyanidin 3-(6-malonyl) glucoside quercetin 3-О-[6-(3-hydroxy-3-methyl-
glutaroyl)-B-D-galactoside 
sanguiin H-6 plus gallic acid moiety 
 myricetin castalagin/vescalagin 
 quercetin 3-methoxyhexoside ellagic acid 
 quercetin 3-oxalylpentoside methyl ellagic acid pentose conjugate (2) 
Compiled from the following references (25, 32, 52). 
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Figure 3.1. Chemical structures of blackberry anthocyanidins  
 
 
 
  
Anthocyanidin R1 R2 R3 
Cyanidin  OH OH H 
Pelargonidin H OH H 
Malvidin OCH3 OH OCH3 
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Figure 3.2. Chemical structures of blackberry flavonol 
 
  
Flavonol R1 R2 
Quercetin OH:  H 
Kaempferol  H  H 
Myricetin OH:  OH 
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Moreover, cyanidin derivatives may vary in blackberries due to genetic differences (28). This 
concept was demonstrated by Fan-Chiang et al. (28) using 51 samples of blackberries as follows: 
cyanidin 3-glucoside 44% to 95%; cyanidin 3-rutinoside trace amounts to 53%; cyanidin 3-
xyloside, undetectable amounts to 11%; cyanidin 3-(malonyl) glucoside, trace amounts to 5%, 
and for cyanidin 3-dioxaloylglucoside, undetectable amounts to 15% (25, 28).  
Similarly, six blackberry genotypes analyzed by Cho et al. (4) demonstrated that 
distribution of cyanidin aglycones in each variety ranged from 75% to 84% for cyanidin 3-
glucoside, 1% to 12% for cyanidin 3-rutinoside, 4% to 8% for cyanidin 3-dioxaloyglucoside, 3% 
to 8% for cyanidin 3-dioloylglucoside and 2% to 3% for cyanidin 3-(malonyl) glucoside (4, 25). 
Reyes-Carmona et al. (44) observed similar differences when comparing three cultivars: Marion, 
Evergreen and Comanche berries. Unlike Marion and Evergreen, Comache contained higher 
amounts of cyanidin 3-rutinoside than cyanidin 3-glucosides; however, Comache’s content of 
cyanidin 3-glucoside was still higher than Evergreen and Marion berries. Furthermore, malvidin 
3-glucoside was identified in Marion and Evergreen, but not in Comanche berries (44). 
Anthocyanins are synthesized during blackberry ripening resulting in the development of a dark 
bluish purple color. Consistent with visual color change total anthocyanins increase markedly as 
the fruit ripens from pink/light red to dark bluish purple stages (20, 33). 
Flavonols 
The structure of flavonols entails a double bond at C2 and C3, a hydroxyl group at C3 
and a ketone group at C4 of the C ring of the flavan nucleus (25) (Figure 2). Quercetin, myricetin 
and kaempferol are the most commonly identified flavonols in berries; their main difference is 
the number and position of OH groups at C3 and C5 (45). The sugars commonly attached at the 
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C3 position are glucose and galactose, but arabinose, rhamnose, rutinose and xylose may also be 
found (45).  
Blackberries contain appreciable amounts of flavonols found exclusively in the fleshy 
part of the drupelet (30) and occur mostly in glycosylated form (23). Reported values for total 
flavonols  calculated as rutin equivalents  are  as follows: 12 to18 mg/100 g FW, 4 to 9 mg/100 
FW,  not detectable to 10 mg/100 g FW, 10 to 16  mg/100 FW, 10 to 16  mg/100 FW and 11-30 
mg/100 FW (4, 23, 30, 32, 35, 46). 
Blackberries have a complex flavonol profile due to the occurrence of nine quercetin and 
three kaempferol derivatives as well as two acylated quercetin-derived compounds (Table 3). In 
addition, quercetin 3-xylosylglucuronide, a different flavonol is reported in some blackberry 
varieties (43). According to Cho et al. (23) quercetin 3-galactoside and quercetin 3-glucoside are 
the main flavonols in five blackberry genotypes, although a few varieties contain high levels of 
the acylated form of quercetin 3-[6-(3-hydroxy-3-methylglutaroyl)]-β-galactoside (23). The 
occurrence of kaempferol and myricetin is not consistent for all blackberry genotypes probably 
due to genetic differences (4, 39, 47). Bilk and Sapers (48), reported that ripe fruits of thorn 
blackberry (Rubus spp.) contain 0.5 to 3.5 mg/100g FW and 0.1 to 0.3 mg/100g FW of quercetin 
and kaempferol respectively (48), while Sellappan and colleagues (32) reported 9.9 mg/100g of 
myricetin in Georgia-grown blackberries. Levels of total flavonols in tropical highland 
blackberries are reported to decline as the fruit ripens from light red (30 mg/100g FW) to dark 
bluish purple (14 mg/100g FW) stages (20).  
Phenolic acids  
Phenolic acids in blackberry fruit range from 7 to 64 mg/100 g FW and are mainly 
hydroxybenzoic acid and hydroxycinnamic acids. These acids occur in conjugated forms of 
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esters and glycosides, but rarely as free acids (25). Esters make up 53.1% of total phenolic acids 
while glycosides and free acids account for 43.6% and 3.3% respectively (49). Blackberry 
hydroxybenzoic acids include: p-hydrobenzoic, protocatechuic, gallic, vanillic, salicylic and 
gentisic acid. Glycosidic and ester forms of salicylic acid are the most common (49).  
Caffeic, m-coumaric, p-coumaric and ferulic acid are hydoxycinnamic acids found in 
blackberries in free, ester and glycosidic forms. The ester forms of m-coumaric, 3,4-
dimethoxycinnamic  and hydroxycaffeic acids are predominant (49). Blackberry hydroxybenzoic 
and hydroxycinnamic acid derivatives have been classified as follows: chlorogenic acid, 
neochlorogenic acid, glucose esters of caffeic, p-coumaric, ferulic, and gallic acids, as well as 
protocatechuic acids and the β-D-glucosides of p-coumaric and p-hydroxybenzoic acids (50) 
Ellagic acid (EA) is a hydroxybenzoic acid, but most of EA found in blackberries is in 
the form of ETs which is a different class of phenolics. Blackberry EA calculated as “ellagic acid 
equivalents” following acid hydrolysis has been reported in several studies to range from: 2 to 4 
mg/100 g FW (30), 2 to 34 mg/100 g FW (49), 12 to 18 mg/100 g FW (46), and 21 to 25 mg/100 
g FW (37), 30 to 34 mg/100 g FW (32), and 59 to 90 mg/100 g FW  (35). Ellagic acid derivatives 
are reported to decline as blackberries ripen from light red (30 mg/100g FW) to dark bluish 
purple (20 mg/100g FW) stages (20).  
Tannins 
Tannins are a group of polyphenolic compounds found in many berry fruits and include 
oligomeric and polymeric constituents (41). Tannins are known to be anti-nutritional because the 
tannins bind to –NH groups of peptides, precipitate them and prevent their hydrolysis in the 
stomach (41). For example flavan-3-ols (catechins) and flavan-3, 4-diols (leucoanthocyanins) 
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interact with proteins, starch and digestive enzymes, to form less-digestible complexes resulting 
in reduced absorption of these nutrients (51). 
Tannins are classified into two groups based on their structure: condensed tannins .i.e. 
proanthocyanidins and hydrolyzable tannins i.e. ellagitannins (ETs) and gallotannins (41). 
Proanthocyanidins are oligomers and polymers of flavonoids and in particular flavan-3-ols 
whereas the hydrolyzable tannins are glycosylated gallic acids (41). Berry fruits contain two 
major types of proanthocyanidins: procyanidins and propelargonidins. The procyanidins and 
propelargonidins are composed exclusively of (epi) catechin and (epi) afzelechin units 
respectively (25). Based on the hydroxylation pattern of A- and B-rings, proanthocyadinins (MW 
2000-4000Da or more) are categorized into three groups: procyanidins, prodelphinidins and 
propelargonidins (41). There are about 50 procyanidins identified from plants (41). Procyanidins 
in blackberries have been found to be predominantly epicatechin units linked through C4→C8 
bond, the so called “B-type” linkage, with an average degree of polymerization of 3.2 (24). 
Blackberries contain monomers (7.3 mg/100g FW), dimers (6.7 mg/100g FW), trimers (3.6 
mg/100g FW), tetramers to hexamers (7.3 mg/100g FW), heptamers to pentamers (4.2 mg/100g 
FW), and low levels of polymers (1.5 mg/100g FW) resulting in a total procyanidin content of 
27.0 mg/100g FW (24). Hydrolysable tannins, specifically ETs of varying molecular weight are 
found in blackberries in appreciable amounts (25).  Ellagitannin and EA derivatives are 
identified using high performance liquid chromatography mass spectrometry (HPLC-MS), and 
results are commonly reported as “ellagic acid equivalents” due to the diversity of ETs in berries, 
and lack of ellagitannin standards (25).  
Blackberry ET structures are complex, large, and diverse, which presents a challenge in 
their characterization (52) (Table 3). The basic structure of ETs consists of a glucose core 
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esterified with hexahydroxydiphenic acid (HHDP) (Figure 3). When hydrolyzed by either an 
acid or a base, HHDP is changed to the dilactone form, EA (25). An ET bis-HHDP 
glucopyranose is also known as pedunculagin, and the galloylated form, or galloylbis-HHDP 
glucopyranose is also known as casuarictin or potentillin (52). Moreover these compounds can 
be found as α-or β-glucopyranosides (53) with the HHDP units R or S configurations relative to 
C4 and C1 of the glucose (54). ETs found in blackberry fruit and leaves are mostly polymerized 
forms of the galloyl-bis-HHDP (52).  
Blackberry seeds contain the highest amount of ETs and EA compared to other parts of 
the fruit i.e. the torus, and flesh (30). In fact, 88% of the ETs and EA is found in the seeds 
compared to only 12% in the pulp. EA derivatives in blackberries range from 1.2 to 3.0 mg/100 g 
whereas ETs range from 51.1 to 68.2 mg/100 mg (46). The seeds of Marion and Evergreen 
blackberry cultivars have higher ellagitannin values than most cultivars containing up to 3230 
and 2120 mg/100 g seed of total ellagic acid, respectively (22). 
Recently, blackberries were investigated by high-performance liquid chromatography-
electrospray ionization-mass spectrometry and matrix-assisted laser desorption/ionization-time 
of-flight mass spectrometry (MALDI-TOF-MS) to identify the ETs (52). The following eleven 
ETs were identified mainly in the seed and torus of the Apache cultivar of blackberries: isomeric 
forms of pedunculagin, castalagin/vescalagin, galloyl-HHDP glucose, lambertianin C, and 
lambertianin D, and galloyl-bis-HHDP glucose, and sanguiin H-6/lambertianin A, EA (52). This 
study also proposed that blackberry fruit may contain sanguiin H-10 (52).  In another recent 
study, ETs and EA conjugates in six blackberry cultivars were identified and quantified using 
ultra high pressure liquid chromatography-quadrapole-time of flight mass spectrometry (UPLC-
Q-TOF-MS) and HPLC-DAD analysis (55). In this study the authors isolated and purified the 
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two major ETs found in blackberries, Lambertianin C and Sanguiin H-6 and used them as 
calibration standards. Besides Lambertianin C and Sanguiin H-6, which account for 67% of the 
total ETs, they identified twelve additional ETs, as well as EA and two EA conjugates. The 
levels of total ETs in the six cultivars ranged from 84.7 to 130.4 mg/100g FW, while total EA 
conjugates ranged from 12.8 to 27.4 mg/100g FW. The ETs, potentillin, pedunculagin and 
casuaricitin have also been identified in leaves and shoots of blackberries (56). Notably, ET and 
ellagic content of blackberries is affected by maturation. For instance, in the tropical highland 
blackberry cultivar, Rubus adenotrichus known to have the highest amount of ETs in an edible 
fruit when light red (380mg ellagic acid equiv/100g   
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A        B  
 
C  D   
Figure 3.3. Structures of gallic acid (A), Ellagic acid (B) and galloyl-bis-HHDP glucose 
(C), Sanguiin H-6/lambertianin A (D) Structures adapted from ref 52. 
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E  
Figure 3.3. continued Structure of lambertianin C (E), structure adapted from ref 52 
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of fresh fruits), the two major ETs Lambertianin C and Sanguiin H-6 decline 33% from light red 
to dark bluish purple stages (20).  
OTHER PHYTOCHEMICALS 
Lignans 
Lignans are biphenolic compounds recognized as phytoestrogens and play an important 
role in prevention of hormone-associated cancers such as breast cancer (57-59), and other 
conditions including cardiovascular disease (60, 61) and osteoporosis (62). Blackberries are 
unique as they contain both secoisolariciresinol (3.72 mg/100 DW) and matairesinol (<0.01 
mg/100 g DW) (26). These lignans are known to be converted to mammalian lignans 
enterolactone and enterodiol by gut microflora (63).  
METABOLISM AND BIOAVAILABILITY 
Although phytochemicals have been studied extensively, there is insufficient information 
regarding changes in content and character of polyphenolic compounds once consumed (64). In 
general, bioabsorption of anthocyanins, which are the most studied and abundant flavonoids, 
occurs very quickly after consumption appearing in plasma 15-60 min postprandial and excretion 
is complete within 6-8 h (65-73). Hollman et al. (74) noted that glycosylation of flavonols and 
their derivatives influence their metabolism, absorption and bioavailability in vivo. Following 
absorption, anthocyanins are metabolized differently based on their aglycones via methylation, 
glucuronidation, and sulfoconjugation (69, 70, 75-77). This pathway uses conjugations with 
glucuronic acid or with sulfate and is considered important in detoxication pathway of many 
drugs and xenobiotic substances (67). These processes are catalyzed by UDP-glucuronosyl 
transferase and sulfotransferase respectively, in the small intestine, liver and or kidney (67). 
Some animal (78, 79) and human studies (73, 80) are consistent with these pathways since 
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glucuronide forms of different subclasses of flavonoids have been found in plasma or urine (81, 
82).  
Anthocyanins are absorbed in intact glycoside forms from the digestive tract into the 
blood circulation system in mammals (83). Although some argue that anthocyanins are too 
hydrophilic to be absorbed into cells of animals and humans (84), there are studies (85, 86) that 
support this pathway for small molecular compounds such as cyanidin-3-glucoside. Other 
polyphenolic compounds such as free simple phenolic acids, aglycones, can also be metabolized 
in the gut and absorbed by enterocytes (87-89). Anthocyanins have also been reported to be 
substrates of bilitranslocase, which is a plasma membrane carrier involved in organic anion 
uptake and mainly expressed at the sinusoidal domain of the liver plasma membrane and in 
epithelial cells of the gastric mucosa (86). Using in situ exposure to tissue, investigators have 
found that absorption occurs in the stomach, jejunum and duodenal tissue possibly through 
interaction with bilitranslocase (65, 85, 90).  
Anthocyanins are also thought to be metabolized via intestinal microflora through 
cleavage of the C-ring to produce a range of phenolic acids which are easily absorbed (75). 
Previously, scientists thought that the absorption of glycosides was not possible in mammals due 
to the lack of suitable β-glycosidases (91), but light has been shed on the role of glycosidases 
from gut microflora in the ileum that aid in metabolism and absorption of glycosides such as 
quercetin glycosides (88, 92). However, this mechanism is unclear since the gut pH affects the 
stability of individual flavonoids and especially anthocyanins, which actually results in increased 
recovery of intact compounds in feces (68, 79, 93). Complex anthocyanins containing di- or 
triglycosides are reported to remain in the gut longer than simple anthocyanins 
(e.g.monoglycosides); and consequently plasma total antioxidant capacity and total anthocyanins 
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remain high longer after feeding (68). It has been suggested that it is by this mechanism that 
anthocyanins provide significant antioxidant protection in the environment of the gut epithelium 
(68). 
Studies on the metabolism of blackberry cyanidin glycosides in particular are limited. In 
general, cyanidin glycosides are absorbed intact in the gut or conjugated with glucuronide or 
methylated in the liver or gut, and either excreted into the bile directly or may enter blood 
circulation and excreted in urine (67, 80, 94). The conjugated compounds identified so far 
include, peonidin monoglucuronide, peonidin-3-glucuronide, and cyanidin 3-glucoside 
monoglucuronide (67). Glucuronidation of cyanidin 3-glucoside has also been established in vivo 
and in vitro (67, 81). It has been suggested that although all four free hydroxyl groups of 
cyanidin have different glucuronidation capacities, glucuronidation of cyanidin-3-glucoside 
occurs most readily at the 3-position (67, 81). Quercetin glycosides which are also abundant in 
blackberries are converted to glucosides resulting in rapid absorption possibly via glucose 
transporters in the gut (92, 95-97).  
Systemic bioavailability of anthocyanins in general is very low across all studies, often 
between 0.02% and 1.8% of the ingested amounts although as low as 0.004 to 0.11% of 
administered dose has been reported (75). A human study by Felgines and others (69) fed 200 g 
of blackberries containing 960 μmol of anthocyanins to five healthy volunteers and found that 
only 0.16% of total amount of anthocyanins ingested were excreted in urine, mainly in the form 
of methylated and glucuronidated conjugates (69). The study identified cyanidin 3-glucoside, 
methylated glycosides, glucuronides of anthocyanidins and anthocyanins, and sulfoconjugate of 
cyanidin, and anthocyanidins.  Monoglucuronides of anthocyanidins accounted for > 60% of the 
total anthocyanins in the urine (69). Findings on the metabolism and bioavailability of 
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polyphenolic compounds may vary due to differences in animal models and experimental 
designs. Additionally, these compounds have different chemical structures and solubility can 
interact with macro and micronutrients, and they also vary in susceptibility to digestion, 
conjugation, methylation, fermentation, and absorption in the gut (91). 
Studies pertinent to the metabolism and bioavailability of blackberry ETs and EA are 
lacking. However, this section will briefly highlight the metabolism and bioavailability of 
various other ETs and EA found in literature and hypothesize that the pathways may be similar. 
A study on punicalagin, an ET found in both blackberries and pomegranate was 
detectable in human plasma and urine after consumption of 180 ml of pomegranate juice (98). 
The juice contained 25 mg and 318 mg of EA and ETs, respectively. The highest concentration 
of EA in human plasma 1hr postprandial was 31.9 ng/ml and EA was eliminated within 4 h (98). 
The authors hypothesized that ETs and EA were metabolized by the colon microbiota hence the 
appearance of free EA in human plasma (98). In rats, ETs are hydrolysable to EA by gut 
microbiota in the small intestine and cecum (99). EA fed to rats was detected in the form of 
urolithin A, also known as 3,8-dihydroxy-6H-dibenzo[b, d]pyran-6-one and an unidentified 
metabolite in urine and feces. Investigators detected as much as 10% of given dose in this study 
(100). Further work using germ free animals showed that these metabolites resulted from action 
by gut microorganisms (100). EA can also be metabolized via conjugation possibly in the liver or 
in the gut as evident by two conjugates of urolithin A found in rats after ingestion of EA (100). A 
mice study using phenol EA (
3
H-EA) also detected free EA and conjugates in urine, bile and 
blood and after gavage and 80% of fecal sample fraction was free EA (101). A study using 
Iberian pigs, demonstrated that ETs release EA in vivo followed by a gradual  metabolism of and 
production of urolithin D, C, A and B in this order from the jejunum to the distal portion of the 
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intestine (102). Furthermore, absorption of these metabolites was found to increase with their 
increasing lipophilicity (102). Therefore, ETs and EA are metabolized by the gut microbiota of 
different mammals (98, 102, 103) resulting in dibenzopyranones, urolithin A and its 
monohydroxylated analog urolithin B, C, and D (104). It is thought that ETs are hydrolyzed to 
EA due to the intestinal pH and or action by gut microflora, and EA is transformed to urolithins 
A, B, C and D by gut microflora through lactone-ring cleavage via decarboxylation, and 
dehydroxylation reactions (102). The Iberian pig study also confirmed enterohepatic circulation 
activity as glucuronides and methyl glucuronides of EA and urolithin A, C, and D derivatives 
were detected in bile and urolithins A, and B, and dimethyl-EA glucuronide were found in 
peripheral plasma (102).  
Because it takes 12-56 h to complete excretion of urolithins and their metabolites, their 
distribution in tissues such as liver, lung kidney, heart, muscle and adipose tissue have been 
investigated. No such metabolites were detected in these tissues in pigs (102), although traces of 
punicalagin metabolites were reported in the kidney and liver of rats (103), and in colon, 
intestinal, and prostate tissues of mice (105). 
In summary, gut microbiota are responsible for hydrolysis of ETs to EA and subsequently 
to glucuronides and methyl glucuronides of EA, and urolithins A, B, C, and D, and urolithin 
derivatives. It has been suggested that differences exist in the metabolism of ETs and EA based 
on food sources, and host colonic microﬂora composition that result in variation in the timing, 
quantity and types of urolithins absorbed and excreted in urine (106). Therefore, metabolism and 
bioavailability of particular blackberry ETs and EA require investigation as a step towards 
exploring their health benefits. 
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HEALTH BENEFITS 
Anthocyanins are reported to exert anti- inflammatory, antiviral, antiproliferant and 
anticarcinogenic properties (51). The consumption of anthocyanins in the U.S. is generally 
higher than other flavonoids due to their widespread distribution and occurrence in fruits and 
vegetables (65, 107), and is estimated to be between 82-215 mg/day. Presently, data on dietary 
intake of blackberry ETs and EA are lacking. However as a reference, daily dietary intake of ETs 
from berries in the Finnish and German populations are 12 and 5 mg/day, respectively (108, 
109).  Health benefits of particular blackberry ETs and EA have also not been explored, although 
a recently published review of ETs and EA is detailed on the anti-inflammatory, antimicrobial, 
prebiotic, antioxidant and estrogenic and/or anti-estrogenic of dietary ETs and EA (110). 
Oxidative stress 
Living organisms have a reduction-oxidation system that is necessary to maintain a 
balance between free radicals generated and antioxidant system (75). The formation of large 
amounts of free radicals may cause oxidative stress (OS) leading to many degenerative diseases 
and aging (75, 111-113). Although some scientists argue that in many instances oxidative stress 
is not the primary cause of disease and that the formation of radicals is secondary to tissue 
damage by disease, (51) there is some evidence linking OS with several chronic diseases (114, 
115). 
Wada and Ou (35) ranked the antioxidant activity of blackberries third highest after 
strawberry and black raspberry based on their oxygen radical absorbance capacity (ORAC) (35). 
This can be attributed to the high amounts of acylated anthocyanins and cyanidin 3-glucoside in 
blackberries. In fact, cyanidin-3-glucoside is ranked high in ORAC activity, and is reported to be 
3.5 times stronger than Trolox (vitamin E analogue), while pelargonidin, also found in 
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blackberries, was reported to have antioxidant activity equivalent to Trolox (107). Acylated 
anthocyanins are highly correlated with antioxidant capacity in fruit (4). Cho et al. observed a 
strong linear relationship between oxygen radical absorbance capacity (ORAC) values and total 
acylated anthocyanins (rxy= 0.91) in blackberry extracts and this correlation was weaker for total 
anthocyanin monoglucosides (rxy =0.69) (4). This correlation is consistent with bioavailability 
studies that demonstrate structural differences in anthocyanins such as sugar   
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Table 3.4. ORAC Values (µmol Trolox Equiv/g) of Blackberries a aFL represents ORAC 
results using fluorescein probe while PE represents ORAC results using B-PE probe 
 
 
 
 
 
 
 
 
 
 
 
 
  
fresh weight  
(µmol Trolox equiv/g) 
dry weight 
(µmol Trolox equiv/g) 
no. of 
cultivars 
source 
63-83FL  6 (4) 
49-76 FL  6 (23) 
34-36 PE  2 (30) 
27-71PE  27 (31) 
20-22FL 121-146FL 3 (33) 
20-25 PE  3 (33) 
28 PE  2 (35) 
- 334-560 FL 11 (44) 
38-76 PE  11 (39) 
17-67FL  15 (117) 
43-62 FL 
 
 
 
 
       4     (118) 
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moieties and acylated groups affect bioavailability, stability and other biological effects of 
anthocyanins (21). It should be noted that biological activities of berry components may vary 
with species and even cultivars (75). 
Anthocyanins work by scavenging free radicals with 3, 4-dihydroxy substituent in the B 
ring (75) being a key criterion for radical scavenging. They react readily with radicals such as 
hydroxyl (∙OH), azide (N3∙) and peroxyl (ROO∙) to form stable flavonoid radicals (51), hence 
reducing oxidative stress (116). Flavonoids however are slower at reacting with lipid peroxl 
(LOO∙) radicals and superoxide (O2−) due to reduced availability of polar flavonoids for reaction 
with the LOO∙ radicals (116). They also enhance fatty acid stability by reacting with α-
tocopherol radicals to form α-tocopherol (51, 116). Anthocyanins also function as antioxidants 
by chelating metal ions at moderate pH levels with their ionized hydroxyl groups of the B ring 
(75). 
Several studies have examined the ORAC of blackberries and results are presented in 
Table 4. When comparing ORAC results by different authors, it should be noted that the use of 
fluorescein probe results in higher ORAC values, typically 1.5 to 3.5-fold compared to older 
studies that used the B-PE probe (119). 
Cardiovascular Disease  
Elevated levels of low density lipoproteins in plasma are an independent risk factor for 
cardiovascular disease (120). Berry phenolic compounds have shown protective effects against 
cardiovascular disease by inhibiting in vitro and in vivo oxidation of LDL by quenching free 
radicals through donation of hydrogen molecules (41). Berry phenolic compounds also protect 
low density lipoproteins (LDL) from hydrogen peroxide-induced oxidative stress in human 
endothelial cell in vitro (75).  
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Blackberries phenolic compounds demonstrated strong inhibitory properties in vitro 
using oxidation assays on human LDL and lecithin liposomes (121). High content of cyanidin 
glycosides in blackberries are responsible for the high antioxidant activity and protection against 
LDL oxidation while the hydroxycinnamic acids are most important in liposome oxidation 
system (121). Anthocyanins, flavan-3-ols and hydroxycinnamic acids have been shown to have 
inhibitory effects in liposomal oxidation (121). Furthermore, anthocyanins have exerted 
protective effects in vitro on human primary endothelial cells by suppressing the secretion of 
cytokine-induced chemokine monocyte chemotactic protein 1 (MCP-1) (72). MCP-1 is a protein 
directly involved in atherogenesis through its role of recruiting macrophages to sites of infection 
or inflammation (72, 122).  
Although not demonstrated directly by blackberry flavonoids, select flavonoids have 
been shown to play a protective role in platelet function which is critical in the pathogenesis of 
cardiovascular disease (123). In vitro studies have shown that flavonoids reduce platelet 
aggregation, decrease platelet production of superoxide anions and increase platelet nitric oxide 
production (123). 
Cancer 
Evidence from epidemiological and clinical studies suggests that 20% or more of all 
cancer cases are preventable with a diet consisting of 400 to 800 g of various vegetables and 
fruits per day (75). Cancer is a complex multistage process that begins with initiation of a cancer 
cell caused by DNA damage, accumulation of mutations, promotion of cell proliferation and 
tumor expansion and finally progression to malignancy and metastasis (124). The potential role 
of berry phenolic compounds to reduce cancer risk has been shown in in vitro, animal and 
clinical studies (75). Berry phytochemicals may act to change the genomic stability of cells at 
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several points along this sequence of cancer formation (124). The phytochemicals may modulate 
initiation, promotion and progression of cancer (124). The possible anti-carcinogenesis 
mechanisms include: antioxidant activity, detoxification activity, induction of apoptosis, anti-
proliferation, and anti-angiogenic activity (75). Anthocyanins have been reported to induce phase 
II enzymes which may inactivate carcinogens activated by phase I enzymes therefore inhibiting 
possible DNA damage by the carcinogens (75). Tate et al. (125) found that blackberry extracts 
from 8 varieties: Arapaho, Choctaw, Hull, Chicksaw, Triple Crown, Kiowa, Navajo, and Chester 
suppressed mutagenesis at varying levels. Mutagenesis is a process characterized by uncontrolled 
cell proliferation and resistance to programmed cell death (124). Furthermore, blackberry 
extracts prepared from 8 varieties inhibited UV-induced mutagenesis in Salmonella typhimurium 
TA100 by 90% based on the Ames test (125). The Ames test is a good in vitro indicator of 
mutagenic potential in vivo, with a 90% correlation between a positive response in assay and 
carcinogenicity in animal models (125).  
Serraino et al. (126) reported that blackberry extracts play a protective role against 
peroxynitrite-induced DNA strand breakage in cultured human vascular endothelial cells. Using 
blackberry extracts containing 80% cyanidin 3-glucoside the authors investigated the antioxidant 
activity of the blackberry extract on the endothelial dysfunction in cells and in vascular rings 
exposed to peroxynitrite. Blackberry extracts at varying dilutions reduced the peroxynitrite-
induced suppression of mitochondrial respiration, and DNA damage in human umbilical vein 
endothelial cells (126).  
In addition, in vitro studies show that blackberry extract inhibits proliferation of A549 
human lung cancer cells and reduced neoplastic transformation in normal epidermal JB6 mouse 
cells exposed to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), tumor promoter 
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(124). Blackberry anthocyanins are thought to suppress cancer cell growth by modifying cell 
signaling pathways such as modulating the expression of activated protein1 (AP-1) and nuclear 
factor kappaB (NFκ B); important proteins that regulate cell proliferation and cell cycle control 
(124). Blackberry extracts have also demonstrated inhibitory properties in cancer-induced AP-1 
and NFκB and suppressed the expression of the two proteins involved in tumor promotion and 
progression, vascular endothelial growth factor and COX-2 (124). Moreover, Seeram et al. (127) 
has demonstrated the dose dependent cancer inhibitory properties of blackberry extracts in vitro 
in a study that used human oral, breast, prostate and colon cancer cell lines. Similarly, a study 
using quercetin extracted from blackberries also demonstrated the anti-carcinogenic properties in 
animal models and in human carcinoma cell lines (HT29 and Caco-2) (75, 128). 
Other health benefits 
Studies on blackberries and their effect on body weight are lacking. However, cyanidin 3-
glycoside (which is the predominant anthocyanin in blackberries) from purple corn has been 
shown to prevent obesity in C57BL/6J mice fed a high-fat diet compared to a mice fed high fat 
diet with no anthocyanins (16). Similarly, purified blueberry anthocyanins have been shown to 
improve body weights and body composition, and reduce obesity in mice (129). Although 
matching health benefits may be expected from blackberry anthocyanins, their effects on obesity 
need to be explored. 
Blackberries are reported to have positive effects on age-related changes and may be 
beneficial for prevention of age-related neurodegenerative diseases such as Alzheimer’s disease 
(15). Shukitt-Hale and others demonstrated that 2% blackberry supplemented in the diet of 19-
month old Fischer rats was effective in improving motor performance on three balance and co-
ordination tasks, and cognitive performance (15). Cyanidin 3-glucoside from blackberries was 
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found in the brain of male Wistar rats after 15 days of feeding a 1.5% blackberry diet (130) 
supporting the potential role of blackberry anthocyanins in neuroprotection.  
Although the antimicrobial activities of blackberry tannins is not documented, 
hydrolyzable tannins from red raspberries have shown antimicrobial activities on Staphylococcus 
and Salmonella bacteria in animal studies (75). Since blackberries provide a rich source of ETs, 
its anti-microbial properties should be investigated.  
Blackberry anthocyanins in particular have not been studied in relation to diabetes; 
however, there is evidence that in general anthocyanins can confer protective effects to the 
vascular system in diabetic patients. Administration of anthocyanins from Bilberry (Vaccinium 
myrtillus) at a dose of 600 mg/day for 6 months demonstrated significant reduction of 
biosynthesis of polymeric collagen and structural glycoprotein that result in capillary thickness in 
diabetes (131). 
A study by Kaume and others (132) has recently demonstrated that supplementation of 
blackberries at the level of 5% but not 10% in  ovariectomized rats modestly increased bone 
mineral density at the tibia by 2.4%, femur by 4.3%, and fourth lumbar vertebra by 2.7% higher 
than ovariectomized control animals (P < 0.05). Further, animals fed 5% blackberry (w/w) had a 
significant decrease in trabecular separation, by 22% less than the ovariectomized control rats. 
More studies on the health benefits of blackberries on bone are necessary to elucidate on the 
mechanism by which these berry compounds modulate bone metabolism. 
Studies on blackberries reveal that their phenolic composition and concentration are 
influenced by many factors including variety, location of cultivation, and maturation. The 
chemistry of blackberry phenolic compounds is well understood. In terms of health benefits, 
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these phenolic compounds have shown protective effects in age-related neurodegenerative 
diseases, and bone loss in vivo, and inhibited LDL and liposomal oxidation in vitro. Blackberry 
extracts have also exerted anti-mutagenic effects by modifying cell signaling pathways and 
suppressing tumor promotion factors in vitro and in vivo. However, the anti-obesity, anti-
diabetic, antimicrobial, and anti-inflammatory properties of blackberry phenolic compounds 
including catabolites from colonic microflora need investigation. In addition, more research is 
needed to explore their metabolism, bioavailability and the mechanisms by which they confer 
health benefits. Furthermore, studies that elucidate in vivo physiologically effective 
concentrations of blackberry phenolic compounds in vivo are necessary.
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IV. CYANIDIN 3-O-Β-D-GLUCOSIDE-RICH BLACKBERRIES IMPROVE 
BONE MASS AND MICROARCHITECTURAL PROPERTIES IN AN 
OVARIECTOMIZED RAT MODEL OF POSTMENOPAUSAL 
OSTEOPOROSIS 
ABSTRACT 
Postmenopausal osteoporosis is characterized by fragility fractures and afflicts 
approximately one third of women over 50 years. Oxidative stress promotes bone loss after 
menopause, and there is evidence that dietary antioxidants may reduce the level of oxidative 
stress in vivo. This study examined the dose dependent effects of blackberries (BB) containing 
mainly cyanidin-3-O-D-glucoside (C3G) in preventing bone loss in an ovariectomized (Ovx) rat 
model. Nine-month-old female (N=38) Sprague-Dawley rats were scanned using dual energy X-
ray absorptiometry to obtain baseline whole body, bone mineral content (BMC) and bone 
mineral density (BMD). One group was sham-operated (Sham) and three groups were 
ovariectomized (Ovx). The groups and corresponding diets were: Sham + control diet (n=12), 
Ovx + control diet (n=12), Ovx + 5% BB (n=7), and Ovx + 10% BB (n=7). Control diet was 
AIN-93M rodent diet, and the Ovx + 5% BB and Ovx + 10% BB were a diet modified to contain 
powdered, freeze dried-BB at levels of 5 and 10% (w/w). Following 100 days of treatment, 
whole body BMC and BMD were reassessed and bone specimens, and blood and 24h urine 
samples were collected for analyses. Findings indicate that ovariectomy (Ovx) compromised 
whole body BMC and trabecular microarchitecture of the proximal tibia and 4th lumbar vertebra. 
C3G-rich BB at the level of 5% modestly protected BMDs loss of the tibia, lumbar vertebra, and 
femur by 2.4, 2.7, and 4.3% respectively. BB5% treatment significantly prevented loss of tibial 
trabecular bone volume and trabecular number by 37% and 21% respectively (p < 0.05); and also 
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significantly prevented tibial trabecular separation by 22%. C3G-rich BB treatments had no 
effects on both biomarkers of bone metabolism and oxidative stress. We conclude that C3G-rich 
BB treatment at the level of 5% (w/w) may modestly reduce Ovx-induced bone loss evident by 
improved tibial vertebral and femoral BMD values, and tibial bone microstructural parameters. 
Bone protective effects may be as a result of the synergistic effects of phenolic compounds; 
however, further work is required to determine blackberries’ specific mechanisms of action. 
 
Key words: Postmenopausal osteoporosis; Blackberries; Polyphenols; Antioxidants; Cyanidin 3-
O-β-D-glucoside 
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INTRODUCTION  
Postmenopausal osteoporosis is characterized by fragility fractures and afflicts 
approximately one out three women over 50 years1 Postmenopausal women experience increased 
oxidative stress due to aging and estrogen loss2,3. Oxidative stress (OS) plays a major role in 
activating osteoclastogenesis and promoting bone resorption in vitro and in rodent studies 4-7. As 
a result of ovarian-hormone-deficiency osteoclasts increase the production of reactive oxygen 
species (ROS), mainly superoxide anion and hydrogen peroxide 6, 8, 9. Heightened OS and 
diminished levels of thiol antioxidant defenses in bone cells 7,10 induce production of pro-
inflammatory factors such as interleukin 1 and 11 (IL-1 and IL-11) and tumor necrosis factor-α 
that further aggravate the progression of osteoclastic activity 9-11.  
The principal goal of osteoporosis therapy is to reduce fracture risk. To this end, drug 
therapies such as alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate 
used with calcium and vitamin D have been effective 12. Nonetheless due to factors such as cost, 
fear, and side effects associated with these drugs, about 50% of patients discontinue medication 
or fail to adhere to treatments regimens in the first year of use, which results in increased fracture 
risk 12, 13. Hence in addition to drugs and lifestyle modifications, practical diet-based approaches 
to reduce the level of oxidative stress and improve bone health are necessary. Growing evidence 
shows that increasing the intake of fruits and vegetables, as part of a nutrient-balanced diet, is 
beneficial to bone health 14-18. Additionally, experiments with dietary antioxidants (e.g. N-acetyl 
cysteine, ascorbic acid, alpha-tocopherol, and β-carotene) have demonstrated their potential to 
promote bone formation 19 and increase levels of enzymatic antioxidants 7. These antioxidants 
may stimulate osteoblast differentiation, suppress osteoclast formation, and decrease TNF-α 
production, hence attenuate the bone resorptive effects of oxidative stress7, 19-22. 
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Apart from the traditional dietary antioxidants such as vitamins A, C and E, phenolic 
compounds from plums and blueberries have demonstrated protective effects against bone 
resorption due to their strong superoxide scavenging capacity 23, 24
,25. Akin to these fruits, is the 
blackberry fruit (Rubus sp.) that has total phenolics range of 114 to 1056 mg/100 g fresh weight 
(FW) 26. The composition of Blackberry (BB) includes anthocyanins 27, ellagitannins 28, 
flavonols, flavan-3-ols 29, procyanidins 30, phenolic acids 26 and low amounts of lignans 31. Most 
berries have several anthocyanins in their phenolic profile; however, BB contains mostly the 
anthocyanin, cyanidin-3-glucoside (C3G) 32. The fraction of C3G in the whole blackberries used 
in this study was 87%. According to studies 33-35 C3G has high anti-inflammatory and 
antioxidative activity and has potential to play an important role in prevention of lipid 
peroxidation of cell membranes. 
Using an Ovx- rat model of postmenopausal osteoporosis, effects of supplementation 
with C3G-rich blackberries at the level of 5% (w/w) and 10% (w/w) were assessed on: (i) bone 
mineral density (BMD), (ii) trabecular microarchitecture (iii) bone biochemical markers, and (iv) 
plasma enzymatic antioxidants.  
MATERIALS AND METHODS 
Animal care and diet 
Nine-month-old female (N=38) Sprague-Dawley rats (Harlan, Indianapolis, IN) were 
housed in an environmentally controlled animal care facility with standard temperature and light: 
dark (12:12) cycles. Following a week of acclimatization the animals were randomly assigned to 
four groups. One group was sham-operated (Sham) and three groups were ovariectomized (Ovx). 
Baseline bone mineral density (BMD) and bone mineral content (BMC) were obtained using 
DXA dual X-ray absorptiometry (DXA; GE Lunar DXA, Waukesha, WI) equipped with enCore 
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software. The groups and corresponding diets were: Sham + control diet (n=12), Ovx + control 
diet (n=12), Ovx + 5% BB (n=7), and Ovx + 10% BB (n=7). Control diet was AIN-93M rodent 
diet, and the Ovx + 5% BB and Ovx + 10% BB were control diet modified to contain powdered, 
freeze dried-BB at levels of 5 and 10% (w/w). Blackberry diets were formulated based on 
proximate analysis of freeze-dried blackberries to contain the same amounts of carbohydrate, 
fiber, fat and protein (data not shown). Rats were weighed on a weekly basis, received free 
access to deionized water, and were match fed to the weekly mean food intake of the sham 
group.  
Animal necropsy 
After 100-d treatment period, the animals were placed in metabolic cages for a 24 h 
period in order to collect a 12-h urine sample. The urine sample was centrifuged at 3000×g for 
20 minutes aliquoted and stored at -20 °C for deoxypyridinoline (DPD) and creatinine analyses. 
After a12-hour fast, animals were anesthetized with a mixture of ketamine and xylazine (70 mg 
and 3 mg/kg body weight, respectively) to measure final BMD and BMC using DXA. The rats 
were then sacrificed by exsanguination via cardiac puncture. Blood samples were collected and 
centrifuged at 3000×g for 20 minutes at 4 °C. Serum was aliquoted and stored at -80 °C until 
analysis. Bone specimens, the tibiae, the 4
th
 lumbar vertebrae and femur, were collected, cleaned, 
and stored at -20°C for BMD and micro-architectural analyses. Uteri were collected and weighed 
for confirmation of ovariectomy.  
All animal procedures used in this study were according to the University of Arkansas 
Institutional Animal Care and Use Committee guidelines. 
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Assessment of bone mineral area, content, and density 
Using procedures previously published 36and DXA equipped with suitable software for 
assessing bone indices in small laboratory animals, bone mineral area (BMA), BMC and BMD 
of the tibiae, the 4
th
 lumbar vertebrae and femur were measured. 
Assessment of bone microarchitecture using microcomputed tomography (μCT) 
To assess the effect of C3G-rich blackberry treatment on bone trabecular structure, the tibiae, 4th 
lumbar vertebrae and femur and were scanned using μCT and methods previously reported 37. 
After analyzing the volume of interest (VOI), the following bone morphometric parameters were 
obtained: bone volume over total volume (BV/TV), trabecular number (Tb.N.), separation 
(Tb.Sp.), thickness (Tb.Th.), connectivity density, and structure model index (SMI). 
Assessment of oxidative stress biomarkers  
Effects of ovariectomy and C3G-rich blackberry treatments on oxidative stress levels were 
assessed using four assays. Thiobarbituric Acid Reactive Substances (TBARS) were measured in 
plasma and were used to determine lipid peroxidation 38, a major indicator of overall oxidative 
stress. TBARS were determined in duplicate using TBARS assay kit (ZeptoMetrix Corporation 
Buffalo NY, USA) according to manufacturer’s instructions and absorbance of 532 nm read on a 
Synergy HT (BioTek; Winooski, VT) microplate reader.  
The activity of antioxidant enzymes: glutathione peroxidase (GPx), superoxide dismutase 
(SOD), and catalase were assessed in plasma using BioVision’s assay kits (BioVision Inc. 
Mountain View, CA, USA) following manufacturer’s instructions. All samples were assayed in 
duplicate and read using Synergy HT (BioTek; Winooski, VT) microplate reader. 
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Assessment of systemic biomarkers bone metabolism 
Effects of ovariectomy and the two doses of C3G-rich blackberry treatment were 
evaluated in four systemic biomarkers of bone metabolism. Alkaline phosphatase (ALP) which is 
required for the hydrolysis of phosphate esters was assessed in serum as an indicator of bone 
formation using an Alfa Wassermann diagnostic technologies kit and ACE Alera clinical 
chemistry system (Alfa Wassermann diagnostic technologies, West Caldwell, NJ, USA). Serum 
osteocalcin (OC), a reliable indicator of bone turnover 39 was measured using Rat-MID™ 
Osteocalcin EIA (Immunodiagnostic Systems Inc. Fountain Hills, AZ, USA). Serum Insulin-like 
growth factor-1(IGF-1), a recognized modulator of bone metabolism involved in proliferation of 
osteoblasts 40was quantified using an enzyme immunoassay (EIA) kit from ALPCO 
immunoassays (ALPCO Diagnostics, Salem NH, USA). In addition, a resorption bone biomarker 
urinary deoxypyridinoline (DPD) was quantified using a competitive enzyme immunoassay kit 
specific for rats (Quidel, Mountain View, CA, USA). The assay is established in DPD molecule 
specificity and hence cross-reaction with other collagen crosslinks such as pyridinoline is highly 
insignificant 41. Urinary creatinine was measured colorimetrically using an ACE Alera clinical 
chemistry system and a commercially available kit from Alfa Wassermann diagnostic 
technologies (Alfa Wassermann diagnostic technologies, West Caldwell, NJ, USA). The final 
creatinine-corrected DPD results were expressed as nmols DPD/mmols creatinine. All serum and 
urine samples were assayed in duplicates for the above biomarkers.  
Statistical analyses 
The data analysis involved estimation of means and SEM using JMP 8 (2009 SAS 
Institute Inc. Cary, NC). The effects of treatment were analyzed by one-way ANOVA model 
followed by post hoc analysis using the Fisher’s least squares means separation test when F 
values were significantly different (P < 0.05).  
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RESULTS 
Bone mineral area, content, and density 
Baseline BMC of the whole body was not different among groups; however, final BMC 
of the OVX+BB10% and sham group was significantly lower than Ovx+control group. Baseline 
BMD of the whole body were not different among groups. Effects of Ovx are observed as final 
BMD values of ovariectomized rats were compared to the sham group (Table 4.1).  
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Table 4.1. Effects of ovariectomy and C3G-rich blackberry treatments on DXA bone parameters of the whole body 
Parameter 
Sham + Control 
(n=12) 
OVX + Control 
(n=11) 
OVX + BB 5% 
(n=6) 
OVX + BB 10% 
(n=7) P value 
Whole Body      
Baseline BMC (g) 9.142 ± 0.223 9.191 ± 0.233 9.617 ± 0.316 9.186 ± 0.292 0.6424 
Baseline BMD 
(g/cm
2
) 0.174 ± 0.002 0.175 ± 0.002 0.179 ± 0.003 0.177 ± 0.003 0.4683 
Final BMC (g) 9.975 ± 0.274
a
 11.564 ±0.287
b
 11.183 ± 0.379
b
 10.557 ± 0.359
b
 0.0026 
Final BMD (g/cm
2
) 0.186 ± 0.002 0.178 ± 0.002 0.180 ± 0.003 0.182 ± 0.003 0.0833 
  
Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly 
different from each other (P < 0.05). Abbreviations used: SHAM: Sham operated; OVX-CTRL: ovariectomized 
control; OVX-BB 5%: Ovariectomized + blackberry 5% (w/w); OVX-BB 10% (w/w): Ovariectomized + blackberry 
10% (w/w).  
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Table 4.2. Effects of ovariectomy and C3G-rich blackberry treatments on DXA bone parameters of the, tibia, 4
th
 
lumbar vertebra and femur 
Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly different from 
each other (P < 0.05).  Abbreviations used: SHAM: Sham operated OVX-CTRL: ovariectomized control OVX-BB 5%: 
Ovariectomized + blackberry 5% (w/w); OVX-BB 10% (w/w): Ovariectomized + blackberry 10% (w/w).  
Parameter 
Sham + Control 
(n=12) 
OVX + Control 
(n=11) 
OVX + BB 5% 
(n=6) 
OVX + BB 10% 
(n=7) P value 
Tibia      
BMA (cm
2
) 1.7425 ± 0.0264 1.6933 ± 0.0264 1.6667 ± 0.0671 1.6429 ± 0.0669 0.2795 
BMC (g) 0.368 ± 0.007
b
 0.341 ± 0.007
a
 0.342 ± 0.012
ab
 0.324 ± 0.012
a
 0.0337 
BMD (g/cm
2
) 0.211 ± 0.002
c
 0.200 ± 0.002
ab
 0.205 ± 0.003
bc
 0.196 ± 0.003
a
 0.0013 
4
th
 lumbar vertebra      
BMA (cm
2
) 0.6267 ± 0.0120 0.5975 ± 0.0122 0.6100 ± 0.0177 0.5950 ± 0.0177 0.2592 
BMC (g) 0.145 ± 0.0041 0.131 ± 0.0042 0.137 ± 0.0063 0.128 ± 0.0063 0.0540 
BMD (g/cm
2
) 0.230 ± 0.004
a
 0.218 ± 0.004
b
 0.224 ± 0.005
ab
 0.214 ± 0.005
b
 0.0437 
Femur      
BMA (cm
2
) 1.9642 ± 0.0542 1.83 ± 0.0602 1.9217 ± 0.0435 1.9886 ± 0.0431 0.2588 
BMC (g) 0.4460 ± 0.0140 0.410 ± 0.0140 0.452 ± 0.0190 0.430 ± 0.0190 0.2870 
BMD (g/cm
2
) 0.2390 ± 0.0030
c
 0.224 ± 0.0030
ab
 0.234 ± 0.0043
bc
 0.215 ± 0.0043
a
 0.0004 
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There were no statistically significant differences in BMA of the tibia, 4th lumbar 
vertebra and femur among groups but tibial BMC of the Ovx group was lower than the sham 
group (Table 4.2). All three bones had BMA and BMC of the Ovx+control group lower to some 
degree than the sham group although not to a statistically significant level. Tibial, vertebral and 
femoral BMDs were significantly reduced by Ovx, 5%, 5% and 6% respectively. C3G-rich BB 
diet at the level of 5% and not 10% (w/w) increased BMD of the tibia, lumbar vertebra, and 
femur by 2.4%, 2.7% and 4.3% respectively compared to the Ovx+control, bringing it up to the 
level of the sham group.  
μCT analysis of tibia and fourth lumbar vertebra 
Four cortical parameters were assessed at the proximal tibia, including cortical area, 
porosity, thickness, and medullary area. Tibial cortical bone microarchitecture was markedly 
compromised by Ovx (Table 4.3). Ovx resulted in decreased cortical thickness and cortical area 
by 7% and 8% respectively, and an increase in cortical percent porosity of 8.5%.  
C3G treatment at the level of 5% but not at 10% (w/w) increased cortical thickness by 
5% bringing it up to the level of the sham group. C3G treatments had no impact on cortical area 
and cortical porosity. Neither Ovx nor dietary treatments had any effects on cortical medullary 
area. 
  
1
0
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Table 4.3. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments on tibia cortical parameters 
Parameter 
Sham + Control 
(n=9) 
OVX + Control 
(n=8) 
OVX + BB 5% 
(n=6) 
OVX + BB10% 
(n=6) P value 
Cortical bone      
Cort Th (mm) 0.5932 ± 0.0113
b
 0.5538 ± 0.0113
a
 0.5820 ± 0.0123
ab
 0.5477 ± 0.0123
a
 0.0510 
Cort Area (mm
2
) 4.5800 ± 0.1000 4.2400  ± 0.1100 4.3800 ± 0.1200 4.3200 ± 0.1200 0.1129 
Med Area (mm
2
) 0.1849 ± 0.0046 0.1860 ± 0.0046 0.1873 ± 0.0050 0.1960 ± 0.0050 0.3293 
Porosity (%) 3.880 ± 0.1300
a
 4.21 ± 0.1300
ab
 4.12 ± 0.1400
ab
 4.35 ± 0.1400
b
 0.1074 
 
 
 
Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly 
different from each other (P < 0.05). Abbreviations used: SHAM: SHAM operated; OVX-CTRLovariectomized 
control; OVX-BB 5% : Ovariectomized+blackberry 5%; OVX-BB 10% (w/w): Ovariectomized + blackberry 10 % 
(w/w) Cort Th: cortical thickness; Cort: cortical; Med: medullary 
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Analysis of data also showed that Ovx considerably compromised all parameters of 
trabecular microarchitecture of the proximal tibia and 4th lumbar vertebra (Figure 4.1) except 
tibial Tb.Th. Ovx-induced changes were characterized by decreased BV/TV (Fig A), Tb.N. (Fig 
B), and Tb.Th. (Fig C) and increased Tb.Sp. (Fig D). Ovx decreased tibial and vertebral BV/TV 
by 23% and 13%, respectively. C3G-rich blackberry treatment at the level of 5% (w/w) 
significantly increased tibial BV/TV by 37% and had no effect on lumbar BV/TV. The higher 
dose of BB 10% (w/w) had a negative impact to vertebral BV/TV significantly reducing bone 
volume by 28% compared to Ovx+control. 
Similarly, tibial and vertebral Tb.N. was decreased in response to Ovx by 11% and 1.7%, 
respectively. C3G-rich BB at the level of 5% (w/w) resulted in significant positive effects on 
tibial but not vertebral Tb.N. Tibial Tb.N. values significantly increased by 21% in the 
Ovx+BB5% group but the higher BB dose had no such effect. Ovx reduced Tb.Th. by 1.7% and 
6.3% in the tibia and vertebra bones, respectively. In regard to treatments, the low BB diet dose 
increased vertebra Tb.Th by 6% to the level of the sham group but the higher dose had no effect; 
and neither treatments had an effect on tibial TbTh. Ovx also increased tibial and vertebra Tb.Sp. 
by 17% and the slight 0.6% respectively. C3G-rich BB treatment at the level of 5% (w/w) 
prevented tibial Tb.Sp. reducing it by 22%, bringing it up to the sham level; but the same dose 
had no positive effects on the vertebral bone. Tibial and vertebral Tb.Sp in animals fed 
blackberry at the level of 10% (w/w) was similar to the Ovx control group. 
Non-metric parameters of the tibial and lumbar trabecular bone, i.e., SMI and 
connectivity density (Figures 4.1E and 4.1F) were modified by Ovx albeit not to a statistically 
significant degree. Higher SMI indicates a more biomechanically compromised trabecular bone 
pattern which is more rod-like as opposed to the favorable plate-like pattern. Tibial SMI 
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increased by 9.4%, and that of the vertebrae by 31%, while connectivity density decreased in 
both bones by 32% and 2.6% respectively, due to Ovx. Though the impact of C3G-rich BB5% 
(w/w) on tibial SMI did not reach significance level, this dose modestly prevented the change of 
trabecular to the unfavorable rod-like pattern by reducing the index by 18% compared to 
Ovx+control. The vertebra SMI was not changed by the lower dose of BB treatment but the high 
dose significantly increased SMI.  Tibial but not lumbar connectivity density in animals fed a 
low dose of C3G-rich BB significantly increased to a value higher than the Ovx and sham 
groups. The higher dose of C3G-rich BB treatment had no positive effects on connectivity 
density of both bones.  
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Figure 4.1. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments on tibia, 
vertebrae and trabecular bone. Values are means ± SEM, bars that do not share the same letters  
or numbers are significantly different (P < 0.05). Sham (n=9), OVX-Control (n=8) OVX-BB 5% 
 and OVX-BB 10% (n=6)  
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Biomarkers of oxidative stress and bone metabolism 
Effects of Ovx and C3G-rich BB treatments were assessed on three antioxidant enzymes, 
SOD, GPX, and catalase and a biomarker of oxidative stress, TBARS. Neither Ovx nor C3G-rich 
BB treatments had any significant effects on these measures.  
Urinary DPD and serum osteocalcin, ALP, IGF-I were measured to assess their response 
to Ovx and C3G-rich BB treatments on bone resorption and bone formation, respectively (Table 
4.4). DPD expressed per unit of creatinine was increased by Ovx, but C3G-rich BB treatments 
did not suppress the urinary excretion of these collagen by-products. Serum osteocalcin was 
significantly increased in the Ovx+control group (37%) in response to Ovx, but not altered by 
C3G-rich BB treatments. ALP was significantly higher in the Ovx rats compared to the sham + 
control group and C3G-rich BB treatment at the level of 10% but not 5% (w/w), decreased ALP 
level the level of the sham group. In response to Ovx, IGF-1 increased by 9%, and C3G-rich BB 
treatments further enhanced these levels in a dose dependent manner; however these changes 
represent only a trend and did not reach the level of statistical significance.  
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Table 4.4. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments 
on antioxidant enzymes and systemic biomarkers of bone metabolism 
Parameter 
Sham + Control 
(n=9) 
OVX + Control 
(n=8) 
OVX + BB5% 
(n=6) 
OVX + BB10% 
(n=6) 
DPD (nmol /mmol creatinine) 16.29 ± 3.41
a
 37.29 ± 3.42
b
 37.6 ± 3.87
b
 31.2 ± 3.87
b
 
Osteocalcin (ng/mL) 85.74 ± 19.46
a
 136.89 ± 19.47
b
 143.93 ± 25.16
b
 144.2 ± 25.16
b
 
ALP (U/L) 34.82 ± 3.97  43.50 ± 3.98 47.83 ± 5.51 43.57 ± 5.51 
IGF-1 (pg/mL) 12.14 ± 0.77 13.33 ± 0.78 13.47 ± 1.40 14.41 ± 1.40 
Values are means ±SEM. Within a row, values that do not share the same superscript letters are 
significantly different from each other (P < 0.05). Abbreviations used: SHAM: SHAM operated; 
OVX-CTRLovariectomized control; OVX-BB 5% : Ovariectomized+blackberry 5%; OVX-BB 
10% (w/w): Ovariectomized + blackberry 10 % (w/w); SOD: superoxide dismutase; GPX: 
glutathione peroxide; TBARS: thiobarbituric acid reactive substances; DPD: deoxypyridinoline; 
ALP: alkaline phosphatase; IGF: insulin-like growth factor 
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DISCUSSION 
Bone loss in response to Ovx is partially due to increased oxidative stress and impaired 
antioxidant systems of the bone tissue 11, 42. In this study, bone loss occurred at all sites measured 
in varying magnitudes. However, modest protection of tibial and femoral BMD by C3G-rich BB 
5% (w/w) reduced fracture risk at these sites; the primary goal in osteoporosis therapy. Such 
findings are encouraging considering that the risk of any fracture in women is about twice as 
high as that of men 12. Similar bone protective effects have been demonstrated in blueberries 
which have an equally high antioxidant capacity 17 
Micro-CT analyses indicated Ovx -induced changes of the cortical and trabecular 
microarchitecture as reported by others 15, 37, 43. Moreover, evaluation of the metaphyseal region 
of the tibia demonstrated C3G-rich BB 5% (w/w)-protection against loss of BV/TV and Tb.N. 
As a consequence of preserved Tb.N, less Tb.Sp. and more connectivity were observed. Tibial 
Tb.Th. remained unaltered by both Ovx and treatment. We speculate that no effect on Tb.Th 
resulted from a compensatory mechanism to correct for loss in connectivity as proposed 
previously 37, and/or lack of statistical power due to limited sample size.  
Rod-like trabeculae are more susceptible to fracture than plate-like patterns 44. Therefore 
by preventing rod-like pattern formation as evidenced by lower SMI values, C3G-rich BB 5% 
(w/w) reduced fracture risk. Such findings are important in providing evidence that supports 
epidemiological studies 16, 45that associate consumption of fruits and vegetables to improved bone 
health. Interestingly, response to treatment at the lumbar vertebrae was weak and these findings 
agree with previous studies 37,46. However, compared to the proximal tibia this site was also less 
vulnerable to the trabeculae deterioration effects of Ovx. 
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In terms of biomarkers, concentrations of urinary DPD increased characteristic of bone 
turnover in favor of resorption due to Ovx. However, C3G-rich BB diets did not suppress bone 
resorption rate as would be expected. Also serum markers of bone formation ALP and 
osteocalcin both of which indicated increased bone turnover following Ovx were unaltered by 
BB treatment. Ovx and BB treatments had no effect on IGF-1. Suppression of Ovx-induced ALP 
and osteocalcin has been reported in blueberry treatment 17 but not in dried plum 15. Similar to 
dried plums treatment 15, C3G-rich BB diets were unable to alter bone mineralization raising the 
question as to the mechanism of action. Systemic markers appear to differ with treatments and 
mechanism of action; therefore further investigations are necessary to elucidate the mechanisms 
by which C3G-rich BB prevent Ovx-induced bone loss. 
Following Ovx, rats suffer depleted intracellular antioxidants, such as glutathione, and 
experience increased osteoclast activity 11. Oxidative stress results in marked regulation and 
expression of antioxidant enzymes including SOD, GPX and catalase 47. Overall, this study 
found no significant changes in these enzymes as result of either Ovx or C3G-rich treatments. 
However, a slight dose-dependent trend in reduction of SOD, GPX and catalase may be 
indicative of reduced need for their expression due reduced oxidative stress by C3G-rich BB. 
TBARS, an indicator of oxidative stress was reduced by C3G-rich BB 5% (w/w) but not 10% 
(w/w) to levels similar to the sham group demonstrating the antioxidant potential of BB 
phenolics.  
Anthocyanin concentration in the blackberries in this study as determined by HPLC and 
HPLC-ESI-MS was 631.3 mg/100 g of dry weight (DW) and cyanidin 3-O-β-D-glucoside was 
87% of total anthocyanins. Therefore we can hypothesize that the bone protective effects seen in 
this study are largely due to the high C3G content; which has one of the highest oxygen radical 
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absorbance capacity activities (ORAC) recorded 48. It is plausible that the dose at 10% (w/w) was 
excessive and therefore ineffective in combating oxidative stress. Also high fiber content in 
blackberries may have inhibited the absorption of essential bone building minerals such as 
calcium, phosphorous. However the mechanisms by which C3G-rich blackberries prevent bone 
loss need to be explored in future studies. To our knowledge no other study has investigated the 
bone-protective effects of blackberry phenolic compounds. 
CONCLUSION 
In conclusion, blackberries supplemented in the diet at the level of 5% (w/w) may 
modestly reduce ovarian hormone-induced bone loss evident by improved tibial vertebral and 
femoral BMD values, and tibial bone microstructural parameters. Bone protective effects may be 
as a result of the synergistic effects of phenolic compounds; however, further work is required to 
determine blackberries’ specific mechanisms of action. 
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ANTIOXIDANT-RICH BERRIES EXERT MODEST BONE PROTECTIVE EFFECTS IN 
POSTMENOPAUSAL SMOKERS WITHOUT IMPROVING BIOMARKERS OF BONE 
METABOLISM 
ABSTRACT 
Smoking aggravates bone loss in postmenopausal women due to increased oxidative stress and 
inflammation. Berries have shown bone protective effects in animal studies partially due to 
antioxidant and anti-inflammatory properties of their phenolic compounds. We hypothesized that 
consumption of 45g of blackberries or blueberries for 9 months will prevent smoking-induced 
bone loss in postmenopausal women. Postmenopausal smokers (n=45) and nonsmokers (NS) 
(n=20) were recruited. Smokers were randomly assigned to one of three treatment groups: 
smoker control (S-C) n=21; smoker + 45 g freeze-dried blackberries (S-BB) n=8; or smoker + 45 
g freeze-dried blueberries (S-BL) (n=16). We measured: bone mineral density (BMD) of total 
body, and other regions at 0 and 9 mo., and urinary deoxypyridinoline, bone alkaline phosphate, 
osteocalcin, thiobarbituric acid reactive substances and highly sensitive C-reactive protein at 0, 
3, 6, and 9 month. Bone loss of total body BMD was statistically significant in S-C and S-BL 
groups, but not in S-BB and NS-C groups (P = 0.0284). No significant changes were noted on 
other parameters. These findings indicate that antioxidant rich blackberries but not blueberries 
modestly protected against smoking-induced bone loss in postmenopausal smokers. The 
mechanisms by which berries prevent bone loss need further exploration. 
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INTRODUCTION 
Postmenopausal osteoporosis is one of the most prevalent and debilitating bone diseases, 
affecting over 200 million women worldwide 1. With regard to etiology and pathogenesis of 
postmenopausal osteoporosis, oxidative stress and inflammation are established mechanisms 
demonstrated in ovariectomized (Ovx) rats 2. Oxidative stress (OS) characterized by increased 
osteoclast production of oxygen derived free radicals occurs as a consequence to lowered thiol 
antioxidant defenses due estrogen loss 2,3. In response to elevated levels of OS, there occurs 
increased expression of pro-inflammatory cytokines including, tumor necrosis factor-α (TNF-α) 
3. Jagger and others 3 have demonstrated that through TNF-α signaling, osteoclastogenesis is 
stimulated and promoted in a rat model of postmenopausal osteoporosis.  
In light of this, postmenopausal smokers have increased risk for osteoporosis 4 due to an 
additional 10
15 
free radicals/g inhaled from cigarette smoke 5. Oxidants from cigarette smoke also 
down-regulate the expression of important mediators of bone formation, osteocalcin, type 1 
collagen and alkaline phosphatase that are essential for bone structure 6. In fact, smokers have 5-
10% less bone than nonsmokers by the age of 45-50 years 7. Furthermore, smokers compared to 
nonsmokers have elevated levels of plasma inflammatory factors, and lipid peroxidation 
biomarkers 8.  
Pharmacological therapies for postmenopausal osteoporosis are aimed at reducing future 
fracture risk, they include: bisphosphonates, raloxifene, strontium ranelate, denosumab and 
parathyroid hormone peptides 9. Though effective, both poor access and adherence to these 
treatments have been reported 10, 11 Treatments such as insulin-growth factor-1, calcium, and 
vitamin D have also demonstrated modest anabolic responses 12. Nonetheless, safe life-long 
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preventive interventions need to be embraced in overcoming the burden of osteoporosis in 
individuals and in the society. 
Nutritional therapies using fruits and vegetables may also be effective in protecting 
against bone loss as suggested by some epidemiological, clinical and animal studies 13-17. A 
growing body of evidence proposes that besides the nutrients, phenolic compounds in fruits and 
vegetables possess strong antioxidant and anti-inflammatory properties that can improve oxidant 
states in vivo 18and exert health benefits.  
With regard to fruits, dried plums, freeze-dried blueberries and freeze-dried blackberries 
have demonstrated bone protective effects in Ovx rats 16, 17, 19. Furthermore, effects of dried plums 
20 but not blackberries and blueberries on bone health have been explored in humans. The 
phenolic composition of blackberries (BB) and blueberries (BL) consists mainly of anthocyanins, 
flavonols, and chlorogenic acid (BL) and ellagitannins and ellagic acid (BB) 21. Anthocyanins are 
known to be powerful antioxidants and make up a large proportion of these berries. However, 
with regard to health benefits, we must consider possible synergetic effects from all berry 
bioactive compounds and their metabolites.  
Healthy postmenopausal smokers were used in the present study to test the hypothesis 
that antioxidant-rich BB and BL can prevent smoking-induced bone loss. To this end, we 
assessed the effects of BB and BL on: bone mineral density (BMD), and bone mineral content 
(BMC), three biomarkers of bone metabolism, a biomarker of oxidative stress and a biomarker of 
inflammation. To our knowledge, the present study is the first to explore bone health benefits in 
postmenopausal smokers after BB and BL consumption. 
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PARTICIPANTS AND METHODS 
Participants 
Guidelines of the Declaration of Helsinki were followed when conducting this clinical study and 
the clinical protocol was approved by the University of Arkansas Institutional Review 
Committee (Fayetteville AR, USA). Participants had to be healthy, 1-10 years postmenopausal, 
and not on hormone replacement therapy for at least 6 months before initiation of the study. 
Participants were not on medication affecting calcium or bone metabolism, and have a BMD t-
score above 2.5 SD of the mean at all sites. In addition, participants with chronic diseases 
including skeletal disorders, diabetes mellitus, cardiovascular disease, gastrointestinal/digestive 
problems, and respiratory problems, thyroid disorder, and impaired liver function were excluded. 
Also excluded from the study were:  participants on anabolic steroids, corticosteroids or 
glucocorticoids, medications for bone, or hormone replacement therapy, and women consuming 
a cup or more of blueberries or blackberries. A total of 212 women responded to advertisement 
on local radio and newspaper, fliers, and brochures. Sixty five eligible women were enrolled in 
the study. Participants signed an informed consent and completed a health and medical history 
questionnaire related to the exclusion criteria. Recruited participants were smokers and 
nonsmokers. Smokers (N=44) were defined as smoking daily and nonsmokers (N=21) were not 
current smokers and none of those recruited had smoked in the previous 10 years. 
Study design 
The study design is summarized in Figure 5.1. Smokers were randomly assigned to one 
of three groups: smoker control (n=21), smoker + 45 g/day freeze-dried blackberries (n=8), or 
smoker + 45 g/day freeze-dried blueberries (n=16) and nonsmokers (n=20) was a control group. 
Participants in berry groups were provided with 45 g BL and BB (WaterShed Foods Gridley, IL 
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USA) pre-weighed and vacuum-packed in moisture-proof bags to ensure food safety, retention of 
nutrition value, and for ease of storage and transportation. Participants were asked to consume 45 
g of their respective berries daily. Participants on berry regimens were advised to adjust their 
daily food intake to account for the energy provided by the freeze-dried berries. Calendars were 
provided to record days on which berries were consumed and participants requested to return any 
unused berries in preceding visits. At baseline and after 9 months, BMD was measured, and at 
baseline, 3, 6 and 9 months, venous blood samples and 2nd void urine samples were collected. 
 
  
1
2
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Figure 5.1. Study design showing the effects of daily consumption 45 g of freeze-dried blackberries and freeze-dried blueberries 
studied in postmenopausal smokers during a 9 month intervention. Abbreviations used:  S-BL: smokers + 45 g blueberries/day; S-BB: 
smokers + 45 g blackberries/day; S-C: Smokers control group; NS-C: nonsmokers control group.  
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Nutrient and phenolic composition of freeze-dried berries 
 Macro and micro-nutrient composition of 45 g of FBB and FBL were analyzed by 
Nutrition Pro® (Axxya Systems; Stafford, TX) software based on USDA references. Proximate 
analyses of blackberries and blueberries were performed in duplicates by the Central Analytical 
Laboratory at the University of Arkansas (Poultry Science Center, Fayetteville AR). In addition 
flavonoid analysis of FBB and FBL was performed in triplicates using high performance liquid 
chromatography (HPLC) confirmed by mass spectroscopy methods as described by Cho and 
others 22. 
Anthropometric measurements, dietary and physical activity assessment  
At baseline, nutrition and medical histories were obtained from each participant by a 
trained staff member. Similarly, anthropometric data were collected at 0, 3, 6 and 9 month visits 
by the same trained staff member and a 114-item, 7-day food frequency questionnaire (FFQ) was 
administered to assess dietary intake. Nutrition data was analyzed by Nutrition Pro® (Axxya 
Systems; Stafford, TX) software based on USDA references. Nutrients of interest are presented 
in Table 5.1. The Five-City Physical Activity Recall was used to assess participants’ seven-day 
hours of physical activity, sleep and other domestic and occupational activities 23 at 0, 3, 6, and 9 
month time intervals. Data collected was used to compute hours spent on physical activity (PA) 
per week. 
Bone biochemical measurements 
Second void urine samples were collected, measured, aliquoted into 1 ml and stored at -
20° C till analysis. Venous blood was obtained by a phlebotomist; 4 ml sample for plasma and 6 
ml sample for serum after an overnight fast at baseline, 3, 6, and 9 months. Blood samples were 
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centrifuged at 3500 g for 15 minutes at 4° C, and the resultant plasma and serum aliquoted into 
200 µl samples and stored at -80° C till analyses. Urine samples were used in evaluation of 
urinary deoxypyridinoline (DPD) which is biomarker of bone resorption. Urinary creatinine, 
which is required to normalize urinary DPD, was measured using a calorimetric assay (Quidel 
Corporation, San Diego, CA, USA). Two markers of bone turnover, serum bone-specific alkaline 
phosphatase (BALP) and serum osteocalcin (OC) were assessed using Elisa kits (Quidel 
Corporation, San Diego, CA, USA).  
Assessment of oxidative stress and inflammation 
Effects of berry treatments on oxidative stress levels were assessed using thiobarbituric 
acid reactive substances (TBARS), a biomarker of lipid peroxidation. TBARS were determined 
in duplicate using TBARS assay kit (Cayman Chemical; Ann Arbor, Michigan). To measure the 
potential anti-inflammatory effects of FBL and FBB, high-sensitivity C-reactive protein (hsCRP) 
was evaluated using a latex particle enhanced immuneturbidimetric assay measured on an ACE 
Alera clinical chemistry system (Alfa Wasserman, Inc.; West Caldwell, NJ).  
Bone density measurements 
At the beginning and end of the treatment period, BMD and bone mineral content (BMC) 
were obtained using dual X-ray absorptiometry (DXA; GE Lunar DXA, Waukesha, WI). The 
densitometry was equipped with enCore software for whole body, lumbar spine (L1-L4), hip and 
forearm BMD and BMC measurements. To ensure stability of the densitometer and accuracy of 
the data, the apparatus was tested using phantom scans before every data acquisition. 
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Statistical analysis 
Since measurements were taken at four time points (months 0, 3, 6 and 9), a split plot 
model was used with treatments (i.e. NS, S-C, and S-BL and S-BB groups) as whole plot and 
time as a split plot. Least square means (LSM) were compared for significance and where 
significant effects were determined, means were compared. Data are reported as LSM ± SEM 
and statistical significance set at P < 0.05. Data analysis was done using ANOVA using PROC 
MIXED in SAS (Version 9.2; SAS Institute, Cary, NC, USA). A 2 sample t-test was also done to 
compare baseline whole body, lumbar spine, and femurs, and forearm BMD and BMC 
measurements of smokers versus nonsmokers. 
RESULTS 
Macronutrient and phenolic composition of freeze-dried berries  
Results of proximate analysis were as follows: carbohydrates 88.4% and 92.1%; crude 
fiber 27.7% and 12.5%; protein 6.4% and 3.6%; and fat 6.3% and 2.3% for blackberry and 
blueberry respectively. Percent carbohydrates were calculated using the formula: 100 – percent 
protein –percent fat. The energy and macronutrients provided by 45 g of FBB and FBL 
computed from these percentages in addition to those calculated by nutrition software are shown 
on Table 5.1. 
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Table 5.1. Nutrient and phenolic compounds composition of 45 g of freeze-dried blackberries and blueberries obtained by 
Nutrition Pro® software, proximate analysis and HPLC analysis.  
  Freeze-dried blackberries Freeze-dried blueberries 
Nutrients Calculated 
Proximate 
analysis Calculated 
Proximate 
analysis 
Energy (kcal) 118.94 195.00 97.95 185 
Total fat (g) 1.07 3.00 0.88 1.00 
Total carbohydrates (g) 28.96 39.00 23.85 42.00 
Protein(g) 1.84 3.00 1.52 2.00 
Fiber (g) 10.44 12.00 8.6 6.00 
Crude fiber (g) 5.59 - 4.61 - 
Vitamin E (IU) 2.19 - 1.81 - 
Vitamin A (RE) 26.41 - 21.75 - 
Vitamin C (mg) 74.86 - 61.65 - 
Folate (μg) 53.19 - 43.8 - 
Ca (mg) 46.81 - 38.55 - 
P (mg) 39.89 - 32.85 - 
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Calculated values from Nutrition Pro® (Axxya Systems, Stafford, TX); analysis based on USDA references. Proximate analyses 
performed in duplicates by the Central Analytical Laboratory at the University of Arkansas. * HPLC phenolic composition performed 
in triplicates; values are mean ± SEM 
 
 
 
K (mg) 384.32 - 316.5 - 
Fe (mg) 1.06 - 0.88 - 
Phenolic composition*  HPLC analysis  - HPLC analysis  
Total anthocyanins (mg) - 284.085 ± 3.915 - 652.14 ± 53.865 
Total flavonols (mg) - 33.48 ± 0.225 - 35.919 ± 3.06 
Total ellagitannins (mg) - 111.96 ± 0.72 - - 
Chlorogenic acid (mg) - - - 72.9315 ± 1.89 
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Estimates of the major phenolics consumed in 45 g of FBB and FBL per day are 
summarized in Table 5.1. In terms of the phenolic profile of FBB, 5 different anthocyanins were 
identified but approximately 87% of the anthocyanins were cyanidin-3-glucoside. In addition, 9 
quercetin glycosides, and 4 ellagitannin compounds, were determined. Twenty nine different 
phenolic compounds were identified in FBL. Of these, 17 were anthocyanins, mainly, cyanidin, 
delphinidin, malvidin, peonidin, and petunidin glycosides. Six flavonols compounds determined 
in FBL were quercetin and myricetin glycosides.  
Participants  
Fifty women completed the 9 month study but data used was for 49 of the participants 
(31smokers and 18 nonsmokers). The overall attrition rate was 24.6%. The most common 
reasons for dropping out of the study were: inconvenience (n=6), medical reasons (n=2), 
relocation (n=1), and inability to consume berries as prescribed (n=5), and quit smoking (n=2). 
Attrition was noted to be highest at the 3 month visit (n=11) compared to 6 month (n=3) and 9 
month (n=2) visits. Attrition affected the experimental groups as follows: S-C, S-BB, S-BL and 
NS reduced by 9, 2, 3 and 2, women respectively.  
Baseline characteristics, anthropometric measurements, physical activity 
measurements and dietary intake  
Characteristics, anthropometrics measurements are presented by treatment group in 
Table 5.2. The participants were predominantly white (98%) aged 46.5-68.0 years and the 
median age was 54.5 years. Baseline characteristics were similar for all smokers in the study. 
The average age of the NS-C was 4 years greater than each of the other experimental groups (p = 
0.0166). All nonsmokers still fit the 1-10 years postmenopausal range specified for eligibility 
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into the study. Since PA improves bone function and strength, data was analyzed to detect 
differences among experimental groups for number of hours spent on PA. No significant 
differences existed in the activity levels of the women throughout the study period.  
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Table 5.2.Baseline characteristics of study participants 
Values represent means ± SEM. Values within a row that do not share the same letters are 
significantly different from each other (P < 0.05).  Abbreviations used: NS-C: Nonsmokers 
control group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL: 
smokers + 45 g blueberries/day. With the exception of age, there were no significant differences 
observed between the experimental groups for these measures at 3, 6 and 9 months 
 
Measures NS-C (n=20) S-C (n=21) S-BB (n=8) S-BL (n=16)  p value 
Age (yrs) 58.0 ± 0.9
b
 54.4 ± 0.9
a
 54.3 ± 1.6
a
 54.2 ± 1.1
a
 0.0166 
Years postmenopausal 7.4 ± 0.7 5.6 ± 0.7 6.9 ± 1.2 6.7 ± 0.8 0.2049 
Weight (kg) 66.0 ± 3.8 72.9 ± 3.6 68.2 ± 6.5 76.5 ± 4.4 0.2980 
BMI (Kg/m
2
) 23.7 ± 1.5 27.8 ± 1.4 25.2 ± 2.5 29.3 ± 1.7 0.1476 
Physical activity (hrs/wk)  1.8 ± 0.3 1.6 ± 0.3 1.7 ± 0.6 1.59 ± 0.4 0.9533 
Cigarettes/day - 17.5 ± 1.7 17.9 ± 3.0 16.1 ± 2.1 0.7378 
Body fat (%) 37.2 ± 1.7 41.5 ± 1.7 38.9 ± 3.8 40.2 ± 1.9 0.3668 
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All P-values of time and treatments and their interaction derived from 7d FFQ data is 
presented in Table 5.3. Treatment effect was significant for vitamin A intake. S-C, S-BL, and S-
BB groups consumed significantly lower amounts of vitamin A when compared to NS-C group. 
Consumption of dietary fiber, vitamin E and vitamin D were significantly different based on 
month and this may be due to seasonal variations. Means of total energy, vitamins and minerals 
as analyzed from the FFQ are presented in Appendixes 3, 4 and 5. 
Based on a 2000 kcal diet, 45 g of FBB and FBL were estimated to contribute 5.9% and 
4.9%, respectively to participants’ total energy intake. Actual percent contribution of total energy 
based on the mean total energy intakes was 5.6% and 4.8%, for FBB and FBL, respectively. 
Blueberries had better acceptance than blackberries due to the large amounts of seeds in BB. 
Nonetheless, both berries were well tolerated. The mean self-reported compliance for S-BL and 
S-BL groups were 85% and 87% respectively.
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Table 5.3.Entries are p-values for the F-tests of treatments and time on daily total energy and nutrient intake in  the 
ANOVA.as calculated from a 7 d FFQ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatments were: nonsmokers control group, smokers control group, smokers + 45 g blackberries/day and smokers + 45 g 
blueberries/day. Time was 0, 3, 6, and 9 months, and treatment*time is the interaction of treatment and time. Significance was 
established at p < 0.05.
 Total energy Protein  Total fat  Carbohydrates  Dietary Fiber  
Treatments  0.7674 0.9698 0.2577 0.6808 0.1413  
Time  0.7937  0.1896  0.9187  0.2770   0.0121  
Treatment*Time 0.7403  0.8888  0.8099  0.7808  0.2183   
 Vitamin C  Vitamin A  Vitamin E  Vitamin K  Vitamin D   
Treatments 0.3726  0.0011  0.0618  0.4782  0.0621   
Time 0.0654  0.6624 0.0017  0.5234  0.0222   
Treatment*Time 0.3151  0.8415  0.5920  0.6802  0.8145   
 Calcium Magnesium Potassium Phosphorus  Sodium Biotin  
Treatments 0.1097  0.1045  0.4291  0.3482  0.8963  0.0929  
Time 0.5182  0.5526  0.3170  0.4091  0.8335  0.4697  
Treatment*Time 0.9053  0.8037  0.8676  0.9695  0.6778  0.2058  
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Bone mineral density and content 
A 2 sample t-test comparing baseline whole body, lumbar spine (L1-L4), hip and 
forearm BMD and BMC measurements showed no significant differences between 
smokers and nonsmokers (data not shown). After the 9 mo. treatment period, bone loss of 
total body BMD was statistically significant in S-C and S-BL groups, but not in S-BB 
and NS-C groups (P = 0.0284). Blackberries but not blueberries demonstrated modest 
bone protective effects in preventing smoking-induced bone loss. Both freeze-dried fruit 
regimens had no significant changes on BMC, and BMD of the lumbar spine, right and 
left femur and ulna.  
Biomarkers of bone metabolism, TBARS and hsCRP 
Berry consumption had no significant effect on neither urinary nor serum biomarkers of 
bone metabolism BAP and OC (Appendix 6). DPD is a stable product of lysine 
breakdown during bone resorption. Though not to a significant degree, DPD levels 
remained somewhat stable for the S-BB group, but slightly fluctuated over the nine 
month periods for the other experimental groups. Similarly, this trend was observed with 
the two serum biomarkers of bone turnover, BAP and OC for all groups.   
Berry regimens had no significant effects on oxidative stress or inflammation 
levels in postmenopausal smokers as shown on Appendix 7. Levels of plasma hsCRP, a 
reliable marker of inflammation, fluctuated in the four experimental groups over 0, 3, 6, 
and 9 month periods.  
TBARS a biomarker of lipid peroxidation decreased in the S-BB and S-BL groups 
and remained low thereafter compared to the levels in S-C and NS groups which 
increased in a time dependent manner.  
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DISCUSSION 
There is paucity of studies regarding potential bone health benefits of blackberries 
and blueberries. Nonetheless, two studies 16, 17 suggest that BB and BL may suppress bone 
turnover and prevent bone loss in animal models.  
Characteristic of ideal randomization, all smokers started with similar baseline 
attributes and they remained unaffected by berry intervention throughout the study. 
Considering data analyzed from the FFQ, there were two main observations: first, freeze-
dried BB and BL supplied 12.5g and 6 g of fiber respectively which may have enhanced 
weight control 24 and prevented weight gain. Secondly, vitamin A, known to suppress 
bone resorption and stimulate bone formation 25
, 26, 27  may have contributed to reduced 
bone loss in N-SC group.  
In terms of BMC and BMD, we propose that age of nonsmokers’ and lack of 
statistical power due to small sample sizes were possible causes for lack of differences in 
baseline BMD measures of smokers versus nonsmokers. However, as expected and 
evidenced by reduced total BMC and BMDs at all sites, all experimental groups lost bone 
within the 9 month period. However, S-C group lost significantly more bone mass than 
the S- BB and NS-C group but not S-BL group. Notably, the ulna experienced more bone 
loss than all other sites in all groups indicating increased fracture risk at this site. Overall 
nonsmokers had the least percent bone loss which is consistent with epidemiological 
findings that smoking aggravates bone loss 7. Findings of this study suggest that 
blackberries showed modest bone protection of only total body BMD and blueberries had 
no effect on bone health. Blackberries supplied 284 mg of ACY, 33 mg of flavonols and, 
112 mg of ellagitannins daily while blueberries supplied 652 mg ACY, 36 mg flavonols 
and 73 mg of chlorogenic acid daily. Although it is plausible that the ACY profile of the 
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berries may be a major factor, BB just like BL did not have a profound effect on BMD in 
other sites measured. These findings are contrary to others 20, 28 that demonstrate bone 
health benefits of consuming fruits and vegetables. Nonetheless, since only smokers 
received berries in this study the question remains as to whether these findings would be 
similar in nonsmokers.  
Mechanisms by which berries may exert health benefits were investigated by 
measuring both markers of bone formation and bone resorption. Levels of BAP and OC, 
now considered bone turnover markers 29-31 are generally correlated with bone mass and 
describe rates of bone formation or resorption. Contrary to our expectations, berry 
regimens had no effect on formation and resorption rates in postmenopausal smokers 
matching the results of bone mass. In the S-BB group, levels of urinary DPD indicated a 
reduced rate of bone breakdown albeit not to a significant degree. Nonetheless, we can 
reasonably propose that the mechanism by which BBs prevented bone loss may involve 
suppression of bone resorption. This is a mechanism that has been postulated in other 
studies that have demonstrated protective effects of dried plum 19, 32.  
Regarding oxidative stress, we expected that berry antioxidants would improve 
the basal level of oxidation that accompanies normal cellular metabolism in smokers. 
After three months of berry consumption, concentrations of TBARS in the berry groups 
(irrespective of the berry type) remained stable compared to control groups. Although 
this did not achieve statistical significance, it is indicative that berry regimens may 
prevent oxidative stress in postmenopausal smokers. To strengthen the argument, we 
observed that, TBARS concentrations in the control groups increased in time-dependent 
fashion as expected due to smoking33 (S-C group ) and estrogen loss34(S-C and NS-C 
groups). With respect to inflammation, smokers had higher levels of hsCRP, similar to 
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findings by Gan et al., 35. Berry regimens did not suppress inflammation resulting from 
smoking and postmenopausal status even though berry phenolic compounds and 
anthocyanins in particular have demonstrated anti-inflammatory properties in animal 
models 36, 37. Conflicting findings concerning effects of phenolic compounds are reported 
in other studies 38,-40. Karlsen et al., 41 found no effect on CRP concentrations after daily 
consumption of 300 mg/d of blueberry anthocyanins in a 3 week study using healthy 
nonsmokers.  
Overall, outcomes of this study are atypical due to growing evidence that dietary 
antioxidants exert modest antioxidant effects in vivo and improve bone indices14, 16, 17, 42. 
Berry intervention may have been affected by one or a combination of several factors: (i) 
composition of gut microbiota in smokers receiving berries 43, (ii) our relatively small 
treatment groups which affected statistical power, (iii) smoking status of participants, and 
(iv) absorption and bioavailability of berry bioactive compounds and their metabolites 
upon which potency is dependent. BB and BL absorption and metabolism though unclear, 
is known to be different 40, 44, 45 and may influence health benefits. 
CONCLUSION 
In conclusion, the findings of this study and the existing literature on berry 
bioactive compounds are conflicting. Blackberries demonstrated only modest protection 
on total BMD and had no effect on other parameters; while and blueberries had no 
positive effects on all parameters determined in postmenopausal smokers. Future studies 
are necessary to explore mechanisms by which berries prevent bone loss and effective 
doses in both postmenopausal smokers and nonsmokers.   
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V. SUMMARY AND CONCLUSIONS 
This conclusions chapter gives a summary of each of the chapters of this 
dissertation.  
The introduction and literature review establishes that postmenopausal 
osteoporosis is a public health burden that manifests in fragility fractures and affects over 
200 million women worldwide 1. In the United States alone nearly half of all women over 
the age of 50 suffer osteoporosis-related fractures, i.e. more than 1.5 million fractures a 
year 2.  
Additionally, smoking in postmenopausal women increases the risk factor of 
osteoporosis 3 by reducing active vitamin D in plasma4, causing malabsorption of 
calcium5, and increased oxidative stress6 and inflammation6
, 7. Moreover, oxidants from 
cigarette smoke down regulate the expression of important genes that mediate bone 
formation and essential for bone structure 8. 
Approximately 34,000 hip fractures that occur in the United States annually are 
attributable to smoking 9. In addition, in females smoking can reduce bone mass at hip, 
lumbar spine, forearm and calcaneus, and increase the lifetime risk of hip fracture and 
lumbar spine by 31% and 13% respectively 7. Moerover, heavy smoking in women, 
throughout adult life can result in 5-10% less bone by the age of 45-50 years, compared 
to non-smokers 5.  
Also, osteoporosis drug therapies fall into two categories: the antiresorptive 
medications that slow the breakdown of bone and the anabolic treatments that help build 
bone. These drugs are effective and work with the body systems to protect bone mineral 
density and reduce the risk of fractures 10. However, due to several factors including cost, 
fear, and side effects associated with these drugs, approximately 50% of patients 
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discontinue medication or fail to adhere to treatments regimens in the first year of use 10,
 
11. 
The literature review emphasizes that phenolic compounds, particularly 
anthocyanins and flavonols found in fruits and vegetables have antioxidative and anti-
inflammatory capacities 
12
. Hence, consumption of diets rich antioxidants is associated 
with health benefits. Blueberry and blackberry phenolics function as antioxidants by 
easily donating hydrogen atoms from their aromatic hydroxyl groups and by supporting 
unpaired electrons 
13
.  
The chapter on the review of blackberries reveals that blackberries are rich in 
phenolic compounds and their composition and concentration is influenced by several 
factors including variety, location of cultivation, and maturation. Blackberries are a rich 
source of phenolics including, anthocyanins 
18
, ETs 
19
, flavonols 
20
, flavan-3-ols, and 
procyanidins 
21
. The berries also contain appreciable levels of phenolic acids 
22
 and low 
levels of lignans 
23
. Total phenolics in blackberries have been shown to range from 114 to 
1056 mg/100 g fresh weight
22
. 
Finally, the review demonstrates that blackberry phenolic compounds have 
protective effects against age-related neurodegenerative diseases, and bone loss in vivo, 
and inhibits LDL and liposomal oxidation in vitro. However, more research is needed to 
explore their metabolism, bioavailability and the mechanisms by which they confer 
health benefits. Furthermore, studies are necessary to elucidate the in vivo effective 
concentrations of blackberry phenolic compounds. 
The animal study was based on the hypothesis that lowering oxidative stress by 
consumption of antioxidant rich foods may prevent bone loss by attenuating 
osteoclastogenesis and bone resorption 14-17. Findings of the animal study demonstrate 
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that blackberries supplemented in the diet at the level of 5% (w/w) may modestly reduce 
ovarian hormone-induced bone loss. Although the mechanism is still unclear, it is 
reasonable to speculate that the compounds work by lowering oxidative stress.  
In chapter five, findings of the clinical study in which postmenopausal smokers 
consumed 45g of blueberries or blackberries were inconclusive, showing only modest 
protection on total BMD by blackberries and not blueberries. Effects of blackberry and 
blueberry consumption on bone health need further elucidation in pre- and 
postmenopausal smokers and nonsmokers. 
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APPENDICES 
Appendix 1. Health and Medical History Questionnaire 
Subject ID:  ____________________ 
Interviewer: ____________________    Date______________ 
 
Age________ Height_______ Weight________ BMI__________ 
 
I.  Medical History 
 
A.  Skeletal Health 
 
Personal history of skeletal disorders: 
 1.  Not known ___________________ 
 2.  Yes: uncontrolled ________________ 
 3.  Yes: Medications _________________ 
 4.  Yes: Exercise program ___________________ 
 5.  Yes: Modified diet ________________ 
 6.  Yes: Surgery __________ 
 7.  Yes: Combined program __________ 
 Give details _______________________________________________________ 
 Type of Medication(s)_______________________________________________ 
 Current dosage _________________ Years taken _________________________ 
 How does this condition affect your activity?  
 
Family history of skeletal disorders: 
 
 1.  None _____ 
 2.  One parent _____ 
 3.  Both parents _____ 
 4.  One close relative _____ 
 5.  More than one close relative _____ 
 
 Relative(s) _______________________________________________ 
 
 Comments: ______________________________________________ 
 
B.  Cardiovascular Function 
Personal history of cardiovascular disease: 
 1.  Not known ___________________ 
 2.  Yes: uncontrolled ________________ 
 3.  Yes: Medications _________________ 
 4.  Yes: Exercise program ___________________ 
 5.  Yes: Modified diet ________________ 
 6.  Yes: Surgery __________ 
 7.  Yes: Combined program __________ 
 Give details _______________________________________________________ 
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 Type of Medication(s)_______________________________________________ 
 Current dosage _________________ Years taken _________________________ 
 How does this condition affect your activity?  
 
Family history of cardiovascular disease: 
 1.  None _____ 
 2.  One parent _____ 
 3.  Both parents _____ 
 4.  One close relative _____ 
 5.  More than one close relative _____ 
 
 Relative(s) _______________________________________________ 
 Comments: ______________________________________________ 
 
C.  Hypertension 
 1.  None known ___________________ 
 2.  Yes: uncontrolled ________________ 
 3.  Yes: Medications _________________ 
 4.  Yes: Exercise program ___________________ 
 5.  Yes: Modified diet ________________ 
 6.  Yes: Yes: combined program__________ 
 7.  Most recent blood pressure  __________ 
 Explain_______________________________________________________ 
 Type of Medication(s)_______________________________________________ 
 Current dosage _________________ Years taken _________________________ 
 Ever taken thiazide diuretics? ____________ 
 
D.  Diabetes 
 1.  No record or indication _____ 
 2.  In past, but not now _____ 
 3.  Yes, well controlled _____ 
 4.  Yes, not controlled _____ 
 Explain ____________________________________________________ 
 Type of Medication(s)_________________________________________ 
 Current dosage _____________________Years taken________________ 
 How does this condition affect your activity? _______________________ 
 
E.  Gastrointestinal/Digestive Problems 
 1.  No record or indication _____ 
 2.  In past, but not now _____ 
 3.  Yes, well controlled _____ 
 4.  Yes, not controlled _____ 
 Explain ____________________________________________________ 
 Type of Medication(s)_________________________________________ 
 Current dosage _____________________Years taken________________ 
 Ever taken steroids (i.e., prednisone)? ______________________ 
 Currently taking antacids? _______________________________ 
 How does this condition affect your activity? ________________ 
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F.  Liver Disease/ Problems 
 1.  No record or indication _____ 
 2.  In past, but not now _____ 
 3.  Yes, well controlled _____ 
 4.  Yes, not controlled _____ 
 Explain ____________________________________________________ 
 Type of Medication(s)_________________________________________ 
Current dosage _____________________Years taken________________ 
How does this condition affect your activity? _______________________ 
 
G.  Respiratory Problems 
 1.  No record or indication _____ 
 2.  In past, but not now _____ 
 3.  Yes, well controlled _____ 
 4.  Yes, not controlled _____ 
 Explain ____________________________________________________ 
 Type of Medication(s)_________________________________________ 
 Current dosage _____________________Years taken________________ 
 How does this condition affect your activity? _______________________ 
 
H.  Thyroid Disorder 
 1.  No record or indication _____ 
 2.  In past, but not now _____ 
 Hyper?  _____ Hypo?  ___ 
 Explain ____________________________________________________ 
 Type of Medication(s)_________________________________________ 
 Ever taken thyroid hormones (i.e., Synthroid)? _____ 
 
I. Reproductive history:  LMP_____________, No. of children______________ 
 
II.  Medication or Drug Use 
A.  Previous or Present Use of Any of the Following (Specify): 
 1.  Anabolic steroids _____________  
 2.  Corticosteroids or glucocorticoids _____prednisone _____ 
 3.  Thiazide diuretics _____ Other diuretics _____ 
 4.  Vitamin D 
5. Medications for bone   Fosamax:  
    Evista (Roloxaphin): ___________________ 
    Miacalcin (Calcitonin): _________________ 
    Teriparatide (Forteo):___________________ 
6. Others: 
 ___________________________________________________  
 ___________________________________________________  
 ___________________________________________________  
 
 
B.  Previous or Present Use of Alcoholic Beverages (Beer, wine, hard liquor). 
 Please indicate: 
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 Frequency of intake (Times/week or times/month): _____ 
 Number of servings at a sitting: _____ 
 Number of years of use: _____ 
 
C.   Estrogen or Hormone Replacement (ERT or HRT) 
 1.  Never ___ move along to section D. 
 2.  Yes, in past ___ at what age? ___ & How long _____ 
 
D.  Currently /previously a smoker?______If yes, number of cigarettes per 
day____________ 
 
III.  Physical Activity 
A.  Occupational Intensity (respond to 1, 2, 3, or 4): 
 1.  Majority of time:  Sitting ___     Standing ___     Walking ___ 
 2.  Equal amount of time: Sitting and Standing ___ 
    Walking and Sitting ___ 
    Standing and Walking ___ 
 3.  Combination: Sitting, Standing, and Walking ___ 
 4.  Much of time: Lifting & Carrying ___ 
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Appendix 2. Telephone Screening Exclusion Criteria 
 
Effect of Dried Fruits on Indices of Bone Status in Postmenopausal Women 
 
Interviewer: study coordinator or trained personnel  
Hello,  
Good morning/good afternoon/good evening 
How are you? 
Thank you for your interest in our study 
Is it a good time for me to go over a few questions with you now? 
Are you a postmenopausal woman? If yes, when was your last period? 
Do you know if you have current or previous history of: 
Bone disorders (osteomalacia, severe osteoporosis, unexplained or stress fractures) 
cancer 
Diabetes mellitus (only Insulin Dependent) 
Eating disorders (anorexia nervosa or bulemia) 
Gastrointestinal or chronic digestive disorders (chrohn’s disease, ulcerative collitis) 
Hypertension (exclude if taking thiazide diuretics) 
Active liver disease 
Parathyroid disorders 
Renal disease/problems 
Thyroid disease/problem 
Other current illnesses? 
 
Are you taking or have taken any of the following medications since the time of cessation of 
your menses? 
 Glucocorticoids 
Anabolic steroids (testosterone, 
androgens) 
 
Anticonvulsants Current use of oral contraceptives 
Calcitonin Progestagens, progesterone (HRT) 
Bisphosphonates  
Estrogens (estrase, premarin, 
prempro)  
 
Teriparatide (Forteo) Recent (<6 months) initiation on of thyroid 
hormones 
 
Are you a smoker? If so, how many cigarettes per day?  
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Appendix 3. Seven Day Food Frequency Questionnaire 
 
Subject Number_________    Date_________ 
 
Vitamin and Mineral Supplement 
 
1.  Do you take any vitamin or mineral supplement(s)? Yes ___No _____ 
2.  If Yes, please, list all names of vitamin or mineral supplements, and how often do you take 
the supplement(s)? 
Name ______________________  How often ____ per day Or ____ per week 
Name ______________________  How often ____ per day Or ____ per week 
Name ______________________  How often ____ per day Or ____ per week 
Name ______________________  How often ____ per day Or ____ per week 
Name ______________________  How often ____ per day Or ____ per week 
This questionnaire asks you about your consumption of foods and beverages over the past week, 
which includes the time from exactly one week ago until the last meal you had before you fill out 
this questionnaire.  The “How Often” columns are for day, week, or rarely/never.  We want you 
to think back over the past week and tell us how many times (per day, if you consume the item 
every day, or per week) you consumed each item.  A medium serving is in parentheses. 
 
EXAMPLES: 
Ate 1/2 grapefruit about twice last week. 
Ate 1 large hamburger four times last week. 
Drank 2 cups of whole milk each day. 
 
Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
Grapefruit (1/2)  2   X  
Hamburger, regular (1 patty, 3 oz)  4    X 
Whole milk (1 cup, 8 oz) 2    X  
 
Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
DAIRY FOODS       
Whole milk (1 cup, 8 oz)       
2% milk (1cup, 8 oz)       
Skim milk (1 cup, 8 oz)       
Cream, whipped (1 Tbsp)       
Sour cream (1 Tbsp)       
Coffee cream (1 Tbsp)       
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Ice cream (½ cup)       
Low fat ice cream (½ cup)       
Frozen yogurt (½ cup)       
Yogurt (1 cup)       
Low fat yogurt (1 cup)       
Cottage cheese (½ cup)       
Cream cheese (1 oz)       
Low fat cream cheese (1 oz)       
Other cheese (1 slice or 1 oz)       
Low fat cheese (1 slice or 1 oz)       
Margarine (1 tsp)       
Butter (1 tsp)       
Reduced fat margarine (1 tsp)       
       
FRUITS, FRUIT JUICES       
Raisins (1 oz or 1 sm box)       
Grapes (20)       
Prunes (½ cup)       
Bananas       
Cantaloupe (¼ melon)       
Watermelon (1 slice)       
Apples, applesauce or pears 
(1 fresh, ½ cup) 
      
Dried Apples (1 oz)       
Apple juice (½ cup)       
Oranges       
Orange juice (½ cup)       
Grapefruit (½ cup)       
Grapefruit juice (½ cup)       
Other fruit juices (½ cup)       
Strawberries—fresh, frozen, or canned 
(½ cup) 
      
Blueberries—fresh, frozen, or canned 
(½ cup) 
 
 
      
Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
Peaches (1 fresh, ½ cup canned)       
Apricots (1 fresh, ½ cup canned)       
Plums (1 fresh, ½ cup canned)       
Honeydew melon (¼ melon)       
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VEGETABLES, 
VEGETABLE JUICE 
      
Tomatoes (1)       
Tomato juice (½ cup)       
Tomato sauce (½ cup)       
Spaghetti sauce (½ cup)       
Red chili sauce, taco sauce, or salsa 
(1 Tbsp) 
      
Tofu or soybeans (3-4 oz)       
String beans, green beans (½ cup)       
Broccoli (½ cup)       
Cabbage (½ cup)       
Cole slaw (½ cup)       
Cauliflower (½ cup)       
Brussels sprouts (½ cup)       
Carrots, raw (½ carrot or 2-4 sticks)       
Carrots, cooked (½ cup)       
Corn (1 ear or ½ cup frozen or canned)       
Peas (½ cup fresh, frozen or canned)       
Lima beans (½ cup frozen, or canned)       
Mixed vegetables (½ cup)       
Beans or lentils, baked or dried (½ cup)       
Summer or yellow squash (½cup)       
Winter squash (½ cup)       
Zucchini (½ cup)       
Yam or sweet potato (½ cup)       
Spinach, (cooked ½ cup, raw 1 cup)       
Iceberg lettuce, romaine or leaf (1 cup)       
Celery (4” stick)       
Beets (½ cup)       
Alfalfa sprouts (½ cup)       
Kale, mustard, or chard greens (½ cup)       
Vegetable, vegetable beef, minestrone 
or tomato soup (1 cup) 
 
 
      
Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
EGGS, MEAT, ETC.       
Eggs (2)       
Chicken or turkey, roasted or broiled       
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with skin (3-4 oz) 
Chicken or turkey, roasted or broiled 
skinless (3-4 oz) 
      
Chicken, fried with skin (3-4 oz)       
Bacon (2 slices)       
Hot dogs (2)       
Low fat hot dogs (2)       
Sausage (2 patties or 2 links)       
Bologna (1 slice)       
Other processed luncheon meat (1 slice)       
Liver, chicken or beef (3-4 oz)       
Hamburger, regular (1 patty, 3-4 oz)       
Hamburger, lean (1 patty, 3-4 oz)       
Meat loaf (3-4 oz)       
Pork, chops, roasts (3-4 oz)       
Lamb (3-4 oz)       
Beef, roast, steak (3-4 oz)       
Beef stew with vegetables (1 cup)       
Ham (3-4 oz)       
Tuna fish (3-4 oz)       
Tuna salad (½ cup)       
Fish, baked or broiled (3-4 oz)       
Fish, fried or fish sandwich (3-4 oz)       
Shrimp, Lobster, Scallops       
Pizza (2 slices)       
Mixed dishes with cheese (1 cup)       
Lasagna or meat pasta dishes (1 cup)       
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Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
BREADS, CEREALS, STARCHES       
Cold breakfast cereal (1 cup)       
Cold breakfast cereal—fortified (1 cup)       
Cooked oatmeal (1 cup)       
Other cooked breakfast cereal (1 cup)       
White bread (1 slice)       
Pita bread (1 piece)       
Dark bread (1 slice)       
English muffin (1)       
Bagel (1)       
Dinner roll (1)       
Hamburger or hotdog bun (1)       
Muffin (1)       
Biscuit (1)       
Corn bread, corn muffin (1)       
Brown rice (1cup)       
White rice (1cup)       
Spaghetti noodles (1 cup)       
Macaroni noodles (1 cup)       
Other pasta noodles (1 cup)       
Bulgar, kasha, couscous (1 cup)       
Pancakes or waffles (2)       
Potatoes, french fries or fried (½ cup)       
Potatoes, baked or boiled (1)       
Mashed potatoes (1 cup)       
Potato chips or corn chips 
(small bag or 1 oz) 
      
Saltine crackers (5)       
Saltine crackers, low sodium (5)       
Saltine crackers, fat free (5)       
Other crackers (5)       
Other crackers, low fat (5)       
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Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
BEVERAGES       
Regular soft drink (1)       
Diet soft drink (1)       
Caffeine free soft drink (1)       
Caffeine free, Diet soft drink (1)       
Lemonade or other non-carbonated drink 
(1 glass, bottle, or can) 
      
Water (1 cup)       
Coffee (1 cup)       
Decaffeinated coffee (1 cup)       
Tea (1 cup)       
Herbal tea (1 cup)       
Beer (1 glass, bottle, or can)       
Red wine (4 oz glass)       
White wine (4 oz glass)       
Whiskey, gin, or other liquor 
(1 drink or shot) 
      
       
SWEETS, BAKED GOODS, MISC.       
Chocolate (1 small bar or 1 oz)       
Candy bar (1 small bar)       
Candy without chocolate (1 oz)       
Cookies, home baked (2)       
Cookies, ready-made (2)       
Brownies (2)       
Doughnuts (2)        
Cake, home baked (1 slice)       
Cake, ready-made (1 slice)       
Sweet roll, coffee cake, or other pastry 
ready-made (1 serving) 
      
Sweet roll, coffee cake, or other pastry 
home baked (1 serving) 
      
Pie, homemade (1 slice)       
Pie, readymade (1 slice)       
Jam, jelly, preserves, syrup, or Honey (1 
Tbsp) 
      
Peanut butter (1 Tbsp)       
Popcorn (1 cup)       
Popcorn, air popped (1 cup)       
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Type of Food How Often Size 
(Medium Serving) Day Week Rarely/ 
Never 
S M L 
Nuts (small packet or 1 oz)       
Bran, added to food (1 Tbsp)       
Wheat germ (1 Tbsp)       
Chowder or cream soup (1 cup)       
Oil and vinegar dressing (1 Tbsp)       
Mayonnaise or other creamy salad dressing, 
Regular (1 Tbsp) 
      
Mayonnaise or other creamy salad dressing, 
Low Fat or Reduced Calorie, Lite (1 Tbsp) 
      
Mayonnaise or other creamy salad dressing, 
Fat Free (1 Tbsp) 
      
Mustard, dry or prepared (1 tsp)       
Salt (1 shake)       
Pepper (1 shake)       
 
Can you think of any other food or drink that you had in the past week that was not on this form? 
If so, what was it? What was the amount? How many times did you have it this past week? 
 
 
Food_________________________________________________________________________ 
  
Amount_________________, How often per day_____________, per week__________ 
  
 
Food_________________________________________________________________________ 
 
Amount_________________, How often per day_____________, per week__________  
 
  
Food_________________________________________________________________________ 
 
Amount_________________, How often per day_____________, per week__________  
 
Food_________________________________________________________________________ 
  
Amount_________________, How often per day_____________, per week__________ 
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Nutrition History Questionnaire 
Subject ID:_________________ 
 
Interviewer:_________________ 
 
Effect of Dried Fruits on Indices of Bone Status in Postmenopausal Women   
        
Date:______________________ 
 
 
Nutrition History 
 
Modified/Specialized Diet(s) 
Followed:___________________________________________________ 
Recommended By___________________  Length of time Followed______________________ 
Recent Changes in Appetite?_________________  Due to______________________________ 
Foods Avoided?___________________________  Due to______________________________ 
History of Problems Digesting Milk?________  When?________  How Long?_______________ 
Diagnosis of Lactose Intolerance?__________  When?________  By whom? __________ 
Intake of Milk/Dairy Products & Calcium-Containing Foods (No Times/Day, Wk or Month, 
Portion Size): 
Milk_______________  Yogurt__________________  Frozen Yogurt_____________________ 
Ice Cream/Milk__________  Pudding/Custard__________  Hard Cheese___________________ 
Mixed Dishes with Cheese_________  Soft Cheese__________  Grated Cheese______________ 
Donuts/Cakes/Cookies____________  Eggs______________  Dark Breads_________________ 
How has this intake changed during that past three years? 
Intake of High Fiber Foods (Specify Type, No Times/Day, Week or Month, Portion Size): 
Whole Grain Products:  Breads___________________  Bran (wheat, oat)___________________ 
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Cereals_______________  Crackers___________  Grains (i.e., popcorn)____________ 
Nuts_____________________  Seeds____________________ Fruits____________________ 
Dried Fruits (prunes/dried apples)____________Vegetables__________________________  
Beans/Legumes (i.e., chili)____________________ 
How has this intake changed during the past three years? 
Nutritional Supplements (Type, Dose, Times/Week, No Years): 
Vitamin Supplements___________________________________________________________ 
Mineral Supplements___________________________________________________________ 
Vitamin/Mineral Supplements____________________________________________________ 
Other Supplements (e.g., cod liver oil, protein powder)__________________________________ 
 
Daily Intake (Typical weekday) 
Time Food/Description        Serving Size Food Code 
Sodium Intake (amount of salt used (tsp)/day): in cooking_________ at the table__________ 
Estimate of Na
+
 Intake/Day:  Salt Shaker_____________ High Na
+
 foods:_________________ 
Beverages Consumed (servings per day): 
Coffee:  reg__________  decaf___________  Cocoa:_________  Tea:  reg______  decaf______ 
Soda:  reg (+caf)_________  diet(+caf)_________  reg (caf free)________  diet (caf 
free)______ 
Milk (oz/day):  reg (3.5%)__________  low fat (2%)___________  skim(1% or1%)__________ 
 During what period(s) of life have you been a milk drinker?  As a(n): 
____1.  Child ____2.  Teenager ____3.  Young adult (20-29) ____4.  Adult (30-39) 
____5.  mid-life adult (40-59)   ____6.  Older adult (60+)      ____7.  Never 
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If you excluded milk during any part of your life, was (is) this due to digestive problems? 
(Explain):_______________________________________________________________   
Milk consumed/day:  child_____  teenager_____  young adult (20-29)_____  adult (30-39)_____ 
mid-life adult (40-59)_____  older adult (60+)_____Juice (type):  _____________  Calcium 
fortified Juice:  _______________  Other:___________ 
Alcoholic Beverages:_________  If yes, please specify: 
Type Times/week or Mo Serving Size No Servings Total/Week or Mo 
Beer: Reg 
 Lite 
 Dark 
 
Wine: White 
 Red 
 Rose 
 (Blush) 
 
Mixed Drink (specify): 
Other (specify):   
 
How did your food or beverage intake differ from the above during your younger years (teenager 
and young adulthood)?  
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Appendix 4. Physical Activity Recall Items  
 
Subject ID: _________________    Interviewer: ________________ 
Date: ______________________ 
 
First we would like to know about your physical activity during the past 7 days. But first, let me 
ask you about your sleep habits. 
 
1. On the average, how many hours did you sleep each night during the last five weekday nights 
(Sunday-Thursday)?  ______hours 
 
2. On the average, how many hours did you sleep each night last Friday and Saturday nights?  
_____hours 
 
Now I am going to ask you about your physical activity during the past 7 days, that is, the last 5 
weekdays and last weekend, Saturday and Sunday. 
 
We are not going to talk about light activities such as slow walking, light housework, or non-
strenuous sports such as bowling, archery, or softball. 
 
Please look at this list which shows some examples of what we consider moderate, hard, and 
very hard activities.  (interviewer:  hand subject the following card and allow time for the 
subject to read it over.) 
 
People engage in many other types of activities, and if you are not sure where one of your 
activities fits, please ask me about it. 
 
3. First, let’s consider moderate activities.  What activities did you do and how many total 
hours did you spend during the last 5 weekdays doing these moderate activities or others like 
them? 
 
Please tell me to the nearest half-hour.  _____hours 
 
4. Last Saturday and Sunday, how many hours did you spend on moderate activities and what 
did you do? 
 
(Probe:  Can you think of any other sports, job, or household activities that would fit into this 
category?) 
_____hours 
 
5. Now, let’s look at hard activities.  What activities did you do and how many total hours did 
you spend during the last 5 weekdays doing these hard activities or others like them?   
 
Please tell me to the nearest half-hour. _____hours 
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6. Last Saturday and Sunday, how many hours did you spend on hard activities and what did 
you do? 
(Probe:  Can you think of any other sports, job, or household activities that would fit into this 
category?) 
________ hours 
 
7. Now, let’s look at very hard activities.  What activities did you do and how many total hours 
did you spend during the last 5 weekdays doing these very hard activities or others like them? 
Please tell me to the nearest half-hour.  
 
(Probe:  Can you think of any other sports, job, or household activities that would fit into this 
category?) 
_________ hours 
 
8. Last Saturday and Sunday, how many hours did you spend on very hard activities and what 
did you do? 
 
(Probe:  Can you think of any other sports, job, or household activities that would fit into this 
category?) 
_________ hours 
 
9. Compared with your physical activity over the past 3 months, was last week’s physical 
activity more, or less, or about the same? 
_____ 1.  More 
_____ 2.  Less 
_____ 3.  About the same 
 
Interviewer:  Please list below any activities reported by the subject, which you don’t know how 
to classify.  Flag this record for review and completion. 
 
Activity(brief description) Hours:  workday Hours:  weekend day 
   
______________________ ______________________ ______________________ 
______________________ ______________________ ______________________ 
______________________ ______________________ ______________________ 
______________________ ______________________ ______________________ 
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Examples of Activities in Each Category 
Moderate activity (3-5 mets) 
Occupational 
Tasks: 
1) Delivering mail or patrolling on foot 
2) House painting 
3) Truck driving (making deliveries, lifting/carrying light objects 
  
Household 
Activities: 
1) Sweeping, mopping, cleaning windows 
2) Mowing the lawn with a power mower 
3) Raking the lawn and yardwork 
4)  Light carpentry 
  
Sports: 
(actual playing 
time) 
1) Table tennis or Ping-Pong 
2) Softball, baseball 
3) Volleyball 
4) Dancing:  folk, square, aerobics (low impact & intensity) 
5) Brisk walking (3 to 4 mile/hr; 15-20 min/mile) 
6) Bicycling on level ground (10-15 mile/hr) 
7) Golfing (walking and pulling/carrying own clubs) 
Calisthenics exercise and weight lifting 
 Hard Activity (5.1 – 6.9 METS) 
Occupational 
Tasks: 
1) Heavy carpentry 
2) Construction work 
  
Household 
Tasks: 
1) Scrubbing floors 
2) Shoveling snow 
3) Moving (lifting furniture and boxes) 
  
Sports: 
(actual playing 
time) 
1) Racket Sports:  badminton, paddleball, tennis (double) 
2) Basketball 
3) Rowing or canoeing leisurely 
4) Dancing: disco, jazz, aerobics (medium impact & intensity 
5) Power walking (>mile/hr; <15 min/mile) or hiking 
6) Vigorous bicycling (16 – 20 mile/hr 
7) Jogging (5 mile/hr) 
8) Swimming  
9) Roller or ice skating 
10)  Stationary bicycling 
 Very Hard Activity (7.0 METS) 
Occupational 
Tasks: 
1) Digging or chopping with heavy tools 
2) Carrying heavy loads, such as bricks or lumber 
  
Sports 
(actual playing 
time) 
1) Racket Sports:  handball, racketball, squash, tennis (singles) 
2) Soccer 
3) Snow skiing (downhill and cross country) 
4) Dancing: aerobics (high impact & intensity) 
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5) Jumping rope 
6) Vigorous bicycling on hillsJogging or running (8 mile/hr) 
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Physical Activity Recall 
 
1. ______ HOURS week-day sleep 
                Total (sum of #1 and #2) _____ 
2. ______ HOURS week-end sleep 
 
3. ______ HOURS week-day moderate/5 = _______ 
 
4. ______ HOURS week-end moderate/2 = _______ 
 
5. ______ HOURS week-day hard/5 = ________ 
 
6. ______ HOURS week-end hard/2 = ________ 
 
7. ______ HOURS week-day very hard/5 = _______ 
 
8. ______ HOURS week-end very hard/2 = _______ 
 
9. 1 _____ 2 ______ 3 _____ 
 
1. Total sleep hours _____ x 1 = ______ 
 
  
2. Average = hours moderate act.______ x 4 = ______ 
 
 
3. Average = hours hard act. _____x 6 = _______ 
4. Average = hours very hard act. ______ x 10 = ______ 
 
 
5. Sum of hours ______ - 24 _____x 1.5 = ________ 
 
10. Sum of 1,2,3,4, & 5     
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Appendix 5. Daily Total Energy and Macro-nutrient Intake Calculated from a 7 D 
FFQ of Control Smokers and Nonsmokers, and Smokers Consuming 45 g of 
Blackberries and Blueberries at Baseline, 3, 6 and 9 Months. 
 Month NS-C S-C S-BB S-BL 
Total Energy 
kcal) 
0 2051.5 ± 142.5 1818.7 ± 206.9 2095.8 ± 212.1 2051.6 ± 154.7 
 3 1997.8 ± 176.4 1789.9 ± 158.4 2367.5 ± 95.8 2141.8 ± 286.5 
 6 2253.8 ± 257.0 1957.4 ± 277.9 2217.3 ± 254.2 1939.5 ± 147.0 
  9 2139.9 ± 196.2 1953.6 ± 235.1 1855.6 ± 299.8 2026.4 ± 231.5 
Protein (g) 0 89.0 ± 6.0 93.1 ± 13.1 88.7 ± 4.4 88.6 ± 11.3 
 3 82.2 ± 6.4 79.9 ± 7.8 91.0 ± 3.6 88.7 ± 16.7 
 6 86.2 ± 6.6 80.0 ± 11.7 87.9 ± 13.0 71.5 ± 5.5 
  9 84.0 ± 5.9 82.0 ± 11.2 71.0 ± 14.7 76.1 ± 9.3 
Total fat (g) 0 89.2 ± 8.7 72.8 ± 10.8 88.7 ± 14.7 84.0 ± 10.0 
 3 87.2 ± 9.3 68.3 ± 11.1 95.1 ± 14.7 87.0 ± 10.0 
 6 103.9 ± 9.7 73.3 ± 11.1 93.5 ± 15.6 77.4 ± 10.3 
  9 96.0 ± 9.3 76.3 ± 11.5 79.2 ± 15.6 79.6 ± 10.6 
Carbohydrates (g) 0 240.5 ± 20.1 196.7 ± 24.9 223.6 ± 34.0 219.2 ± 23.2 
 3 242.0 ± 21.2 200.8 ± 25.6 266.0 ± 34.0 261.8 ± 23.2 
 6 242.6 ± 22.0 229.9 ± 25.6 230.4 ± 35.6 250.9 ± 23.7 
  9 236.8 ± 21.2 224.4 ± 26.3 236.5 ± 35.6 247.8 ± 24.2 
Dietary Fiber (g) 0 27.2 ± 2.3 19.8 ± 2.9 27.0 ± 3.9 20.2 ± 2.5 
 3 27.5 ± 3.2 19.7 ± 1.9 36.5 ± 2.0 29.8 ± 4.1 
 6 29.7 ± 2.9 23.5 ± 2.9 34.4 ± 2.8 26.9 ± 2.4 
  9 30.5 ± 3.9 21.6 ± 2.8 29.1 ± 3.6 29.9 ± 4.3 
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Values are means ± SEM. Abbreviations used: NS-C: Nonsmokers control group; S-C: Smokers 
control group; S-BB: smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day. 
NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C: baseline n=21, 3 mo. n=15, 
6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo. n= 6 and final n=6; and S-BL 
baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to attrition. 
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Appendix 6. Daily Intake of Selected Vitamins Calculated From a 7 D FFQ of Control 
Smokers and Nonsmokers, and Smokers Consuming 45 g of Blackberries and Blueberries 
at Baseline, 3, 6 and 9 Months. 
 Month NS-C S-C S-BB S-BL 
Vitamin C 
(mg) 
0 200.6 ± 21.1 145.0 ± 29.2 143.1 ± 18.7 140.1 ± 15.8 
 3 185.5 ± 27.3 139.6 ± 19.6 235.8 ± 32.2 207.0 ± 30.4 
 6 202.2 ± 23.7 152.7 ± 28.1 185.9 ± 16.9 197.2 ± 26.0 
  9 174.9 ± 29.6 139.3 ± 9.5 174.3 ± 15.4 182.5 ± 23.1 
Vitamin A 
(RE) 
0 1844.8 ± 212.1 1095.8 ± 156.2 1114.0 ± 402.7 1162.6 ± 147.4 
 
3 1497.2 ± 158.6 
906.184 ± 
139.4 
1122.8 ± 159.4 1108.0 ± 193.4 
 6 1712.0 ± 179.9 1071.8 ± 215.2 744.3 ± 142.2 891.4 ± 189.8 
  9 2010.0 ± 445.8 1220.3 ± 271.2 712.8 ± 230.6 963.9 ± 238.7 
Vitamin E 
(mg) 
0 6.4 ± 0.9 4.4 ± 0.6 6.7 ± 1.2 4.3 ± 0.7 
 3 6.6 ± 0.9 5.2 ± 0.7 9.2 ± 2.1 6.0 ± 1.0 
 6 8.2 ± 1.5 4.6 ± 0.9 12.6 ± 2.8 7.4 ± 1.2 
  9 9.7 ± 1.6 6.2 ± 1.3 9.6 ± 2.6 8.1 ± 1.7 
Vitamin K 
(µg) 
0 95.6 ± 15.8 75.8 ± 13.1 56.5 ± 14.8 90.8 ± 16.1 
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Values are means ± SEM. Abbreviations used RE; retinol equivalents: NS-C: Nonsmokers 
control group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL: 
smokers + 45 g blueberries/day. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; 
S-C: baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 
mo. n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to 
attrition. 
  
 3 85.8 ± 16.5 52.8 ± 5.9 59.7 ± 15.7 92.9± 36.1 
 6 88.6 ± 15.3 62.6 ± 17.7 49.3 ± 16.2 72.5 ± 20.6 
  9 70.6 ± 9.9 76.9 ± 17.2 56.37 ± 13.1 46.5± 12.0 
Vitamin D 
(ug) 
0 3.8156 ± 0.7 3.8 ± 0.8 2.7 ± 0.7 1.7 ± 0.5 
 3 3.3128 ± 0.7 3.5 ± 0.9 2.7 ± 0.8 1.7± 0.4 
 6 3.9821 ± 0.8 3.6 ± 0.9 3.2 ± 1.0 1.2 ± 0.4 
  9 2.2758 ± 0.6 3.0 ± 0.7 1.7 ± 0.6 1.1 ± 0.3 
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Appendix 7. Daily Intake of Selected Minerals Calculated From a 7 D FFQ of 
Control Smokers And Nonsmokers, and Smokers Consuming 45 g of Blackberries 
and Blueberries at Baseline, 3, 6 And 9 Months. 
 Month      NS-C       S-C S-BB S-BL 
Ca (mg) 0 1066.9 ± 94.4 897.6 ± 111.2 821.8 ± 77.4 790.8 ± 73.1 
 3 1126.3 ± 172.3 801.2 ± 126.5 925.1 ± 77.2 787.2 ± 106.6 
 6 1017.6 ± 79.3 946.2 ± 159.6 810.8 ± 112.9 784.5 ± 125.6 
  9 913.5 ± 77.9 805.4 ± 126.8 760.7 ± 127.2 760.7 ± 97.5 
Mg (mg) 0 411.6 ± 30.2 316.2 ± 34.03 428.2 ± 42.6 332.1 ± 29.7 
 3 414.1 ± 33.6 328.9 ± 34.0 437.2 ± 31.0 367.9 ± 46.1 
 6 442.8 ± 41.3 351.2 ± 43.3 434.1 ± 49.4 334.1 ± 23.1 
  9 420.8 ± 41.3 320.1 ± 42.5 348.3 ± 64.4 369.0 ± 31.9 
K(mg) 0 4041.6 ± 284.5 3468.3 ± 318.1 3978.0 ± 260.7 3583.3 ± 283.5 
 3 4121.8 ± 363.7 3397.7 ± 387.8 4428.8 ± 301.0 3859.2 ± 449.9 
 6 4207.6 ± 303.0 3650.7 ± 498.7 4127.5 ± 388.4 3490.8 ± 288.1 
  9 4009.7 ± 342.4 3287.8 ± 454.7 3388.2 ± 599.5 3750.9 ± 347.3 
P (mg) 0 1606.4 ± 102.3 1500.2 ± 185.4 1547.8 ± 125.1 1369.5 ± 134.0 
 3 1610.3 ± 147.7 1349.7 ± 152.2 1624.67 ± 81.2 1428.6 ± 220.1 
 6 1616.2 ± 124.6 1428.6 ± 199.1 1558.3 ± 187.6 1283.5 ± 108.6 
  9 1562.3 ± 121.0 1353.1 ± 191.2 1286.1± 259.4 1325.9 ± 123.4 
Na(mg) 0 2132.4 ± 178.8 1981.3 ± 289.2 2044.6 ± 243.2 2134.9 ± 237.9 
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Values represent least square means ± SEM. Abbreviations used: NS-C: Nonsmokers control 
group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL: smokers + 
45 g blueberries/day. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C: 
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo. 
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to 
attrition. 
.
 3 1835.6 ± 186.6 2084.3 ± 322.1 2429.4 ± 137.5 1991.3 ± 232.5 
 6 2128.2 ± 265.3 2205.4 ± 476.1 2360.3 ± 399.7 1914.7 ± 140.5 
  9 2018.1 ± 198.5 2285.1 ± 298.0 1978.1 ± 334.6 1751.0 ± 255.6 
Biotin (µg) 0 21.7 ± 2.4 23.3 ± 7.0 12.6 ± 2.1 15.0 ± 1.5 
 3 23.4 ± 3.5 12.4 ± 2.9 16.0 ± 3.1 15.4 ± 2.2 
 6 25.2 ± 5.4 15.2 ± 2.7 13.3 ± 2.1 11.2 ± 1.9 
  9 19.0 ± 2.4 13.8 ± 2.5 14.3 ± 1.8 13.1 ± 1.9 
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Appendix 8. Effects of freeze-dried blackberries and blueberries on bone biochemical 
measurements in postmenopausal smokers  
Values represent means ± SEM. α, β, and γ represent, treatment, time, and treatment x time p 
values respectively. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C: 
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo. 
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to 
attrition. Abbreviations: NS-C: Nonsmokers control group; S-C: Smokers control group; S-BB: 
 Month NS-C S-C S-BB S-BL p values 
nmol DPD/mmol 
creatinine 
0 5.77 ± 0.40 7.16 ± 0.41 6.10 ± 0.75 8.14 ± 1.10 0.3415α 
 3 6.74 ± 0.64 6.30 ± 0.50 6.32 ± 0.33 8.02 ± 0.91 0.8273β 
 6 6.74 ± 0.39 6.87 ± 0.67 6.14 ± 0.54 6.36 ± 0.83 0.1229γ 
 9 6.57 ± 0.39 7.39 ± 0.62 6.12 ± 0.94 7.35 ± 0.46  
BAP (U/L) 0 29.45 ± 4.89 28.88 ± 1.90 25.56 ± 3.21 39.96 ± 3.02 0.3777α 
 3 31.28 ± 5.63 28.82 ± 2.21 24.67 ± 2.83 34.02 ± 2.42 0.5284β 
 6 30.92 ± 3.41 29.52 ± 2.34 30.37 ± 3.76 29.95 ± 2.42 0.0811γ 
 9 29.00 ± 3.11 29.32 ± 2.05 24.19 ± 2.44 32.72 ± 3.45  
OC (ng/mL) 0 8.35 ± 1.13 9.14 ± 0.86 10.13 ± 1.64 9.37 ± 1.20 0.6848α 
 3 9.18 ± 1.27 9.30 ± 1.63 6.28 ± 2.25 11.18 ± 1.09 0.6146β 
 6 11.30 ± 1.06 10.62 ± 0.83 9.22 ± 1.77 8.34 ± 1.09 0.0521γ 
 9 10.12 ± 0.93 9.95 ± 1.37 6.99 ± 1.52 9.43 ± 1.02  
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smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day: BAP: bone alkaline 
phosphatase; DPD: deoxypyridinoline; OC: osteocalcin 
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 Appendix 9. Effects of freeze-dried blackberries and blueberries on 
biomarkers of oxidative stress and inflammation in postmenopausal smokers  
Values represent means ± SEM. α, β, and γ represent treatment, time, and treatment x time p 
values respectively. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C: 
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo. 
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to 
attrition. Abbreviations: NS-C: Nonsmokers control group; S-C: Smokers control group; S-BB: 
smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day: TBARs: thiobarbituric 
acid reactive substances; hsCRP: high-sensitivity C-reactive protein.
 Month NS-C S-C S-BB S-BL p values 
TBARS 0 10.46 ± 0.89 9.95 ± 0.61 11.77 ± 0.74 11.19 ± 1.10 0.5359 α 
 3 9.32 ± 0.82 12.44 ± 1.17 11.16 ± 1.25 10.58 ± 0.95 0.3396β 
 6 11.41 ± 1.17 13.51 ± 1.78 10.70 ± 0.92 13.21 ± 1.87 0.7531γ 
 9 13.26 ± 3.19 15.35 ± 2.60 10.94 ± 1.79 11.53 ± 1.06  
hsCRP 0 1.54 ± 0.59 3.02 ± 0.53 2.97 ± 0.97 1.92 ± 0.67 0.1256α 
 3 1.00 ± 0.61 2.67 ± 0.62 2.56 ± 0.97 1.78 ± 0.66 0.1638 β 
 6 1.31 ± 0.59 3.03 ± 0.62 3.73 ± 1.01 2.30 ± 0.67 0.9905γ 
 9 1.12 ± 0.59 2.57 ± 0.64 2.41 ± 1.01 1.81 ± 0.67  
  
 
 
 
 
 
 
 
 
 
